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ABSTRACT 
Premenstrual dysphoric disorder (PMDD) is a distressing and disabling syndrome causing 
a significant degree of impairment on daily functioning and interpersonal relationships in 
3-8% of the women.1-3 With the convincing evidence that PMS is inheritable and that 
serotonin is important in the pathogenesis of PMS, and failure of initial studies to 
demonstrate significant associations between key genes controlling the synthesis, 
reuptake and catabolism of serotonin and PMDD, the main aim of this thesis was to 
target the functional polymorphisms of serotonin receptors. 
Bioinformatics were used to identify the evolutionary relationship between the various 
serotonin receptors and their subtypes by drawing the phylogenetic tree and delineating 
the primary, secondary and tertiary structures of the receptors. We concluded that 
although close to the rest of the serotonin receptors in the evolution tree, 5-HT3 
receptors constitute a separate family of receptors. Hence we hypothesize that the clad 
containing the 5-HT1,2,4,5,7 group of receptors comprises a series of homologous genes 
arisen by gene duplication and share common structural features.  
Applying genomic techniques we analysed and looked for association between PMDD and 
the candidate genes 5HT1A, 5HT1B, 5HT2A, 5HT2C and 5HT7, selected according to the 
following criteria: involvement of the genes in the function of serotonin; representative of 
the common receptor protein structure and equally spread around the evolutionary tree. 
The polymorphisms selected 5HT1A C(-1019)G, 5HT1B (A-161T), 5HT2A (T102C), 5HT2C 
(Cys23Ser) and 5HT7 (Pro279Leu) have been previously described and their suitability for 
genotyping assessed. 
This is the first study linking the 5HT1A C(-1019) allele and PMDD. There was a marked 
over-representation of the C/C genotype of 5-HT1A C(-1019)G polymorphism in the 
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PMDD  group. The presence of at least one C allele was associated with a 2.5-fold 
increased risk of PMDD. There were no significant associations between the other tested 
genotypes, allelic distribution and clinical category. These findings do not support a major 
role for common polymorphisms in contributing to susceptibility to PMDD.  
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CHAPTER 1: 
PREMENSTRUAL SYNDROME/ PREMENSTRUAL DYSPHORIC 
DISORDER: LITERATURE REVIEW 
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1.1 INTRODUCTION 
Majority of premenopausal women experience some level of premenstrual somatic, 
affective and behavioural symptoms4. The nature and severity vary from minimal to 
disabling, only 3-8% of these women suffer from extreme premenstrual symptoms to 
such a degree that it interferes with normal functioning and are diagnosed with 
premenstrual dysphoric disorder (PMDD). 1-3;5-7 
There was lack of credibility and interest among practitioners regarding premenstrual 
syndrome, but due to increasing social impairment and need for medical care raised 
concerns among psychiatrists. More recently with the diagnosis criteria generalization, 
the understanding, aetiology and response to medication has brought specialist from 
worldwide together to understand and treat this syndrome better.   
Symptoms of Premenstrual Syndrome have been described from the time of Hippocrates, 
“the blood of females is subject to intermittent agitations and as a result the agitated 
blood make its way from the head to the uterus whence it is expelled.”8 Centuries passed 
before premenstrual symptoms were identified or referred to again. First time in 1931 
Robert Frank, described Premenstrual Tension on paper at the Academy of Medicine, 
New York.9 Frank brought it to the attention of the medical world the relationship of 
premenstrual symptoms to Ovarian Cycle. Later the recurrent and cyclical nature of 
premenstrual tension was highlighted by Karen Horney in 1931.10  The word Premenstrual 
Syndrome was coined by Katharina Dalton in 1953,11 the term is still widely used by 
women and practitioners. She published and reported many of her case studies where 
she showed that treatment with progesterone was invariably successful in the 
management of Premenstrual Symptoms.11  
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In 1983 in the United States, the National Institute of Mental Health conference devoted 
to this topic proposed the first diagnosis criteria, requiring a prospective and daily 
assessment of the symptoms. In 1987, the American Psychiatric Association, in the DSM 
III-R, introduced the Late Luteal Phase Dysphoric Disorder diagnosis that became in 1994 
in the DSM IV the Premenstrual Dysphoric Disorder, with the same diagnosis criteria.12 
Recently International Society for Premenstrual Disorders (ISPMD) group has developed 
an international universally acceptable multidisciplinary agreement regarding definition, 
quantification and clinical trial design of premenstrual disorders (PMD).13  
Many theories have been proposed and investigated to establish the aetiology of 
Premenstrual Syndrome including Ovarian Hormone imbalance, water & electrolyte 
imbalance, deficiency of vitamins and minerals, allergy, hypoglycaemia, hyper-
insulinaemia and psychology theories. Most of the studies diagnosed premenstrual 
syndrome randomly based on the patient’s perception of her symptoms or the clinician’s 
diagnosis from the history; hence a great effort has been put into evolving a Diagnostic 
Criteria and to Quantify Premenstrual Syndrome. In 1990 the DRSP (Daily Record of 
Severity of Problems) form was developed to aid in the diagnosis and evaluation of 
PMDD(Premenstrual Dysphoric Disorder)13;14 
There is a wide range of treatment options available, and are being used to treat the 
PMDD symptoms worldwide. The research into the neurobiology of PMS/PMDD has been 
directly influenced by the successful management of these symptoms with the use of 
SSRI’s (Selective Serotonin Reuptake Inhibitors).  
Over these centuries research and studies have left no doubt that normal endocrine 
ovarian cycle provokes or triggers premenstrual symptoms in women with CNS sensitivity 
to these hormonal changes. Research using molecular genetics, endocrinology and brain 
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imaging will help explaining this sensitivity of neurotransmitters in CNS to endocrine 
changes. 
1.2 THE SYNDROME/PMDD 
Premenstrual syndrome (PMS) is a recurrence of negative behavioural (e.g. fatigue), 
psychological (e.g. irritability) and physical symptoms (e.g. headaches) that occur during 
the luteal phase of the menstrual cycle and remit by the follicular phase.4 
1.3 PREVALENCE 
In the literature, prevalence rates are very heterogeneous according to the diagnosis 
criteria used and to the populations studied. It has been sited that the incidence of the 
severe dysphoric symptoms necessitating the need for women to seek help and warrant 
treatment is 3-9%. 3;5-7;15 
Even though premenstrual symptoms are described in women from menarche to 
menopause, it is unclear whether symptoms remain stable or increase in severity with 
age.2;16 Irritability has been identified as the most common premenstrual symptom in US 
and European samples.3;16;17 Some cultures emphasize somatic rather than emotional 
premenstrual symptoms.18 Symptom severity peaks on or just before the first day of 
menses.17;19;20 Studies examining age, menstrual cycle characteristics, cognitive 
attributions, socioeconomic variables, lifestyle variables and number of children have not 
identified these variables as predisposing factors.16;21 An elevated lifetime prevalence of 
major depressive disorder (MDD) in women with PMDD has been reported in several 
studies,22 as has an elevated lifetime prevalence of postpartum depression.23  
5 
 
1.4 BURDEN OF THE ILLNESS ON WORK AND FAMILY 
Hellman et al in 1987 have reported an increase in the number of sick days taken by 
women suffering from PMS.24 The diagnosis of PMDD requires the confirmation of luteal-
phase impairment of social and/or work functioning that is due to premenstrual 
symptoms. The functional impairment reported by women with PMDD is similar in 
severity to the impairment reported in MDD and dysthymic disorder.25;26 One study 
identified anxiety, irritability and mood lability as the premenstrual symptoms most 
associated with functional impairment.27 The burden of illness of PMDD results from the 
severity of symptoms, the chronicity of the disorder and the impairment in work, 
relationships and activities.28 It has been estimated that women with PMDD cumulatively 
endure 3.8 years of disability over their reproductive years.25 A study of 1194 women who 
prospectively rated their symptoms reported that women with PMDD were more likely to 
endorse hours missed from work, impaired productivity, role limitations and less 
effectiveness.29 Borenstein and colleagues30;31 have published studies examining 
functioning and health service use in 436 women who prospectively charted their 
symptoms for 2 cycles. Women with confirmed PMS reported significantly lower quality 
of life, increased absenteeism from work, decreased work productivity, impaired 
relationships with others and increased visits to health providers, compared with control 
women. These authors also reported that, given a 14% absenteeism rate and a 15% 
reduction in productivity, PMDD was associated with US$4333 indirect costs per patient 
per year.32 The economic burden associated with PMDD is more related to self-reported 
decreased productivity than to direct health care costs.29;32 However, women with PMDD 
do report increased health services use, with visits to health care providers and use of 
prescription medications and alternative therapies.29;31 Small studies of women with 
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prospectively confirmed PMDD have also reported decreased interpersonal and work 
functioning and reduced quality of life in comparison with women without PMDD.33;34 
Larger studies of women diagnosed retrospectively according to PMDD criteria have also 
reported substantial functional impairment in work and interpersonal roles.2;35-37 Recently 
Heinemann LA; has reemphasised in his recent web based study that moderate-to-severe 
PMS/PMDD seems to be associated with work productivity impairment and increased 
absenteeism, and thus poses a potential economic burden.38;39 They have also shown that 
moderate-to-severe PMS/PMDD has a negative impact on HR-QOL(health related quality 
of life), hobbies and social activities, and relationships with others.40 
1.5 CLINICAL PRESENTATION 
Millions of women of reproductive age have recurrent emotional, cognitive, and physical 
symptoms related to their menstrual cycles. These symptoms often recur discretely 
during the luteal phase of the menstrual cycle and may significantly interfere with social, 
occupational, and sexual functioning. Symptoms last for several days to two weeks before 
the menses and remit during the menstrual flow. More than 300 type of symptoms have 
been identified in the premenstrual phase.25 In addition to increases in dysphoric mood 
during the luteal phase, women with PMDD also report impairments in cognitive abilities 
such as concentration, memory and motor coordination that interfere with their 
productivity and efficiency.12;41 However, the extent to which various aspects of 
psychomotor or cognitive performance are actually impaired during the luteal phase in 
women with PMDD has not been extensively studied and the results have been 
inconsistent, with studies reporting no differences42 or only subtle differences on isolated 
tasks.43-45 For instance, although Keenan and colleagues46;47 assessed a range of 
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neuropsychological tasks, women with PMDD were only impaired on a verbal learning 
task compared to a group of control women and this impairment was not related to 
menstrual cycle phase. In another well-controlled study that evaluated a range of tasks, 
the only performance impairment observed was that women with PMDD showed more 
psychomotor slowing during the luteal phase compared to control women.45 Another 
study done by Morgan and Rapkin in 2002,48 also assessed a full series of neurocognitive 
tasks reported no performance differences between women with PMDD and control 
women, despite a relatively large sample size. Evans in his study,49 assessed changes in 
mood and performance as a function of menstrual cycle phase in women with confirmed 
PMDD after placebo or alprazolam administration. When placebo was administered, 
motor coordination (via a balance task) and performance on the Digit Symbol Substitution 
Task (DSST) were impaired in the luteal phase. Limitations of that study included only 
administering placebo one day in each phase and the lack of a control group. Regardless, 
one major distinction between the Evans study49 and all the other studies mentioned 
above is that task performance was assessed multiple times over the day, not just once. 
The fact that most previous studies only assessed performance on a single occasion each 
phase may be one reason for the inconsistencies observed across studies.  
Women with PMDD also report changes in appetite, food intake and specific food 
cravings during the luteal phase12 and these changes appear to be correlated with 
premenstrual mood changes, primarily depression.50-52 Most studies relied on 
retrospective reports of PMDD and retrospective food cravings, typically using a single 
question that did not specify food type.50;53 Evans also assessed food cravings54 and food 
intake in 19 women with PMDD and showed that craving for foods, specifically those 
containing fat, were significantly increased in the luteal55;56 phase compared to the 
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follicular phase, while desires for CHO alone did not change as a function of menstrual 
cycle phase. In that same study, when placebo was administered there was no 
corresponding increase in actual food consumption at lunch during the luteal phase. Reed 
in his study found that women with PMDD in their luteal phase had increased dysphoric 
mood; had impaired cognitive performance; had an increased desire for food items high 
in fat (both savory and sweet); and ate more calories (particularly fat) at lunch compared 
to when they were in their follicular phase and/or compared to women without PMDD.57 
Premenstrual exacerbation and co-morbidities need to be identified if present. Many 
symptoms of other gynaecological problems may be exacerbated or present just before 
menses for example; primary dysmenorrhea due to release of prostaglandins from the 
secretory endometrium, secondary dysmenorrhea, dyspareunia etc in case of 
endometriosis. Menstrually related migraines last longer and resistant are to routine 
medication, but are related to ovulatory cycles.58-61 
64% of premenopausal women report of worsening pre-existing depression symptoms 
premenstrualy. 62 Many women with anxiety or depression seek treatment for PMS63;64 
but these symptoms are not limited to luteal phase. Premenstrual exacerbation of several 
conditions, are dealt with treating the primary condition and increasing the doses during 
the luteal phase if premenstrual exacerbation exists.    
Recently International Society for Premenstrual Disorders (ISPMD) group in Montreal in 
September 2008 has developed an international universally acceptable multidisciplinary 
agreement regarding definition, quantification and clinical trial design of premenstrual 
disorders (PMD).13;65 
ISPMD has classified Premenstrual disorder into two types Core PMD and Variant PMD 
(Figure 1)65 
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Figure 1: Classification of Premenstrual Disorder according to the ISPMD  
1.6 AETIOLOGY 
Currently, there is no consensus on the cause of PMDD. The aetiology of severe PMS and 
PMDD is largely unknown, but the current consensus seems to be that, normal ovarian 
function (rather than hormone imbalance) is the cyclical trigger for the premenstrual 
related biochemical events within the central nervous system and other target organs.66 
1.6.1 Normal Physiology of Menstrual cycle 
The menstrual cycle extends from the first day of period to the onset of next menstrual 
bleeding and comprises of two phase, Follicular phase and Luteal phase. The 
Hypothalmic- pituitary- Ovarian axis is responsible for the menstrual cycle, which remains 
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blocked throughout childhood until the age of 11-12yrs. The pulsatile release of 
Gonadotrophic releasing hormone (GnRH) from the hypothalamus regulates the synthesis 
and release of Luteinising hormone (LH) and Follicle stimulating Hormone (FSH) from the 
pituitary. LH and FSH are responsible for the ovarian activation. LH stimulates the 
synthesis of androstenedione and testosterone from the well vascularised theca cells 
which are the precursors for the formation of oestrogen. 
FSH acts on the granulosa cells increasing the mitosis of these cells and increasing their 
surface LH, FSH receptors and also acquisition of aromatase activity. The aromatase is 
responsible for conversion of androgens to oestrogen, which is released into the 
circulation. Oestrogen and Inhibin B has a feedback effect on the hypothalamus pituitary 
level augmenting the LH level and inhibiting the FSH release, critical to achieve 
monofollicular development. The LH surge last approximately for 24-48hrs and ovulation 
occurs 36hrs67 after the peak level of serum LH is achieved. LH surge resumes the meiosis 
step before leading to series of inflammatory events causing follicle to rupture. High 
levels of LH also lead to decidualization of the granulosa cells which produce the 
progesterone. This production of progesterone by corpus luteum slows the release of 
hypothalamic GnRH secretion via the effect on γ- aminobutyric acid (GABA), 
noradrenergic and opiodergic systems. Once corpus luteum collapses FSH levels rise 
causing development of new follicles.68    
Estradiol levels in the blood gradually rise in the follicular phase and abruptly fall for 24-
48hrs following follicular rupture; this may lead to various symptoms including transient 
PMS like symptoms, mittelschmerz or bleeding. Steroidogenic activity of the corpus 
luteum, causes oestrogen and progesterone levels to rise again for 10-12 days. This 
function of the corpus luteum is maintained by the release of LH for 10-12 days following 
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which the function can be prolonged by hCG if conception takes place. There is wide 
fluctuation in the progesterone levels secondary to the fluctuation in the levels of LH on 
the corpus Luteum.   
Serial measurements of testosterone and free testosterone levels has shown no 
difference in the women suffering with PMS or controls.69 
1.6.2 Pathophysiology 
Several reviews exist of pathophysiological hypotheses of PMS and PMDD and the 
evidence for them.25;55;70;71 Most studies do not identify consistent abnormalities in 
hormones of the hypothalamic-pituitary-gonadal (HPG) axis, although a few studies have 
suggested altered luteinizing hormone (LH) pulse.72 As well, studies have not identified 
clear abnormalities in thyroid hormones, cortisol, prolactin, glucose, prostaglandins, β-
endorphins, vitamins or electrolytes.25;70 Since specific abnormalities in the HPG axis have 
not been identified in women with PMDD when compared with control subjects, it is 
thought that premenstrual symptoms occur as a result of a differential sensitivity to the 
mood-perturbing effects of gonadal steroid fluctuations in women with PMS and PMDD.73 
It is probable that the aetiology of the “differential sensitivity” is multifactorial and in part 
genetically determined.74 The recently identified allelic variation in the oestrogen 
receptor α gene in women with PMDD may underlie the neurotransmitter and 
neuropeptide differential sensitivity owing to oestrogen receptor influence on synthesis, 
receptors, transporters and cell signalling.75 
Although the specific neurotransmitter, neuroendocrine and neurosteroid abnormalities 
in women with PMDD are not known, serotonin, norepinephrine, γ-aminobutyric acid 
(GABA), allopregnanolone (ALLO, an anxiolytic metabolite of progesterone that acts at the 
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GABAA receptor), endorphins and factors involved in calcium homeostasis may all be 
involved. Women with PMDD are more sensitive to the anxiogenic properties of carbon 
dioxide inhalation, lactate infusion, cholecystokinin tetrapeptide and flumazenil.25 
Increased adrenergic receptor binding may reflect abnormal noradrenergic function.25 
Women with PMDD have abnormal melatonin secretion and other circadian system 
abnormalities.76 It has been proposed that women with PMDD have altered affective 
information processing and regulation during the luteal phase, with abnormal activation 
patterns in specific brain regions.74 Imaging studies have demonstrated altered functional 
magnetic resonance imaging responses to negative and positive stimuli in the 
orbitofrontal cortex, amygdala and ventral striatum in women with PMDD compared with 
control subjects.77 A recent study reported significantly increased negative bias in the 
recognition of emotional facial expressions during the luteal phase in women with PMDD 
when compared with control women.78 Physiological, psychological, environmental and 
social factors all seem to play a part. Genetic influences mediated phenotypically through 
neurotransmitters and neuroreceptors seem to play a significant role in the aetiology. 
That PMS and PMDD are physiological (rather than psychological or psychosocial) 
phenomena is primarily underscored by recent, convincing evidence of the heritability of 
premenstrual symptoms79 and the elimination of premenstrual complaints with 
suppression of ovarian cyclicity73 or surgical menopause.80;81 This viewpoint encourages 
investigation of the neuroendocrine-modulated central neurotransmitters and the role of 
the hypothalamic-pituitary-gonadal (HPG) axis in PMDD. Increasing evidence suggests 
that, of all the neurotransmitters studied to date, serotonin (5-HT) may be important in 
the pathogenesis of PMDD.82;83   PMDD also shares many of the features of other mood 
and anxiety disorders that have been linked to serotonergic dysfunction.84-86 In addition, 
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reduction in brain 5-HT neurotransmission is thought to lead to poor impulse control, 
depressed mood, irritability and increased carbohydrate craving - all mood and 
behavioural symptoms associated with PMDD. Animal studies have established 
reciprocity between fluctuations in ovarian steroid levels and serotonergic function, 
showing that oestrogen and progesterone influence central serotonergic neuronal 
activity. In the hypothalamus, oestrogen induces a diurnal fluctuation in 5-HT87 whereas 
progesterone increases the turnover rate of 5-HT88 Several challenge tests have also 
suggested abnormal 5-HT function in women with premenstrual dysphoria. A blunted 
growth hormone and cortisol response to tryptophan89 as well as a blunted or delayed 
prolactin response to fenfluramine and buspirone challenges have been reported by 
most90-92 but not all93 investigators. These studies imply, at least in part, a recurrent, cyclic 
5-HT dysfunction in women with premenstrual mood changes. 
Taken together, most research indicates that women with PMDD may be behaviourally or 
biochemically sub- or supersensitive to biological challenges of the serotonergic system. It 
is not yet clear whether these women present with a trait or state marker of PMDD. 
 
Acute treatment with SSRIs increases synaptic serotonin without the down-regulation of 
serotonin receptors needed for improvement in overt depression. This finding suggests 
that PMDD is possibly caused by altered sensitivity in the serotoninergic system in 
response to phasic fluctuations in female gonadal hormone. Other studies also favour the 
serotonin theory as a cause of PMDD. In particular, the efficacy of L-tryptophan,94 a 
precursor of serotonin, and of pyridoxine,95 which serves as a cofactor in the conversion 
of tryptophan into serotonin, also favours serotonin deficiency as a cause of PMDD. 
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Carbohydrate craving, often a symptom of PMDD, is also mediated through serotonin 
deficiency. 
Because PMDD only affects women of reproductive age, it is reasonable to assume that 
female gonadal hormones play a causative role, possibly mediated through alteration of 
serotoninergic activity in the brain. Oestrogen and progesterone seem to modulate levels 
of monoamines, including serotonin. Eliminating the effect of ovarian gonadal hormones 
through the use of a gonadotropin-releasing hormone (GnRH) agonist relieves PMDD 
symptoms.96 Subsequent administration of oestrogen and progesterone causes 
symptoms to return in women with PMS but not in those without PMS symptoms. 
1.7 GENETICS OF PMS 
Evidence for a genetic component in a complex and phenotypic traits can be shown by 
various studies: 
1. Family Studies: the proportion of common genes shared may be predicted by the 
degree of relatedness. 
2. Adoption Studies: Studies have shown there is little change in the rate of recurrence 
of a disease regardless of whether a child is reared by its adopted or biological parents 
in different or same environment. 
3. Twin studies: concordance is the parameter used in the twin studies. 
Inheritance plays a major role in behaviour as shown by selection and strain studies for 
animal behaviour and by twin and adoption studies for human behaviour. The conclusion 
of these studies in behavioural genetics can be difficult and controversial. The main areas 
of concern are that early twin studies were small, moreover it is difficult to define 
personality traits and disorders. Also the adoption and twins reared apart may not have a 
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very different environment because the adoption agencies tend to match the original 
environment. Unlike simple Mendelian characteristics, genetic variance for behavioural 
dimensions and disorders rarely accounts for more than half of the phenotypic variance, 
and multiple genes with small effects appear to be involved rather than one or two major 
genes.97  
Genetic factors are also pertinent to the aetiology of PMDD : 70% of women whose 
mothers have been affected by PMS have PMS themselves, compared with 37% of 
women whose mothers have not been affected.98 There is a 93% concordance rate in 
monozygotic twins, compared with a rate of 44% in dizygotic twins.98 Genetic influences 
mediated phenotypically through neurotransmitters and neuroreceptors seem to play a 
significant role in the aetiology. 
A recent study is the first to demonstrate allelic variation on the oestrogen receptor α 
gene in women with PMDD when compared with control women.75 In addition, the allelic 
variation was only significant in women who had a valine/ valine genotype for the 
catechol-O-methyltransferase enzyme. This significant study may identify a source of 
abnormal oestrogen signalling during the luteal phase that leads to premenstrual 
affective, cognitive and somatic symptoms.75 Previous studies had failed to identify gene 
polymorphism differences between women with PMDD and control subjects in regard to 
the serotonin transporter,99;100 the transcription factor activating protein 2,101 tryptophan 
hydroxylase and monoamine oxidase A promoter100 genes. Overlap of PMDD with genetic 
liability for MDD, seasonal affective disorder and personality characteristics has been 
suggested.102;103 
Thus, while there is strong evidence for an inherited contribution to the mood disorders, 
the mode of genetic transmission and the genes involved remain unclear. It is likely that a 
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number of genetic factors contribute to increase vulnerability to the illness, and that 
these factors vary among families, greatly increasing the difficulty of identifying genetic 
factors. In addition, environmental factors also play a critical etiologic role, further 
complicating genetic and epidemiologic analyses. 
1.8 DIAGNOSIS AND QUANTIFICATION 
Many women with a premenstrual disorder go undiagnosed, because of underreporting 
by the women or due to difficulty in diagnosing the disorder by the clinicians.104. To 
diagnose the syndrome after taking the complete personal and family history 2 months of 
prospective symptom ratings, employing 1 of a number of validated instruments should 
be used.  
Premenstrual disorders are characterized by numerous moods, somatic and behavioural 
symptoms that occur during the late luteal phase of a woman's menstrual cycle and abate 
soon after the onset of menses. Diagnostic criteria for premenstrual syndrome (PMS) 
were published by the American College of Obstetricians and Gynecologists in 2000; the 
American Psychiatric Association had previously established very specific diagnostic 
criteria for premenstrual dysphoric disorder (PMDD). Both diagnoses require 2 months of 
prospective symptom ratings, which can be accomplished using forms designed by 
individual clinicians or employing 1 of a number of validated instruments. The patient will 
need to provide a complete family and personal history of mental disorders and medical 
diseases. A thorough physical examination and certain basic laboratory tests should either 
identify or rule out many potential causes of the symptoms. The diseases, disorders or 
situations considered in the differential diagnosis of PMS and PMDD will depend on the 
woman's presenting symptoms. Many women with a bothersome or debilitating 
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premenstrual disorder go undiagnosed, either because they do not report their 
symptoms to a clinician or because the clinician has difficulty diagnosing the disorder. 
In the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV), PMDD is 
classified as “depressive disorder not otherwise specified” and emphasizes emotional and 
cognitive-behavioural symptoms.12  At least five of the 11 specified symptoms must be 
present for a diagnosis of PMDD (Table 1). These symptoms should be limited to the 
luteal phase and should not represent amplification of pre-existing depression, anxiety, or 
personality disorder. In addition, they must be confirmed prospectively by daily rating for 
at least two consecutive menstrual cycles. A symptom-free period during the follicular 
phase of the menstrual cycle is essential in differentiating PMDD from pre-existing anxiety 
and mood disorders. 
Researchers have developed a reliable and valid self-reporting scale called the Daily 
Symptom Report.105 Patients rate each symptom on a five-point scale, from zero (none) 
to 4 (severe). The scale provides guidance for scoring the severity of each symptom and 
may be used in the office setting by primary care physicians for diagnosis and assessment 
of PMDD. 
The psychiatric, medical and psychosocial screens, together with verification of the timing 
of symptoms, enable the clinician to make a diagnosis. Possible diagnoses after screening 
include the ISPMD classification of PMD (Figure 1):65 1) Core PMD as PMS or PMDD; 2) 
Variant PMD either as Premenstrual Exacerbation, PMD with anovulatory ovarian activity, 
PMD with absent menstruation or progestogen-induced PMD; 3) Other psychiatric or 
medical illness only; or, 5) no diagnosis (situational, psychosocial stressors). 
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1.8.1 Diagnosis and Statistical Manual of Mental Disorders (DSM IV) 
There is little question that the creation of diagnostic criteria has improved the 
generalisability of findings in psychiatric research by assuring greater cross-study sample 
homogeneity. While this has certainly been true for PMS, questions can be legitimately 
raised about the stringency of the criteria and the means of their operationalisation.  
a. In most menstrual cycles during the past year, five (or more) of the following symptoms were 
present for most of the time during the last week of the luteal phase, began to remit within a few 
days after the onset of the follicular phase, and were absent in the week post-menses, with at least 
one of the symptoms being either (1), (2), (3), or (4):  
1. markedly depressed mood, feelings of hopelessness, or self-depreciating thoughts 
2. marked anxiety, tension, feeling of being ‘keyed up’ or ‘on edge’ 
3. marked affective lability (e.g. feeling suddenly sad or tearful or increased sensitivity to 
rejection) 
4. persistent and marked anger or irritability or increased interpersonal conflicts 
5. subjective sense of difficulty in concentrating 
6. lethargy, easy fatigability, or marked lack of energy 
7. marked change in appetite, overeating, or specific food cravings 
8. hypersomnia or insomnia 
9. a subjective sense of being overwhelmed or out of control 
10. other physical symptoms, such as breast tenderness or swelling, headaches, joint or 
muscle pain, a sensation of ‘bloating’, weight gain. 
 
Note: In menstruating females, the luteal phase corresponds to the period between ovulation and the onset 
of menses, and the follicular phase begins with menses. In non-menstruating females (e.g. those who have 
had a hysterectomy), the timing of luteal and follicular phase may require measurement of circulating 
reproductive hormones. 
b. The disturbance markedly interferes with work or school or with usual social activities and 
relationships with others (e.g. avoidance of social activities, decreased productivity and efficiency 
at work or school). 
c. The disturbance is not merely an exacerbation of the symptoms of another disorder, such as major 
depressive disorder, panic disorder, dysthymic disorder, or a personality disorder (although it 
may be superimposed on any of these disorders). 
d. Criteria A, B and C must be confirmed by prospective daily ratings during at least two 
consecutive symptomatic cycles. (The diagnosis may be made provisionally prior to this 
confirmation.) 
 
Table.1. Diagnosis and Statistical Manual of Mental Disorders IV Criteria 
 
Unfortunately the DSM IV does not specify for how many days the symptoms should 
exist, nor does it specify that how soon the symptoms should remit. For clinical trials, 
inclusion criteria usually specify ‘severe symptoms for at least 4 days’ or average severity 
during 7 days.106 The possibility that different lengths of premenstrual period may be 
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associated with different phenotypes and underlying mechanisms has not been fully 
elucidated.   
Many of the scales listed in (Table.2) have been used to make the distinction between 
premenstrual dysphoric disorder alongside other disorders, in particular the Beck 
Depression Inventory,107 Profile Of Mood States108 and Hamilton Depression Scale.109 
Other scales which can be administered to assess the women’s underlying psychiatric 
morbidity include the Hospital Anxiety Depression Scale,110 General Health 
Questionnaire,111 Self Reporting Questionnaire and the Structured Clinical Interview for 
DSM IV (SCID).12 
1.8.2 Methods of Measurement Reported to Date 
Early research projects attempted to use rating scales that were essentially established 
and designed to quantify other psychiatric and psychological conditions.  Examples of this 
are the use of the Hamilton Rating Scale for depression109 and the Beck Depression 
Inventory.107 The lack of specificity of these techniques to quantify PMS led to the 
development of new “bespoke” techniques.  
The earliest published measure specific to premenstrual symptoms was the Moos’ 
Menstrual Distress Questionnaire (MDQ)112 which used a 47 item 0-6 rating scale. The 
first use of visual analogue scales (VAS) was published as the Premenstrual Mood Index 
which was used for the first time within the context of a randomised clinical trial of 
spironolactone at University of Nottingham,UK.113  
Visual Analogue Scale 
VAS techniques demonstrate admirably the character and cyclicity of symptoms. It is 
likely that visual analogues scales (VAS) are the most sensitive measure of PMS/PMDD as 
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they allow a continuous rating.  The VAS can be used to look at individual scores and their 
response to therapy or a Global score (Figure2). Visual analogue scales have been found 
to be an effective tool in measuring the change in premenstrual symptoms over time and 
their validity and reliability have since been well documented.113-115 The 100mm line has 
both positive and negative mood adjectives with the midline being “a normal day”. The 
anchors are 0 = “not at all” (that is the way you normally feel when you don’t have 
premenstrual symptoms) and 100 = “extreme symptoms” (that is, the way you feel when 
your premenstrual symptoms are at their peak) 
 
Figure.2.Daily visual analogue scale scores for psychological symptoms 
Other Rating Scales 
Newer techniques rate from zero to 3,4,5,6 or 7 using categorical rating scales. Early 
scales included Clinical Global impression Scale (CGIS), the Global Assessment Scale 
(GAS),116 the Steiner Self Rating Scale,117 Later; the more widely used scales included 
Premenstrual Assessment Form (PAF),118 Prospective Record of the Impact of Menstrual 
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Symptoms (PRISM),119 and the Calendar of Premenstrual Experiences (COPE).120 These 
and many other tools used over the past 30 years are summarised in the following table2. 
Reference Method Comment 
* Hamilton 1960121  Hamilton rating Scale for depression 
(HAM-D) 
Observer-rated instrument to assess 17/21 
items in premenstrual mood disturbance. 
* Beck et al 1961107    Beck Depression Inventory (BDI) 21-item self-report questionnaire; 
symptoms rated 0-3 to give an overall 
depression score 
Moos 1968112 Moos’ Menstrual Distress Questionnaire 
(MDQ) 
47 symptom rated on a six-point scale  
* McNair et al 1971108  Profile of Mood States (POMS) 65 symptoms rated on 0-4 scale 
combined to give summary scores for 
five dimensions 
* Weissman and 
Bothwel 1976122  
Social Adjustment Scale (SAS) Self-report instrument containing 56 
questions in seven different sections 
Endicott et al 1976116  Global Assessment Scale (GAS) Has not been used extensively 
* Guy 1976123  Clinical Global Impression Scale (CGIS) Seven-point observer/patient-rated global 
scale 
* Derogatis et al 
1977124   
Symptom Checklist-90 (SCL-90) general index of psychological and 
physical symptoms plus additional nine 
subscales  
O’Brien et al 1979113  
 
Visual Analogue Scale (VAS).  
Premenstrual Mood Index 
100-mm line at either end of which are 
opposing adjectives representing the 
symptoms 
 
Steiner et al 1980117 Self-rating Scale for Premenstrual Syndrome A 36 item yes/no rating scale 
Steiner et al 1980117  Premenstrual Tension Syndrome-Observer 
(PMTS-O) and Self Rating (PMTS-SR) 
Assess symptoms in 10 different 
domains. 36 symptom with severity 
ranging from 0 to 4 
Halbreich et al 1982118 Premenstrual Assessment Form (PAF) Retrospective questionnaire based on 
psychological and behavioural symptoms 
Reid 1985119  Prospective Record of the Impact and Severity 
of Menstrual Symptoms (PRISM)  
Daily chart records a large number of 
symptoms rated 1-3 
Rubinow et al 1984115 Visual Analogue Scale (VAS) 100-mm line at either end of which are 
opposing adjectives representing the 
symptoms 
Magos and Studd 
1986125  
Modified Moos’ Menstrual Distress 
Questionnaire (MDQ) 
Ten items derived from MDQ, usually 
subjected to Trigg’s trend analysis 
Casper and Powell 
1986114  
Visual Analogue Scale (VAS) 100-mm line at either end of which are 
opposing adjectives representing the 
symptoms 
Magos and Studd 
1988126 
Premenstrual Tension-Cator (PMT-Cator) Five symptoms rated 0-3S 
Mortola el 1990120 Calendar of Premenstrual Experiences 
(COPE) 
 
Endicott & Harrison 
1990127 
Daily Record of Severity of Problems  22-item rated 0-6 specifically for 
symptoms of PMDD 
* Rivera-Tovar and 
Frank 1990128  
Daily Assessment Form (DAF) 33-item symptom checklist rated from  0 
(none) to 6 (extreme) 
Steiner et al 200335  Premenstrual Screening Tool (PSST) Retrospective 0-3 Scale. Retrospective 
for PMDD  
Table.2. Techniques used to quantify premenstrual syndrome.   
*=methods originally designed for diagnoses other than PMS or PMDD. 
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The Daily Record of Severity of Symptoms 
During the evolution of these various methods, the DSM III and DSM IV criteria12 were 
developed for LLPDD and then PMDD. In line with that, in 1990, Endicott and Harrison127 
published the somewhat simple tool named Daily Record of Severity of Problems (DRSP). 
DRSP was developed to help individual women and their therapist assess the nature, 
severity and timing of onset and offset of problems which may129 develop during specific 
phases of the menstrual cycle. The feelings and behaviours which are to be rated each 
day are those which make up the diagnostic criteria for PMDD. Completion of such rating 
is essential to determine the nature of the problem being experienced127 
Daily ratings made for several menstrual cycles helps to establish when specific symptoms 
first appear or become more severe, how severe they become, how much impairment in 
functioning they cause, and when they go away or become less severe. The pattern of 
change in the symptoms helps the women and her therapists determine which of the 
following conditions are most likely to be present (Jean Endicott, PhD, discusses the 
DRSP): 
1. Premenstrual worsening of her on going condition which is present throughout her 
cycle 
2. PMDD with patterns of changes that clearly meet criteria 
3. PMS which is clearly present but does not meet the severity or impairment criteria for 
PMDD 
4. Symptoms and impairment which show no evidence of being linked to phases of the 
menstrual cycle. 
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The reason such a diagnostic evaluation is important is that it will guide the treatment of 
the condition (Figure 3). 
 
DAILY RECORD OF SEVERITY OF PROBLEMS 
Name or Initials----------------------------------------Month/Year--------------------------------------------- 
Each evening note the degree to which you experienced each of the problems listed below. Put an “x” in the box which corresponds to 
the severity: 1 - not at all, 2 - minimal, 3 - mild, 4 - moderate, 5 - severe, 6 - extreme. 
 
BLEEDING                    
 
Cycle Day 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 40 
Felt depressed, sad, “down”, or “blue”                    
Felt hopeless                    
Felt worthless or guilty                    
Felt anxious, tense, “keyed up” or “on edge”                    
Had mood swings (eg suddenly felt sad or 
tearful) 
                   
Was more sensitive to rejection or my feelings 
were easily hurt 
                   
Felt angry, irritable                    
Had conflicts or problems with people                    
Had less interest in usual activities                    
Had difficulty concentrating                    
Felt lethargic, tired, fatigued, or had a lack of 
energy 
                   
Had increased appetite or overate                    
Had cravings for specific foods                    
Slept more, took naps, found it hard to get up 
when intended 
                   
Had trouble getting to sleep or staying asleep                    
Felt overwhelmed or that I could not cope                    
Felt out of control                    
Had breast tenderness                    
Had breast swelling, felt “bloated”, or had 
weight gain 
                   
Had headache                    
Had joint or muscle pain                    
Impairment as demonstrated by interference with 
normal work, school or home activities or 
interference with usual social activities and 
relationships with others 
                   
At work, at school, at home, or in daily routine, 
at least one of the problems noted above caused 
reduction or productivity or inefficiency 
                   
At least one of the problems noted above 
interfered with hobbies, or social activities (eg 
avoid or do less) 
                   
At least one of the problems noted above 
interfered with relationships with others 
                   
 
Figure 3. Daily record of severity of problem 
The Premenstrual Symptoms Screening Tool (PSST) 
PSST is a simple user friendly screening tool devised by Steiner et al 200335 to identify 
women who suffer from severe PMS/PMDD and who are likely to benefit from treatment.  
The PSST reflect and translates categorical DSM IV criteria into a rating scale with degrees of 
severity and impact of premenstrual symptoms. It is less time consuming and more practical than  
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two cycles of prospective charting, hence, an important starting point for further 
assessment (figure 4). 
 
Do you experience some or any of the following premenstrual symptoms which 
start before your period and stop within a few days of bleeding? 
(please print and mark an “X” in the appropriate box) 
 
SYMPTOMS NOT AT ALL MILD MODERATE SEVERE 
1. Anger/irritability      
2. Anxiety/tension     
3. Tearful/Increased sensitivity to rejection     
4. Depressed mood/hopelessness     
5. Decreased interest in work activities     
6. Decreased interest in home activities      
7. Decreased interest in social activities     
8. Difficulty concentrating     
9. Fatigue/lack of energy     
10. Overeating/food cravings     
11. Insomnia     
12. Hypersomnia (needing more sleep)     
13. Feeling overwhelmed or out of control     
14. Physical symptoms: breast tenderness, 
      headaches, joint/muscle pain, bloating  
      weight gain 
    
Have your symptoms, as listed above, interfered with: 
 NOT AT ALL MILD MODERATE SEVERE 
A. Your work efficiency or productivity     
B. Your relationships with coworkers     
C. Your relationships with your family      
D. Your social life activities     
E. Your home responsibilities       
Scoring 
The following criteria must be present for a diagnosis of PMDD 
1. at least one of #1, #2, #3, #4 is severe 
2. in addition at least four of #1 - #1 4 are moderate to severe 
3. at least one of A, B, C, D, E is severe  
The following criteria must be present for a diagnosis of moderate to severe PMS 
1. at least one of #1, #2, #3, #4 is moderate to severe 
2. in addition at least four of #1 - #14 are moderate to severe 
3. at least one of A, B, C, D, E is moderate to severe 
 
Figure 4. Premenstrual symptoms screening tool 
 
When using any chart for either research or clinical purposes, ideally symptoms should be 
rated prospectively in order to avoid the inaccuracies inherent in retrospective rating.  
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The National Institute of Mental Health definition states that premenstrual changes 
should show at least 30% increase from the intensity of symptoms measured in the 
follicular phase, that is, in days 5-10 of the menstrual cycle, compared with those 
measured in the premenstrual phase (on the 6 days before menstruation). The 30% 
change in the ratings of symptoms has been shown to be too liberal and a poor 
discriminator when comparing women with self-reported severe PMS, women using 
contraceptives whose natural cyclicity has been suppressed and women with normal 
cyclicity who report no premenstrual symptoms.34;130 Gallant et al emphasise that what 
may be more clinically relevant is women’s perceptions of variations in social and 
occupational functioning and “the way in which having PMS is meaningful in a women’s 
life”. The authors’ concern is that ever more stringent criteria might result in the 
exclusion from studies or treatment of significantly troubled individuals. As early as 1986 
Magos & Studd had applied Trigg’s Trend analysis125 to evaluating severity and cyclicity 
producing and produced quite a useful tool for this purpose. 
Ekholm et al,131 compared four different methods to assess the cyclicity and severity, 
based on the daily prospective symptoms rating. The methods compared were: a) the 
non-parametric Mann-Whitney U-test, b) effect size, c) Run-test and d) a 30% of change 
in symptom degree between the follicular and the luteal phases. They concluded that the 
three of the methods used seemed to correctly identify the same patients as having or 
not having cyclical changes.  However some differences in the outcome of validity testing 
and the 30% change methods seemed less valid than the other three methods. 
Menstrual Symptometrics 
Various researchers have attempted to address the simplification of data collection.  One 
of the simplest was the PMT-cator which was a gadget like an obstetric wheel calculator – 
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although novel, it was never validated nor used in any further research. There have been 
several attempts at data acquisition, documentation and transfer into a database by 
electronic means.  Mini-Doc method has had limited use. At least one research study 
using this technique was terminated prematurely because of difficulties with the system; 
the authors have been unable to locate other publications using the technique of voice 
recognition. North Staffordshire Hospital/keele University and Nottingham University, 
investigated the Menstrual Symptometrics device which was developed and validated 
against paper based techniques. This method used a very early PDA (Amstrad Pen Pad) 
which is now obsolete.  Visual analogue scales were used to record scores for symptoms 
of PMS, dysmenorrhoea and perception of blood loss.  It also incorporated the Menstrual 
Pictogram which is a previously published pictorial method of measuring menstrual blood 
loss volume - hence all symptoms related specifically to disorders of the menstrual cycle 
could be measured.95;132   
Menstrual Symptometrics is a simple ‘palmtop’ personal computer system which is 
programmed to collect the daily menstrual cycle symptoms of PMS, blood loss and pain 
and also to assess the women’s quality - quality of life (using SF-36) and simple measure 
of underlying psychological disorder (GHQ) was also documented with other 
questionnaires incorporated into the system.  It avoided the need to measure by hand the 
visual analogue scales, as the touch sensitive screen allowed the instant measuring of 
visual analogue scales. It has a high level of patient acceptability and can provide instant 
pictorial feedback on symptoms for patients and clinicians.       
This method is now obsolete because of advances in PDA technology and is no longer 
valid because menstrual sanitary products acceptable to most women have changed 
dramatically 
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1.9 MANAGEMENT  
A wide range of therapeutic interventions have been tested in the treatment of 
premenstrual symptoms. For women who do not meet criteria for PMDD or other 
physical and psychological disorders, conservative treatments are appropriate, and 
nonpharmacologic management should be encouraged. Unfortunately, there have been 
few randomized controlled trials to determine the efficacy of these more conservative 
interventions (Table 3); however, there is some evidence that these patients may best 
respond to individual or group cognitive-behavioural psychotherapy in combination with 
lifestyle changes. Recommended dietary changes (especially during the luteal phase) 
should include reducing or limiting intake of tobacco, chocolate, caffeine and alcohol. 
Some women report improvement as a result of eating small, frequent meals high in 
complex carbohydrates, as well as taking vitamins and minerals in moderation. A recent 
study identified the efficacy of a specially formulated carbohydrate-rich beverage 
compared with placebo.133 Patients should be encouraged to decrease excess sodium in 
the diet when edema or fluid retention occurs and, if possible, to reduce their body mass 
index to less than 25 kg/M2.134 Regular exercise is important,135;136 and particularly 
effective when combined with the regular practice of stress management techniques. 
Patients should also be taught to review their own monthly diaries and identify triggers 
that exacerbate symptoms. Most nonpharmacologic interventions that have been proven 
efficacious require a series of interventions. Cognitive-behavioural therapy in the form of 
12 weekly individual sessions significantly improved symptoms and functional impairment 
in women with PMS randomly assigned to immediate treatment, compared with those in 
the waiting-list control group.137 Ear, hand and foot reflexology administered once weekly 
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for 8 weeks by a trained reflexologist significantly decreased premenstrual symptoms in 
women who received treatment compared with those who received "sham" 
reflexology.138  
 
                      Conservative  Interventions to Treat PMS and PMDD 
Charting  Daily charting of symptoms 
Diet Reduction or elimination, especially in the luteal phase of, salt, 
chocolates, caffeine and alcohol. Small frequent meals high in complex 
carbohydrates, vitamins and minerals in moderation.  
Exercise  Moderate, regular aerobic exercise  
Stress reduction Stress management counselling or courses if necessary; or both  
Relaxation Relaxation courses or audiotapes  
Relationships Assertiveness course or marital counselling if necessary; or both  
Self help groups If available  
Education Self help books 
Table 3.  Conservative Interventions to treat PMS and PMDD 
Of the low-risk pharmacologic interventions that have been studied under controlled 
conditions (Table 4), calcium carbonate (1000 to 1200 mg daily) significantly improved 
affect and alleviated water retention, food cravings and pain after 3 treatment 
cycles.139;140 Magnesium supplementation (200 mg or 360 mg daily during the luteal 
phase) significantly reduced premenstrual fluid retention after 2 cycles of 
treatment.141;142 There have been enough studies of vitamin B6 to allow for a systematic 
review, which concluded that doses of up to 100 mg daily are likely to be of moderate 
benefit in treating premenstrual symptoms and depression.95 Additional treatments that 
have demonstrated efficacy include nutritional supplements143;144 and daily 
administration of vitamin E.145 A systematic review of evening primrose oil concluded that 
this intervention was ineffective for this disorder.146 Mefenamic acid given premenstrually 
alleviated fatigue, headache, aches and pains, and improved mood,147 whereas 
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premenstrual administration of naproxen reduced pain in one study,148 and daily 
naproxen administration improved menstrual migraine in another.149 Daily or luteal-
phase administration of spironolactone appears efficacious for somatic and physical 
symptoms, including weight gain and bloatedness.113;150-152 For mastalgia, bromocriptine 
(1.25 to 7.5mg daily during the luteal phase) was helpful in 10 of 14 randomized trials.153 
Supplement  Dosage  
Vitamin B6 100mg daily 
Calcium  1000 to 1200 mgs daily 
Magnesium ions 200 0r 360 mgs daily (14 days before menses) 
Vitamin E 400 IU daily 
Table 4.  Low Risk Pharmacological interventions supported by the evidence 
The pharmacological approaches to PMDD and severe PMS include psychotrophic 
medications and hormonal interventions. The newer antidepressants in particular, 
including many of the selective serotonin reuptake inhibitors (SSRIs)129;154-169as well as 
clomipramine170;171 and L-tryptophan,94 have demonstrated excellent efficacy and 
minimal side effects in women with severe PMS and PMDD in whom conservative 
treatment has failed (Table 5). There is increasing evidence that intermittent low-dose 
SSRI treatment significantly improves both psychological and physical premenstrual 
symptoms within the first few cycles of treatment.129;165-171  Intermittent treatment 
typically consists of starting medications 14 days before menstruation starts and 
continuing daily treatment until menstruation or shortly thereafter. In spite of 
considerable differences in chemical structure, all SSRIs appear to be effective for PMDD 
and PMS. SSRI treatment is not contraindicated for women taking oral contraceptives. 
The anxiolytics alprazolam172-174 and buspirone175 have also demonstrated efficacy in 
most trials; however, the magnitude of the therapeutic effect is less than that of SRIs, 
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while the side effect profile and potential for dependence are cause for caution. 
Remission rates of PMS are low on cessation of treatment with SSRI.176;177 
Drug Class Drug Dosage 
Antidepressant  Fluoxetine 20mg daily or during luteal phase 
 Sertraline  50-150mg daily or during luteal phase 
 Paroxetine  10-30mg daily or during luteal phase 
 Citalopram  5-20mg daily or during luteal phase 
 Clomipramine  25-75mg daily or during luteal phase 
Anxiolytics  Alprazolam  
Buspirone 
 
Ovarian Suppressants  
(GnRH aginists)   
Buserline 400-900mg/day (intranasal)  
 Leuprolide 3.75-7.5mg/month (intramuscular)  
 Danazol  
Table 5. Pharmacological Interventions to treat PMS or PMDD Supported by Evidence 
 
Oral contraceptives (OCs) have been commonly prescribed by gynecologists and primary 
care clinicians for the treatment of PMS even though there were few studies 
demonstrating their efficacy until recently. Two older randomized controlled trials (RCTs) 
in samples of women with prospectively confirmed PMS reported a lack of efficacy with 
monophasic and triphasic OCs.178;179 Surveys of population cohorts without defined PMS 
or PMDD have reported that OCs do not alter mood in most women, but a subset of 
women report improvement of premenstrual symptoms, and another subset of women 
report the production of negative premenstrual symptoms.180;181 After the introduction in 
the late 1990s of an OC containing ethinyl estradiol 30 μg and a unique progesterone, 
drospirenone 3 mg, improved mood and quality of life during the luteal phase began to 
be reported in nonclinical population cohorts.182-184 In addition, a 6-month extended 
regimen of this OC was reported to be associated with fewer premenstrual emotional and 
physical symptoms than the normal 21/7 monthly administration in women not seeking 
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care for problematic premenstrual symptoms.185 An RCT comparing the OC containing 
ethinyl estradiol 30 μg and drospirenone 3 mg with placebo in 82 women with PMDD 
reported that both the OC and placebo improved most premenstrual symptoms and that 
the OC was significantly more effective than placebo in decreasing food cravings, 
increased appetite and acne only.186 However, 2 recent studies of YAZ (Bayer HealthCare), 
an OC containing ethinyl estradiol 20 μg and drospirenone 3 mg, administered as 24 days 
of active pills followed by a 4-day hormone-free interval (24/4), have reported superiority 
in reducing premenstrual emotional and physical symptoms when compared with 
placebo.187;188 
Yonkers and colleagues187 reported on a parallel design study in which YAZ or placebo was 
administered to 450 women with PMDD over 3 months. Pearlstein and colleagues188 
reported on a crossover design study in which YAZ or placebo was administered to 64 
women with PMDD over 7 months with a middle washout cycle. Both studies reported 
that self-rated symptom, functioning and quality of life measures, along with clinician-
rated symptom and functioning measures, all significantly improved with YAZ in 
comparison with placebo. In both studies, adverse effects that were more common with 
YAZ, compared with placebo, included nausea, intermenstrual bleeding and breast 
pain.187;188 In 2006, YAZ received United States Food and Drug Administration (FDA) 
approval for the treatment of PMDD in women desiring oral contraception. The efficacy 
of this particular OC for reducing premenstrual symptoms may be due to its 
administration in a 24/4 regimen, which provides more stable hormone levels and 
reduces adverse symptoms that can occur during withdrawal bleeding.189;190 Differential 
efficacy of this OC may also be due to the unique anti-mineralocorticoid and anti-
androgenic properties of drospirenone.184;187;188 
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The second line of pharmacological treatment includes hormonal agents. In particular, 
gonadotrophin releasing hormone (GnRH) agonists can temporarily suppress the 
menstrual cycle (often called "medical ovariectomy" or "medical menopause"). In clinical 
trials, GnRH agonists have proven very successful in relieving physical symptom (Table 5). 
Unfortunately, the long-term use of GnRH agonists is limited by the occurrence of side 
effects that mimic menopause and the potential for hypo-oestrogenism and osteoporosis. 
Preliminary evidence suggests that "add-back" therapy with low-dose oestrogen and 
progesterone replacement therapy may prevent some of these side effects.191 Intranasal 
buserelin192;193 or intramuscular leuprolide,194 are the most appropriate GnRH treatments 
for clinical use. In clinical trials, danazol has also been effective,195-199 most recently in the 
treatment of premenstrual mastalgia.200 The final line of treatment is ovariectomy. Two 
open studies have demonstrated the effectiveness of ovariectomy in the complete relief 
of severe premenstrual symptoms.80;81 Oral contraceptives suppress ovulation while 
maintaining menstruation due to periodic withdrawal. 
Women who manifest severe physical symptoms or a psychiatric disorder with 
premenstrual magnification should be treated for their primary condition. Premenstrual 
symptoms usually remit considerably with successful treatment of the primary condition, 
and residual symptoms can be treated as indicated. SSRIs and reproduction. Perhaps the 
most troublesome SSRI side effect for women is sexual dysfunction, defined as "normal 
libido and arousal with delayed or absent orgasm." This side effect can be reduced by 
reducing the dose, taking "drug holidays," substituting another agent or augmenting 
treatment with various agents. 
To date, no single intervention has proven to be equally effective in treating all women 
with severe PMS or PMDD, although SSRIs have demonstrated tolerability and efficacy in 
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more than 60% of patients studied.16;21;201 Patients should be assessed every 2 weeks (i.e., 
during both the follicular and luteal phases) within the first month of commencing 
therapy and instructed to continue to chart their symptoms daily. Dosage strategies vary; 
however, most recent investigations have demonstrated the efficacy of most therapeutic 
drugs at low dosages. If efficacy has not been attained after several increases in dosage, 
other treatment options should be considered. There is also evidence that response will 
be relatively immediate in women with PMS or PMDD; thus, if there is no change in 
symptoms within 2 to 3 menstrual cycles, an alternative therapy should be considered. 
Continued symptom charting helps to track efficacy, symptom response to changes in 
dosage, symptoms upon termination of therapy, and real versus perceived side effects. 
For example, women who report headaches or nausea as side effects are often surprised 
to see that they rated these symptoms as just as severe before commencing therapy. 
Investigators have yet to reach a consensus on how to define efficacy. Clinically, the 
easiest way to define efficacy is by the reduction of luteal symptoms (that is, the luteal 
symptoms remit significantly or the difference between the follicular and luteal phases is 
less than 30%). It has become obvious that intervention alone cannot predict efficacy, and 
more consideration is now being given to psychiatric history as well as to family 
psychiatric history, especially to mood disorders in the families of women with PMDD. 
There are 3 major concerns regarding the prognosis in severe PMS or PMDD: 1) the 
average age of onset is around 26 years, 2) there is evidence that symptoms gradually 
worsen over time, and 3) there is evidence that symptoms recur when treatment is 
halted.16;201  For these reasons, therapeutic goals must be set to ensure maximal safety 
and efficacy for the patient (Figure 5). 
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Figure 5. Possible Treatment Regimen for the Management of Severe PMS (Green top guideline 
no 48) 
 
1.10 RELATIONSHIP OF PMDD TO DEPRESSION 
Features of PMDD and depressive disorders, specifically atypical depression overlap 
considerably. Symptoms of atypical depression (i.e., depressed mood, interpersonal 
rejection hypersensitivity, carbohydrate craving, and hypersomnia) are similar to those of 
PMDD. Thirty to 76 percent of women diagnosed with PMDD have a lifetime history of 
depression,202 compared with 15 percent of women of a similar age without PMDD. A 
family history of depression is common in women diagnosed with moderate to severe 
PMS.16 There is significant co morbidity between depression and PMDD. Like most 
individuals with depression ladies with PMDD also complain of altered cognitive 
functioning during the symptomatic phase.41 While there is growing evidence that PMDD 
and MDD (major depressive disorder) share similar biological underpinnings such as 
serotonergic dysregulation158;159 low plasma gamma-aminobutyric acid levels203, and 
FIRST LINE
•B6 Exercise, cognitive behavioural therapy, vitamin
•Combined new-generation pill, such as Yasmin®, Cilest® (cyclically or continuously)
•Continuous or luteal phase (day 15–28) low-dose SSRIs
SECOND  
LINE
•Estradiol patches (100 micrograms) + oral progestogen such as duphaston 10 mg D17-
D28 or Mirena®
•Higher-dose SSRIs continuously or luteal phase
THIRD LINE
•GnRH analogues + addback HRT (continuous combined estrogen + progestogen or 
tibolone)
FOURTH 
LINE
•Total abdominal hysterectomy and bilateral oophorectomy + HRT (including 
testosterone)
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circadian desynchronization98;204;205, it remains unclear whether observable cognitive and 
behavioural correlates of these substrates exist in PMDD.  
Despite this relationship, many patients with PMDD do not have depressive symptoms; 
therefore, PMDD should not be considered as simply a variant of depressive disorder.206 
The effectiveness of selective serotonin reuptake inhibitors (SSRIs), administered only 
during the luteal phase of the menstrual cycle,129;165-169 highlights the difference between 
PMDD and depressive disorder. 
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CHAPTER 2:  
GENETICS OF PREMENSTRUAL SYNDROME: INVESTIGATION OF 
SPECIFIC SEROTONIN RECEPTORS POLYMORPHISM: 
INTRODUCTION & HYPOTHESIS 
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INTRODUCTION 
2.1 WHAT IS SEROTONIN 
Serotonin or 5-Hydroxytryptamine (5-HT) is a monoamine neurotransmitter that is 
primarily found in the gastrointestinal (GI) tract and central nervous system (CNS) of 
humans and animals. Serotonin was first isolated from blood in 1948 and shortly later 
associated with the nervous system.207 
Approximately 95 percent of the human body's total serotonin is located in the 
enterochromaffin cells in the gut, where it is used to regulate intestinal movements.208 
Out of the remainder, 1% of total body stores is synthesized in serotonergic neurons in 
the CNS where it has various functions, including the regulation of mood, appetite, sleep, 
muscle contraction, and some cognitive functions including memory and learning. 
Modulation of serotonin at synapses is thought to be a major action of several classes of 
pharmacological antidepressants. 
Serotonin secreted from the enterochromaffin cells eventually finds its way out of tissues 
into the blood. There, it is actively taken up by blood platelets, which store it. When the 
platelets bind to a clot, they disgorge serotonin, where it serves as a vasoconstrictor and 
helps to regulate hemostasis and blood clotting. Serotonin also is a growth factor for 
some types of cells, which may give it a role in wound healing. 
Serotonin is eventually metabolized to 5-HIAA by the liver, and excreted by the kidneys. 
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2.2 SEROTONIN PATHWAY 
Not all cells that contain 5-HT synthesize it. For example, platelets do not synthesize 5-HT; 
rather, they accumulate 5-HT from plasma by an active-transport mechanism found on 
the platelet membrane. Certain brain cells do synthesize 5-HT. 
2.2.1 Biosynthesis:  
Serotonin or 5-hydroxytryptamine is synthesized from L-tryptophan. The initial step in the 
synthesis of serotonin is the facilitated transport of the amino acid l-tryptophan from 
blood into brain. The primary source of tryptophan is dietary protein. The daily 
recommended allowance of tryptophan is 200mg. Only the tryptophan which is free and 
unbound to albumin crosses the blood brain barrier. This transport of tryptophan is 
limited by competitive transfer of other neutral amino acids, such as phenylalanine, 
leucine and methionine. The entry of tryptophan into brain is related not only to its 
concentration in blood but is also a competitive relation to the concentrations of other 
neutral amino acids as stated above. Consequently, lowering the dietary intake of 
tryptophan while raising intake of the other amino acids that tryptophan competes with, 
lowers the serotonin content in brain changing certain behaviours associated with 
serotonin function. This method of  reducing the brain content of serotonin has been 
used clinically to evaluate the importance of brain serotonin in the mechanism of action 
of psychotherapeutic drugs.209 Transformation of tryptophan into serotonin involves two 
steps (Figure 6):  
1. Hydroxylation in 5-hydroxytryptophan catalysed by tryptophan hydroxylase, which is 
the rate limiting enzyme of the synthesis. This enzyme requires for its activity the 
presence of tetrahydrobiopterine, oxygen, NADPH2 and a metal, iron or copper. 
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Recently, it has been discovered that there are two TPH enzymes, TPH1 and TPH2, 
which define two independent 5-HT systems 210;211. TPH1 generates more than 95% of 
the bodily 5-HT in the gut, from where it is transported by platelets to all organs 
except the brain since it cannot cross the blood-brain barrier. In the brain, TPH2 is 
exclusively responsible for the first step of 5-HT synthesis 212-214. 
2. Decarboxylation of 5-hydroxytryptophan is catalysed by L-aromatic amino acid 
decarboxylase with pyridoxal-phosphate as coenzyme.  
The combination of the hydroxyl group in the 5th position of the indole nucleus and a 
primary amine nitrogen serving as a proton acceptor at physiological pH makes 5-HT a 
hydrophilic substance. As such, it does not pass the lipophilic blood—brain barrier readily. 
Thus, its discovery in brain indicated that 5-HT is synthesized in brain, where it might play 
an important role in brain function. Various theories have been proposed linking 
abnormalities of 5-HT function to the development of a number of psychiatric disorders, 
particularly schizophrenia and depression. Psychotherapeutic drugs are now available 
that are effective in depression, anxiety disorders and schizophrenia; some of these drugs 
have potent, and in some cases selective, effects on serotonin neurons in brain. 
The other enzyme involved in the synthesis of serotonin, aromatic l-amino acid 
decarboxylase (AADC), is a soluble pyridoxal-5′-phosphate-dependent enzyme which 
converts 5-HTP to 5-HT. It has been demonstrated that administration of pyridoxine 
increases the rate of synthesis of 5-HT in monkey brain, as revealed using position 
emission tomography. This presumably reflects an interesting issue of the use of 
pyridoxine supplementation in situations associated with 5-HT deficiency. 
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Figure 6.  Synthesis of serotonin 
The initial hydroxylation of tryptophan, rather than the decarboxylation of 5-HTP, appears 
to be the rate-limiting step in serotonin synthesis. Evidence in support of this view 
includes the fact that 5-HTP is found only in trace amounts in brain, presumably because 
it is decarboxylated about as rapidly as it is formed. As might be expected if the 
hydroxylation reaction is rate-limiting, inhibition of this reaction results in a marked 
depletion of the content of 5-HT in brain. The enzyme inhibitor most widely used in 
experiments is parachlorophenylalanine (PCPA) by incorporating itself into the enzyme to 
produce an inactive protein. This results in a long-lasting reduction of 5-HT levels.215 
Transformation of serotonin into melatonin, which should not be regarded as a 
degradation pathway because melatonin is also active, is carried out primarily in the 
pineal gland. It involves two steps:  
1. Acetylation of the amine group by N-acetyl transferase leading to N-acetyl-serotonin.  
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2. Methylation of the OH group by 5- hydroxyindole-O-methyltransferase catalysing the 
transfer of a methyl group from S-adenosyl-methionine to obtain acetyl-5-
methoxytryptamine or melatonin.  
The concentration of melatonin in the pineal gland presents circadian variations: it 
follows the variations of N-acetyl transferase activity, increasing during the night and 
decreasing during the day, darkness and light playing a regulatory role via 
catecholamines. Light inhibits melatonin biosynthesis. 
2.2.2 Distribution: 
Serotonin is found in many tissues:  
1. Digestive tract contains about 95% of the total amount of serotonin of the body, 
localized in enterochromaffin cells.  
2. Platelets: practically all blood serotonin (concentration going from 100 to 200 
micrograms per litre) is found in platelets which do not synthesize it, but take it from 
plasma where it is released by these enterochromaffin cells. The uptake of serotonin 
by platelets is very fast and Serotonin released from platelets in plasma has a 
relatively localized effect on the vessels where it is released, for example during 
migraine.  
3. Central nervous system of all species: higher concentrations are found in brainstem 
than in cortex. Serotonin, released by presynaptic serotonergic neurons in synaptic 
clefts, activates specific receptors and is partly reuptaken by presynaptic neurons.  
The neurons of the raphe nuclei are the principal source of 5-HT release in the brain.216 
The raphe nuclei are neurons grouped into about nine pairs and distributed along the 
entire length of the brainstem, centered around the reticular formation. Axons from the 
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neurons of the raphe nuclei form a neurotransmitter system, reaching almost every part 
of the central nervous system. Axons of neurons in the lower raphe nuclei terminate in 
the cerebellum and spinal cord while the axons of the higher nuclei spread out in the 
entire brain. 
Serotonin is released into the space between neurons, and diffuses over a relatively wide 
gap (>20 µm) to activate 5-HT receptors located on the dendrites, cell bodies and 
presynaptic terminals of adjacent neurons. 
5-HT receptors are the receptors for serotonin. They are located on the cell membrane of 
nerve cells and other cell types in animals and mediate the effects of serotonin as the 
endogenous ligand and of a broad range of pharmaceutical and hallucinogenic drugs. 
With the exception of the 5-HT3 receptor, a ligand gated ion channel, all other 5-HT 
receptors are G protein coupled seven transmembrane (or heptahelical) receptors that 
activate an intracellular second messenger cascade cAMP.217 
Serotonergic action is terminated primarily via uptake of 5-HT from the synapse. This is 
through the specific monoamine transporter for 5-HT, SERT, on the presynaptic neuron 
(Figure 7). Various agents can inhibit 5-HT reuptake including MDMA (ecstasy), 
amphetamine, cocaine, dextromethorphan (an antitussive), tricyclic antidepressants 
(TCAs) and selective serotonin reuptake inhibitors (SSRIs). 5-HT clearance may also be 
monoamine transporter, known as PMAT.218  
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Figure 7. Schematic diagram of 5-HT metabolism 
The half-life of serotonin is long in platelets and intestine, and very short, a few minutes, 
in the brain. The concentration of a compound in an organ, static view of a dynamic 
phenomenon, is not necessarily a good representation of metabolic activity and turn-
over.  
Melatonin found in plasma is released from the pineal gland. Its plasma concentration 
decreases during ageing. 
2.2.3 Inactivation 
Serotonin is converted into inactive molecules by biotransformation in the liver. 
Oxydative deamination of the lateral amino chain by monoamine oxidase, leads to 5-
hydroxy-indol-acetaldehyde which is then oxidized into 5-hydroxy-indol-acetic acid (5-
HIAA). 5-HIAA is excreted from the kidneys in urines in quantities normally lower than 10 
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mg/24 h (Figure 8). Low levels of 5-HIAA are found in the CSF of patients with personality 
disorders, anxiety, suicide and other psychiatric problems.219;220 
 
 
 
Figure 8.  Serotonin Metabolism 
 
 
2.3 OVARIAN STEROIDS AND SEROTONERGIC PATHWAY  
Many studies have shown that Oestrogen and Progesterone are neuroprotective.221;222 
Gonadal steroids have shown to play a role in all stages of neural development including 
survival and death.223 
The receptors for the gonadal steroids modulate the synthesis of the enzymes and 
receptor proteins for many neurotransmitters and neuropeptides.224 Serotonin neurons 
contain oestrogen receptor-β225 and progestin receptors. Oestrogen and progesterone 
regulate gene and protein expression in serotonin neurons in a manner that would 
increase serotonin production, increase serotonin turnover, increase serotonin neural 
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firing and decrease serotonin degradation.226-228 The protein receptors for the 17β 
Estradiol and progesterone are located in the cell nucleus of the dorsal raphe, 
hypothalamus and limbic areas.229;230 Hence these receptors function as the transcription 
factors and modulate gene expression related to serotonin and serotonin receptors.227;231 
Recently a study on macaques showed the mRNA for tryptophan hydroxylase (TPH), the 
committal enzyme in serotonin synthesis, increased significantly with the Oestrogen 
treatment and remained elevated when the progesterone was added to the Oestrogen 
regimen. Serotonin reuptake transporter (SERT) mRNA decreased significantly with the 
oestrogen treatment and addition of progesterone had no further effect.227 
There is enough evidence to show that oestrogen stimulates serotonin neurons and 
down-regulates the expression and activity of 5-HT1A autoreceptors.227;228;232 There is a 
sex difference on the effect of steroids on the 5-HT1A receptor and hence more release of 
serotonin in females in response to some medications.233   
Studies designed to identify the chemical messenger in the CNS that mediate Oestrogen 
control of the serotonin of pituitary gonadotrophin led to the discovery that Oestrogen 
increases the density in forebrain of the serotonin 2A receptor. The ERβ in the, 
hypothalamus, periventricular nuclei and supraoptic nucleus234 have been shown to 
increase the density of  5HT2A receptors in this area involved in mood and reproductive 
status.235 The density of these receptors has been shown to especially increase during the 
Oestrogen induced LH surge and this response has been shown to be absent following 
ovariectomy236  and reversing with Oestrogen replacement.237 This receptor has been 
implicated in mood disorders as well as in schizophrenia. 
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Together this data indicate that ovarian hormones and their synthetic analogues could 
modify cognitive and autonomic neural functions by acting on the serotonin neural 
pathway. 
2.4 PMS/PMDD AND ABNORMALITIES OF SEROTONERGIC PATHWAY 
Many studies have identified various abnormalities in the serotonin system in women 
with PMS and PMDD. These include abnormal levels of whole blood serotonin, serotonin 
platelet uptake and platelet tritiated imipramine binding; abnormal responses to 
serotonergic probes such as L-tryptophan, buspirone, metachlorophenylpiperazine and 
fenfluramine; and exacerbation of premenstrual symptoms after metergoline or 
tryptophan depletion.25;55;238  
A review article by Halbreich U et.al (1993) the data presented suggested that 
postsynaptic serotnergic responsivity might be altered during the late-luteal-
premenstrual phase of the menstrual cycle.239 Some serotonergic functions of the women 
with PMS might be altered during the entire cycle and be associated with a vulnerability 
trait. It is shown that gonadal hormones might change the activity of 5-HT systems as part 
of a multidimensional interactive system. 
Inoue Y et.al (2007) showed the serotonergic function in the follicular phase was higher in 
PMDD subjects but lower in luteal phase compared to women with PMS without PMDD 
and normal controls.240 Hence suggesting that PMDD women have fluctuating 
serotonergic function across their menstrual cycles and that the pattern may be different 
from PMS without PMDD. 
   Several studies have also suggested that women with PMDD have decreased luteal-
phase levels of GABA, abnormal ALLO levels and decreased luteal-phase sensitivity of the 
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GABAA receptor.25;56;71;182 Imaging studies have reported altered serotonin function241;242 
and altered GABAergic function243;244 in women with PMDD when compared with healthy 
control subjects. It is possible that the rapid efficacy of selective serotonin reuptake 
inhibitors (SSRIs) in PMDD may be due in part to their ability to increase ALLO levels in the 
brain and enhance GABAA receptor function.245 Alternative hypotheses for the fast action 
of SSRIs in PMDD include enhanced function of 5-HT2C receptors246 and inhibition of the 
serotonin transporter with resulting decreased LH production.247 It has also been 
hypothesized that the increase in ALLO after SSRI administration underlies the 
improvement in depressive symptoms of MDD in both sexes.248-250 PMDD subjects 
showed higher serotonergic function in follicular phase but lower serotonergic function in 
luteal phase, compared with women with PMS without PMDD and normal controls. Thus 
we can conclude that women with PMDD have fluctuating serotonergic function across 
their menstrual cycles and their pattern may be different from PMS without PMDD. 240 
 
2.5 SEROTONIN RECEPTORS 
The initial suggestion that there might be more than one type of receptor for serotonin 
came from experiments on the isolated guinea pig ileum. In the 1970s, the development 
of radioligand-binding assays furthered our understanding of subtypes of receptors for 
serotonin. Bradley and associates in 1986 proposed a classification scheme with three 
major types of receptors for serotonin, using pharmacological criteria and functional 
responses primarily in peripheral tissues. 207 The receptors were called “5-HT1-like,” 5-HT2 
and 5-HT3. 
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Molecular biological techniques have led to the rapid discovery of additional serotonin-
receptor subtypes and their properties. The current classification scheme is based on 
operational criteria, such as drug-related characteristics and intracellular signal-
transduction mechanisms and amino acid sequence of the receptor protein. The study of 
these receptor protein have been carried out by localising the protein  by the use of 
antibodies (immunocytochemistry), its mRNA could be detected (in situ hybridization), or, 
it could be localized by virtue of its binding by a radiolabeled ligand (receptor 
autoradiography). Each of these methods provides a distinct class of information. 
Modern Serotonin Receptor Classification and Subtypes251 show there are three serotonin 
receptor subfamilies, the 5-HT1 family; the 5-HT2 family; and the family that includes the 
5-HT4, 5-ht6 and 5-HT7 receptors, represent the three major classes of serotonin receptor 
that are members of the G protein-coupled receptor superfamily. Unlike the 5HT1 and 
5HT2 families which inhibit the adenylate cyclase activity, the 5HT4, 5HT6 and 5HT7 
stimulate adenylate cyclase.  The 5-HT3 receptor is a ligand-gated ion channel and is a 
separate subfamily. Although each serotonin receptor can be activated potently by 
serotonin, differences in signal-transduction mechanisms, neuroanatomical distribution 
and affinities for synthetic chemicals create opportunities for drug discovery and make 
each serotonin receptor subtype a potential therapeutic target. The most important and 
well-studied are 5-HT1A, 5-HT2A, 5-HT2C for mood regulation.252;253 
2.5.1 The 5-HT1 Receptor Family 
The 5-HT1 receptor family contains receptors that are negatively coupled to adenylyl 
cyclase and includes the 5-HT1A, 5-HT1B, 5-HT1D, 5-ht1E and 5-ht1F receptors.251  
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The 5-HT1A receptor is coupled via G proteins to two distinct effector systems: (i) 
inhibition of adenylyl cyclase activity and (ii) the opening of K+ channels, which results in 
neuronal hyperpolarization. In terminal field areas of serotonergic innervation, such as 
the hippocampus, 5-HT1A receptors are coupled to both effector systems (Table 6). 
However, in the dorsal raphe nucleus, 5-HT1A receptors are coupled only to the opening 
of potassium channels. 5-HT1A receptors are present in high density in the hippocampus, 
septum, amygdala, hypothalamus and neocortex (Table 6). Destruction of serotonergic 
neurons with the neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) does not reduce 5-HT1A 
receptor number in forebrain areas, indicating that 5-HT1A receptors are located 
postsynaptically in these brain regions. Many of these serotonergic terminal field areas 
are components of the limbic system, the pathway thought to be involved in the 
modulation of emotion. This indicates that the reported effects of 5-HT or serotonergic 
drugs on emotional states could be mediated by 5-HT1A receptors.254 The presence of 5-
HT1A receptors in the neocortex suggests that this receptor also may be involved in 
cognitive or integrative functions of the cortex. 5-HT1A receptors are also present in high 
density in serotonergic cell body areas, in particular the dorsal and median raphe nuclei, 
where they function as somatodendritic auto receptors, modulating the activity of 
serotonergic neurons. Activation of these auto receptors causes a decrease in the rate of 
firing of serotonergic neurons and a reduction in the release of 5-HT from serotonergic 
terminals. Neurotoxin-induced destruction of serotonergic cell bodies dramatically 
reduces the number of 5-HT1A receptors in these areas, consistent with their location on 
serotonergic soma. 
The 5-HT1B and 5-HT1D receptor subtypes are also linked to inhibition of adenyl cyclase 
activity (table 6). In the substantia nigra, where a high density of 5-HT1B or 5-HT1D 
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receptors has been demonstrated by radioligand-binding studies, these serotonin 
receptors are linked to the inhibition of adenylyl cyclase through a G protein. 
Although biochemical, pharmacological and functional data suggest that the 5-HT1B 
receptor found in rats and mice and the 5-HT1D receptor found in other species, including 
humans, are functionally equivalent species homologs, the story has been complicated 
somewhat by the discovery of two genes encoding the human 5-HT1D receptor, 5-HT1Dα 
and 5-HT1Dβ.251 Radioligand-binding studies currently do not allow the differentiation of 5-
HT1Dα and 5-HT1Dβ receptors, and the binding profiles of these receptor subtypes match 
the previously described 5-HT1D-binding site Because there are no compounds currently 
available to differentiate between the 5-HT1Dα and the 5-HT1Dβ receptors, they are 
referred to as 5-HT1D.  
The 5-HT1B receptor in rats and mice and the 5-HT1D receptor in bovine and human brain 
are located in high density in the basal ganglia, particularly in the globus pallidus and the 
substantia nigra (Table 6). Functional studies indicate that the 5-HT1B and 5-HT1D 
receptors are located on presynaptic terminals of serotonergic neurons and modulate the 
release of serotonin. Release of 5-HT from the dorsal raphe nucleus also appears to be 
under the control of 5-HT1B/1D receptors, although it is unclear whether these receptors 
are located on serotonergic terminals or cell bodies. The 5-HT1B and 5-HT1D receptors 
also are located postsynaptically, where they may modulate the release of other 
neurotransmitters, such as acetylcholine (ACh) in the hippocampus and DA in the 
prefrontal cortex. The presence of these receptors in high density in the basal ganglia 
raises the interesting possibility that they may play a role in diseases of the brain which 
involve the basal ganglia, such as Parkinson's disease. 
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The 5-ht1E receptor originally was identified in homogenates of human frontal cortex by 
radioligand-binding studies with [3H]5-HT in the presence of 5-carboxamidotryptamine (5-
CT) to block 5-HT1A and 5-HT1D receptor sites. Because of the lack of specific radioligands 
for the 5-ht1E receptor, the overall distribution in brain is unknown.  
With the cloning of the various subtypes of receptors for serotonin, knowledge of 
receptor sequences has been used to generate radioactive probes for mRNAs encoding 
individual serotonin receptor subtypes. Using in situ hybridization histochemistry, the 
localization of these mRNAs and, thus, the distribution of cells expressing the mRNAs for 
serotonin receptors can be established in brain. 5-ht1E receptor mRNA has been found in 
the caudate putamen, parietal cortex and olfactory tubercle.255 The function of the 5-ht1E 
receptor in intact tissue is not known due to the lack of selective agonists or antagonists. 
In transfected cells, the 5ht1E receptor is coupled to the inhibition of adenylyl cyclase 
activity. The 5-ht1E receptor displays a higher degree of homology with the 5-HT1D 
receptor (64%) than any other 5-HT1 receptors.251 
The 5-HT1F receptor was cloned and sequenced in 1993 and shares the greatest sequence 
homology with the 5-ht1E receptor (61%). 5-ht1F receptor mRNA is found in cortex, 
hippocampus, dentate gyrus, nucleus of the solitary tract, spinal cord, trigeminal ganglion 
neurons, uterus and mesentery. In transfected cells, the 5-ht1F receptor is coupled to the 
inhibition of adenylyl cyclase.251 Because selective agonists or antagonists for the 5-ht1F 
receptor have not been available until very recently, little is known about the distribution 
or function of the 5-ht1F receptor in brain. The selective agonist radioligand has been used 
to demonstrate the presence of 5-ht1F receptor sites in cortex, striatum, hippocampus 
and olfactory bulb. Activation of 5-ht1F receptors in vivo inhibits neurogenic dural 
inflammation and dural protein extravasation. 
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2.5.2 The 5-HT2 Receptor Family 
The 5-HT2 receptor family includes the 5-HT2A, 5-HT2B and 5-HT2C (formerly the 5-HT1C) 
receptor subtypes. 5-HT2A receptor-mediated stimulation of phosphoinositide hydrolysis 
has been well characterized in cerebral cortex and the choroid plexus (table5). Activation 
of 5-HT2A receptors also mediates neuronal depolarization, a result of the closing of 
potassium channels.  
Cloning of the 5-HT2A receptor has been used to gain insight into a controversy over the 
nature of agonist binding to the 5-HT2A receptor. A single gene produces a protein with 
two separate binding sites, 5-HT2A receptor antagonist [3H]ketanserin and the 5-HT2 
receptor agonist [3H]DOB substantiating the view that agonist and antagonist binding are 
to different states, rather than to two different subtypes, of the 5-HT2A receptor. 
A high density of 5-HT2A receptors is found in many cortical areas. These receptors are 
particularly concentrated in the frontal cortex. 5-HT2A receptors also are found in high 
density in the claustrum, a region which is connected to the visual cortex; in parts of the 
limbic system; and in the basal ganglia and the olfactory nuclei (Table 6). 
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FAMILY MECHANISM POTENTIAL SUBTYPE MAIN 
SIGNALLING 
PATHWAY 
MAIN EXPRESSION SITES IN 
CNS 
KNOCK OUT PHENOTYPE 
 
 
 
 
 
 
 
 
5-HT1 
 
 
 
 
 
 
 
 
↓ cAMP 
 
 
 
 
 
 
 
 
Inhibitory 
5HT1A Gi/oAC i Widespread in brain (mainly 
hippocampus,cortex, raphe nuclei) 
Increased anxiety, 
Antidepressant-like phenotype Cognitive 
impairment  
5HT1B Gi/oAC i  
 
Widespread in brain (mainly basal ganglia, 
cortex) 
 
Increased aggression  
Decreased anxiety, 
Enhanced learning performance , Enhanced 
cocaine response  
5HT1D Gi/oAC i  Basal ganglia, hippocampus, cortex  
5HT1E Gi/oAC i  
 
Cortex, caudate putamen, claustrum (not existing in mice) 
 
5HT1F Gi/oAC i Dorsal raphe nucleus, hippocampus, cortex, 
claustrum, caudate nucleus, brainstem 
 
 
 
 
 
5-HT2 
 
 
 
 
↑ IP3, ↑DAG 
 
 
 
 
Excitatory 
5HT2A Gq/11 PLC s  
 
Cortex, claustrum, hippocampus, 
hypothalamus, basal ganglia 
Decreased anxiety   
 
5HT2B Gq/11 PLC s  
 
Cerebellum, septum, hypothalamus, 
amygdala 
 
5HT2C Gq/11 PLC s  
 
Choroid plexus, cortex, hippocampus, 
amygdala, striatum, substantia nigra 
Increased appetite, overweight  
Spontaneous convulsions  
Cognitive impairment  
Enhanced cocaine response 
 
5-HT3 
 
Depolarising 
plasma membrane 
 
 
Excitatory 
5-HT3A with 
5-HT3B,C,D, 
And E 
Ligand gated Na+ 
and K+ channel 
Widespread in brain (mainly area postrema, 
nucleus tractus solitarius, dorsal vagal 
complex, limbic structures) 
Reduced pain perception 
(5-HT3A)  
5-HT4 ↑cAMP Excitatory 5HT4 GsAC s Basal ganglia, cortex, septum, hippocampus Decreased stress response,  Increased 
convulsive response  
 
5-HT5 
 
↓ cAMP 
 
Inhibitory 
5HT5A  
 
Gi/oAC i Hippocampus, hypothalamus, olfactory 
bulb, cortex, thalamus, striatum, pons 
Increased exploratory activity, Altered LSD 
response  
5HT5B  
  
? Habenula, raphe nuclei, hippocampus(in 
rodents); pseudogene (in humans) 
 
5-HT6 ↑cAMP Excitatory 5HT6 
 
GsAC s  Widespread in brain (mainly 
striatum,amygdala, hippocampus, cortex) 
Altered alcohol response 
5-HT7 ↑cAMP Excitatory 5HT7 
 
GsAC s  Thalamus, hippocampus, cortex, amygdala, 
suprachiasmatic nucleus 
 
Antidepressant-like phenotype Disturbed 
circadian rhythms, Disturbed 
thermoregulation 
Table 6: Serotonin receptors Classification and Subtypes
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5-HT2A receptors in the cortex are thought to be located postsynaptically on intrinsic 
cortical neurons as destruction of projections to the cortex does not reduce 5-HT2A 
receptors. Because of the lack of selective agonists to differentiate between members of 
the 5-HT2 receptor family, many of the functional and clinical correlates of the 5-HT2A 
receptor may very well involve or be attributed to the 5-HT2C receptor. 
Although the 5-HT2B receptor is the most recently cloned of the 5-HT2 receptor class, it 
was among the first of the serotonin receptors to be characterized using pharmacological 
criteria. The first report of the sensitivity of rat stomach fundus to serotonin was 
published by Vane in 1959. This receptor, whose activation results in the contraction of 
fundus smooth muscle, originally was placed in the 5-HT1 receptor class by Bradley and 
associates207 because of its sensitivity to serotonin and because responses mediated by it 
were not blocked by 5-HT2 or 5-HT3 receptor antagonists. It has been reclassified as a 5-
HT2 receptor because of its similar pharmacological profile to the 5-HT2C receptor. The 
recombinant receptor expressed in clonal cells is coupled to the stimulation of inositol 
lipid hydrolysis. However, in rat stomach fundus, the 5-HT2B appears not to be coupled to 
phosphoinositide hydrolysis. 5-HT2B receptor-mediated contraction of rat stomach fundus 
is dependent on the influx of calcium through voltage-sensitive channels, intracellular 
calcium release and activation of PKC.256 The effector system to which this receptor is 
coupled in the CNS remains to be established. In humans, 5-HT2B receptor mRNA has been 
found peripherally and in cerebellum, cerebral cortex, amygdala, substantia nigra, 
caudate, thalamus, hypothalamus and retina. 251 
5-HT2C receptors are present in high density in the choroid plexus. High-resolution 
autoradiography has shown that they are enriched on the epithelial cells of the choroid 
plexus. It has been proposed that 5-HT-induced activation of 5-HT2C receptors could 
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regulate the composition and volume of the cerebrospinal fluid. 5-HT2C receptors also are 
found throughout the brain, particularly in areas of the limbic system, including the 
hypothalamus, hippocampus, septum, neocortex and regions associated with motor 
behaviour, including the substantia nigra and globus pallidus. 5-HT2C receptors are 
present in much lower concentrations in these areas than in the choroid plexus (Table 6).  
5-HT2C receptor gene are widely located in the brain and have been shown to be involved 
in the regulation of endocrine responses, including the production and secretion of 
adrenocorticotropic hormone (ACTH)257, Oxytocin258  and Prolactin.259 
2.5.3 The 5-HT3 Receptor 
The 5-HT3 receptor belongs to the ligand-gated ion channel superfamily. The 5-HT3 
receptor is a serotonin-gated cation channel that causes the rapid depolarization of 
neurons (Table 6). The depolarization mediated by 5-HT3 receptors is caused by a 
transient inward current, specifically the opening of a channel for cations. A single subunit 
of the 5-HT3 receptor, the 5-HT3-A receptor subunit, has been cloned. An alternatively 
spliced variant, the 5-HT3-As receptor subunit, has been identified in mouse, rat and 
human. The cloned receptor subunit exhibits sequence similarity to the α subunit of the 
nicotinic acetylcholine receptor and to the β1 subunit of the GABAA receptor. It is not 
known whether the native 5-HT3 receptor is composed of this single subunit or several 
different subunits. Although single subunits of members of the ligand-gated ion channel 
receptor family can form functional receptors, they generally lack some of the properties 
of the native, multisubunit receptor. The cloned subunit of the 5-HT3 receptor has been 
studied in Xenopus oocytes injected with mRNA encoding this receptor. Although the 
expressed 5-HT3-A and 5-HT3-As receptors are functional, they do not display all of the 
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characteristics of native 5-HT3 receptors. The 5-HT3 receptor, like other members of the 
ligand-gated ion channel superfamily, appears to possess additional pharmacologically 
distinct recognition sites for alcohols and anesthetic agents, by which the function of this 
receptor can be allosterically modulated.260 
5-HT3 receptors initially appeared to be confined to peripheral neurons, where they 
mediate depolarizing actions of 5-HT and modulate neurotransmitter release. 5-HT3 
receptors are found in high density in peripheral ganglia and nerves, including the 
superior cervical ganglion and vagus nerve, as well as in the substantia gelatinosa of the 
spinal cord. Their localization in spinal cord and medulla suggests that 5-HT could 
modulate nociceptive mechanisms via the 5-HT3 receptor. 5-HT3 receptors facilitate the 
release of substance P in the spinal cord.261 The localization of 5-HT3 receptor-binding 
sites in cortical and limbic areas of the brain is consistent with behavioural studies in 
animals which suggest that 5-HT3 receptor antagonists may have potential anxiolytic, 
antidepressant and cognitive effects. 5-HT3 receptors are located postsynaptically, where 
they modulate the release of neurotransmitters such as ACh or DA. 5-HT3 receptors 
modulate the activity of dopaminergic neurons in the ventral tegmental area. In the 
cortex and hippocampus, the majority of neurons expressing 5-HT3 receptor mRNA are 
GABAergic. The highest density of 5-HT3 receptor sites in the brain is in the area 
postrema, the site of the chemoreceptor trigger zone (Table 6). 
2.5.4 The 5-HT4 , 5-ht6 and 5-HT7 receptors 
5-HT4 , 5-ht6 and 5-HT7 receptors are included in a family of serotonin receptors coupled 
to the stimulation of adenylyl cyclase. The 5-HT4 receptor originally was described in 
cultured murine collicular neurons as a serotonin receptor coupled to the stimulation of 
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adenylyl cyclase activity, possessing pharmacological characteristics distinct from those of 
the 5-HT1, 5-HT2 or 5-HT3 receptors. The 5-HT4 receptor gene has been cloned from rat 
brain RNA by reverse transcriptase (RT)-PCR.262 Two different cDNA clones, the long 
isoform, 5.5-kb 5-HT41, and the short isoform, 4.5-kb 5-HT4s, have been isolated and are 
most likely the result of alternative splicing of 5-HT4 receptor mRNA. 
Studies of the 5-HT4 receptor, originally characterized by measuring cAMP production in 
cultured mouse collicular neurons, have been hampered by the absence of a high-affinity 
radioligand. The synthesis and development of specific radioligands, [3H]GR 113808 and 
[125I]SB 207710, have provided the necessary tools for the study and characterization of 
the 5-HT4 receptor. 5-HT4 receptor binding sites are localized with high densities in the 
striatum, substantia nigra and olfactory tubercle and have been reported in the 
hippocampus as well (Table 6). The 5-HT4 receptor indirectly mediates the enhancement 
of striatal DA release by 5-HT, although 5-HT4 receptors do not appear to be located on 
striatal DA terminals. In the alimentary tract, 5-HT4 receptors are located on neurons, for 
example, the myenteric plexus of the ileum, smooth muscle cells and secretory cells, 
where they evoke secretions and the peristaltic reflex. 
 
The 5-ht6 receptor is approximately 30% homologous to other serotonin receptors. When 
expressed in transfected cells, it shows high affinity for [125I]LSD and [3H]5-HT. The 
pharmacology of this recombinant receptor is unique. Interestingly, this receptor has high 
affinity for various antipsychotic and antidepressant drugs, such as clozapine, 
amitriptyline, clomipramine, mianserin and ritanserin. The 5-ht6 receptor stimulates 
adenylyl cyclase when expressed in some, but not all, cell systems. The function of the 5-
ht6 receptor in intact tissue has not been characterized due to the lack of selective 
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agonists or antagonists. Expression of 5-ht6 receptor mRNA has been detected in the 
striatum, nucleus accumbens, olfactory tubercle, hippocampus and cerebral cortex.251 
The 5-HT7 receptors are widely expressed in central nervous system and peripheral 
tissues including human vascular smooth muscle cells.263-265  There are at least four 5-HT7 
receptor isoforms that are produced by alternative splicing266, but the differences in their 
pharmacological profiles are not yet known. Studies have provided evidence that 5-HT7 
receptors may be involved in the regulation of emotions, thermoregulations, circadian 
rhythmicity, memory process and smooth muscle relaxation.267;268  
5-HT7 receptor-binding sites in the rat brain have been described using receptor 
autoradiography in layers 1–3 of the cortex, septum, thalamus, hypothalamus, amygdala 
and superior colliculus269 (Table). The 5-HT7 receptor has been suggested as a target for 
treating depression since inactivation or blockade of the receptor has an antidepressant-
like behavioural effect.270 A putative neuroendocrine role for 5-HT7 receptors has also 
been suggested in immortalized hypothalamic neurones in culture (GT-1 cells), where 
they were directly involved in the 5-HT-induced release of luteinizing hormone-releasing 
hormone.271 It was also shown that the effect of 5-HT on aldosterone secretion in rat 
adrenal glands is mediated by 5-HT7 receptors.272 
2.5.5 The 5-ht5A and 5-HT5B receptors 
The 5-ht5A and 5-HT5B receptors may constitute a new family of serotonin receptors 
mainly found in the central nervous system. The receptor proteins are 77% identical to 
each other, whereas the homology to other serotonin receptors is low. The 5-HT(5) 
receptors remain as two of the least studied and understood receptor subtypes. 
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5-ht5A receptor mRNA transcripts have been detected by in situ hybridization in the 
cerebral cortex, hippocampus, granule cells of the cerebellum, medial habenula, 
amygdala, septum, several thalamic nuclei and olfactory bulb of the rat, mouse and 
human. The 5-ht5A gene was located  on human chromosome 7 (position 7q36). 5-HT5B 
mRNA has been detected by in situ hybridization in the hippocampus, habenula and the 
dorsal raphe nucleus of rat and is the first example of a brain-specific protein that is 
absent in human.251 
The 5-ht5A receptor has been demonstrated to couple to G proteins through Gi/o to 
inhibit adenylyl cyclase activity.273 At the present time, the functional correlate and 
transductional properties are unknown for the 5-HT5B receptor. 
Few recent studies implicate 5-ht5A receptor may control the circadian rhythms, mood 
and cognitive function from brain localisation and functional studies, whilst gene 
association studies implicate the receptor in the aetiology of schizophrenia. Much is still 
to be learnt about the function of the 5-ht5A receptor and selective ligands may show 
utility in psychiatric disorders 
HYPOTHESIS: 
Premenstrual Dysphoric Disorder like many other psychiatric and behavioural disorders is 
complex and multifactorial.274 From our literature review we have gathered strong 
evidence supporting serotonin dysregulation in PMS94;275-278 with ovulatory progesterone 
or progestogens providing the trigger.227;279 This is further emphasised by the fact that 
serotonin selective reuptake inhibitor (SSRIs) are an effective and acceptable first-line 
treatment for severe PMS.154;280-287 Evidence from family and twin studies suggests that 
PMDD is in total or in part genetically determined as well.288-290 It may be associated with 
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a single or multiple genetic cause in combination with environmental and lifestyle 
factors.290 Initial studies of key polymorphisms of genes regulating the synthesis 
(tryptophan hydroxylase 1), membrane reuptake (serotonin transporter), and catabolism 
(monoamineoxidase A) of serotonin failed to demonstrate a significant association 
between genotype and premenstrual dysphoria.291;292  
With the convincing evidence that PMS is inheritable and that serotonin is important in 
the pathogenesis of PMS, we are convinced that one of the polymorphisms in the genes 
involved in the biosynthesis of Serotonin maybe related to PMDD. Furthermore, failed 
initial studies on the synthesis, reuptake and catabolism of serotonin, we can hypothesise 
that functional polymorphisms of the serotonin receptor genes are involved in the 
pathogenesis of Premenstrual Dysphoric Disorder.  
AIM: 
The aim of this study falls under two broad categories:  
A) Using Bioinformatics to identify the evolutionary relationship between the various 
serotonin receptors and their subtypes by drawing the phylogenetic tree and delineating 
the primary, secondary and tertiary structures of the receptors we aim to select the most 
likely candidate genes to regulate serotonergic receptors’ function. 
B) Apply genomic techniques to investigate any association between commonly known 
polymorphic genotypes in the identified candidate genes and the Premenstrual Dysphoric 
Disorder phenotype. 
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Summary Of Study Protocol 
• Prospective clinical categorisation
• Anonymised blood sample
• DNA Extraction
• PCR for GAPDH Housekeeping gene 
• PCR for Polymorphisms 
• Restriction Digests
• Genotyping by two independent assessors
• Statistical Analyses 
• Conclusion
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CHAPTER 3:  
GENETICS OF PREMENSTRUAL SYNDROME: INVESTIGATION OF 
SPECIFIC SEROTONIN RECEPTORS POLYMORPHISM: 
BIOINFORMATICS
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3.1 AIM 
I am interested in learning about the evolutionary science and the structural relationship 
in between the Serotonin receptor proteins using Bioinformatics. Serotonin is a 
neurotransmitter which plays an important role in a number of physiological and 
pathological processes in many organs.293 Serotonin functions through one of the seven 
different types of receptors    5-HT1-7, grouped on the basis of sequence identity and on 
the nature of the second-messenger systems to which they are coupled.294 Apart from 
5HT3 receptor, which are inotropic all other receptors are G protein coupled receptors.  In 
the brain the function of these 5-HT receptors can be associated with various overlapping 
functions.   
My aim is firstly to understand the function of serotonin receptors and similarity if any 
between them. We are going to be investigating the human serotonin receptor 
phylogeny. Secondly, knowing a protein's 3-dimensional structure helps us to understand 
its functionality and provides means for planning experiments and drug design. To 
achieve this, first we will use phylogenetic analysis to examine the relationship between 
the sequences of various serotonin receptors including 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-
HT1F, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3A, 5-HT3B, 5-HT3C, 5-HT3D, 5-HT3E, 5-HT4, 5-HT5, 5-HT6, 
and 5-HT7 using various bioinformatics tools. Here we assume the fact that homologous 
sequences are evolutionarily related. 
Then we will predict and provide the transmembrane structure using the TMFMM 
method and the secondary and tertiary structure for the serotonin receptors. 
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3.2 METHODOLOGY and RESULTS 
3.2.1 PHYLOGENETIC ANALYSIS: The evolutionary relationship between the serotonin 
receptors 
Raw Sequence Data: The first step in constructing a tree is building the dataset, this 
means finding and retrieving sequences from the public domain.  
Protein sequence for various serotonin receptors was retrieved using Protein database 
BLAST in NCBI (FATSA). http://www.ncbi.nlm.nih.gov/sites/entrez. It is the most 
commonly used database search tool. (Appendices 1) 
Alignment 
Alignment of serotonin receptor protein sequences was done using ClustalX 
(http://www.clustal.org/download/current/clustalx-2.0.12-win.msi ). The default 
alignment parameters were applied. Clustal295 X is a windows interface for the Clustal W 
multiple sequence alignment program and performs multiple sequence and profile 
alignments and analyses the results.296 The sequence alignment is displayed in a window 
on the screen. Usually manual alignment is advocated.297 Clustal X is formatted as PHYLIP 
tree file and can be imported into other tree drawing programs.  
Annotation 
The aligned sequence are annotated using CHROMA. The programme can be downloaded 
from (http://www.llew.org.uk/chroma/download/CHROMA.msi). Chromatic 
Representation of Multiple Alignments (CHROMA) is a tool for generating annotated 
multiple sequence alignments in a convenient format for publication. CHROMA runs only 
under Microsoft windows operating systems. 
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Alignment of serotonin receptor protein sequencing was done using ClustalX and the 
aligned sequences are annotated using CHROMA. (Appendices 2) 
Generation of Phylogenetic Tree: 
The alignment from ClustalX was viewed using Seaview (http://pbil.univ-
lyon1.fr/software/seaview.html) here we aligned the sequence and then made the tree 
using Phyml (maximum length) by bootstapping 100 replicates, the file was saved as 
unrooted tree. This tree was opened using fig tree. The tree used to guide the final 
multiple alignment process are calculated from the distance matrix using the neighbour 
joining method.298 This produces the unrooted trees with branch lengths proportionate to 
the estimated divergence along each branch. The root is placed by a pinpoint method.299 
Trees generated showing all the serotonin receptors is shown in (Figure 9).  
Even though the phylogentetic tree for all serotonin receptors most likely shows a 
Common Evolutionary Ancestors ‘Divergent Evolution’, that is one serotonin receptor 
gene dividing to give many receptors types but all bind to one common serotonin 
ancestor. Sequences that are the most closely related are drawn as neighbouring 
branches on a tree.  The phylogenetic analysis can help determine which genes are likely 
to have equivalent functions. 
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Figure 9.  Phylogenetic tree for serotonin receptors  
 
Phylogenetic Analysis of the Two Families of Serotonin Receptors done Separately : 
It becomes increasingly difficult to find good alignments and to evaluate all the receptors 
simultaneously as more divergent sequences were included. Also in view of the large 
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distance in between 5-HT3 receptors and others, the phylogenetic trees for the two 
groups were dealt with separately. 
Alignment of serotonin receptors 5-HT1,2,4,5,6,7 protein sequences was done using 
ClustalX and the aligned sequence are annotated using CHROMA (Appendices 3). 
Tree generated for the 5-HT1,2,4,5,6,7 receptors (Figure 10) 
Figure 10: Phylogenetic tree for Serotonin Receptors  
 
Alignment of serotonin receptors 5-HT3 protein sequences was done using ClustalX and 
the aligned sequence are annotated using CHROMA (Appendices 4)  Tree generated for 5-
HT3 receptor subtypes (Figure 11) 
The alignment was impossible to improve by eye when 5HT3 receptor was considered 
separately to other receptors; hence a useful result was achieved. 
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Figure 11: Phylogenetic tree for Serotonin Receptors  
3.2.2 PROTEIN STRUCTURE: Prediction of the serotonin receptors structure 
Structure of various receptors makes them capable of transducing an extracellular signal 
into the cell. The serotonin (5-hydroxytryptamine, or 5-HT) class of Gprotein-coupled 
receptors (GPCR) serve as neurotransmitters involved in many processes in the central 
nervous system, including the regulation of feeding, aggression, mood, perception, pain 
and anxiety.293  
Trans-membrane Prediction (TMHMM model) 
TransMembrane prediction using Hidden Markov Models -- is a program for predicting 
transmembrane helices based on a hidden Markov model. TMFMM predicts the 7 
transmembrane segments of GPCRs exactly.300  The TMHMM was used to predict the 
structure of all 7 types of serotonin receptors including 5HT1A, 5HT1B, 5HT2A, 5HT2C, 5HT3A, 
5HT4, 5HT5, 5HT6, 5HT7. 
FASTA was used to format all the sequences by Search SMART (Simple Molecular 
Architectural Research Tool) database http://smart.embl-heidelberg.de/smart/ 
(Appendices 5). TMHMM was used to predict the trans-membrane structure 
69 
 
http://www.cbs.dtu.dk/services/TMHMM/ . The lengthy results include the graphical plot 
for the protein structure and the following information. (Table 7)  
1. Length: the length of the protein sequence 
2. Number of predicted TMHs: The number of predicted transmembrane helices. 
3. Exp number of AAs in TMHs: The expected number of amino acids in 
transmembrane helices. If this number is larger than 18 it is very likely to be a 
transmembrane protein (OR have a signal peptide) 
4. Exp number, first 60 AAs: The expected number of amino acids in transmembrane 
helices in the first 60 amino acids of the protein. If this expected number of amino 
acids is more than 60, one should be warned that a predicted transmembrane 
helix in the N-term could be a signal peptide.  
5. Total prob of N-in: The total probability that the N-term is on the cytoplasmic side 
of the membrane. 
RECEPTOR LENGTH Number of 
predicted 
TMHs 
Exp number 
of AAs in 
TMHs 
Exp number, 
first 60 AAs 
Total prob 
of N-in 
 
5-HT1A 
 
422 
 
7 
 
158.05958 
 
21.53471 
 
0.00307 
 
5-HT1B 
 
390 
 
7 
 
155.62023 
 
9.99705 
 
0.00939 
 
5-HT2A 
 
471 
 
7 
 
159.64767 
 
0.0018 
 
0.00302 
 
5-HT2C 
 
458 
 
7 
 
179.77408 
 
27.51182 
 
0.97688 
 
5-HT6 
 
440 
 
7 
 
156.66362 
 
23.05112 
 
0.00002 
 
5-HT7 
 
479 
 
7 
 
154.44007 
 
0.00361 
 
0.00138 
 
5-HT3 
 
510 
 
4 
 
91.81364 
 
0.4317 
 
0.01408 
Table 7: Results obtained with prediction of TMHMM structure of serotonin receptors 
 
The results showed the prediction of the 7 transmembrane helices for all the G protein 
coupled receptors (5HT-1,2,4,5,6,7) (Table 8) (Figure 12) except 5HT-3 (Figure 13) 
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The results confirmed the GPCR protein super family shows definitive common features 
of:  
1. Seven hydrophobic transmembrane α helices 
2. Three extracellular loops and three or four intracellular loops in the cytoplasm 
3. Extracellular N-terminus 
4. Intracellular C-terminus 
5. They are related to Class A GPCR’s (rhodopsin and adrenergic receptors) 
 
RECEPTOR NUMBER OF 
TRANSMEMBRANE 
HELICES 
PREDICTED 
PREDICTION TO 
HOMOLOGY TO 
GPCR’s 
E-value  
5HT-1A 7 √ 2.10e-05  
5HT-1B 7 √ 1.0e-02  
5HT-2A 7 √ 1.8e-03  
5HT-2C 7 √ 5.8e-03  
5HT-4 7 √   
5HT-5 7 √   
5HT-6 7 √ 2.4e-07  
5HT-7 7 √ 3.90e-02  
5HT-3A 3 χ   
 
Table 8: TMHMM Structure of Serotonin Receptor 5-HT 1A, 1B, 2A, 2C, 6, 7 
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Figure 12: TMHMM Structure of Serotonin Receptor 5-HT 1A, 1B, 2A, 2C, 6, 7 
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In contrast to the other receptors 5HT-3 which is a ligand-gated ion channel shares 
features of the ion channel family members. It has: 
1. A large extracellular cysteine loop 
2. Four hydrophobic transmembrane segment  
3. A large intracellular loop between the third and the fourth transmembrane region 
4. Extracellular C-terminus 
 
Figure 13: TMHMM Structure of Serotonin Receptor 5-HT3A 
 
 
Secondary Protein Structure: We selected the representative  5-HT1A and the 5-HT3 
receptors and predicted the secondary structure for the GPCR receptors (Figure 14) and 
the ionic channel receptors (Figure 15). 
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We used PSIPRED (Protien Sequence analysis workbench) - a highly accurate method for 
secondary structure prediction for serotonin receptors. 
http://bioinf.cs.ucl.ac.uk/psipred/. 
 
 
 
Figure 14: 5HT1A Secondary structure 
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Figure 15: 5-HT3 Serotonin Receptor Secondary Structure 
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Tertiary Protein Structure: To crystallise serotonin, purification is a very slow and 
laborious procedure, hence currently there is no known serotonin structure. The 
prediction method that I have used is the Comparative modelling method, If the sequence 
to model has a homologue in the PDB (Protein Data Bank) which it is very similar to, the 
homologue may be used as the target and a structural model is built on the basis of this 
template. 
To get the crystalloid structure of serotonin receptor structure, get the receptor sequence 
using The Basic Local Alignment Search Tool (BLAST) which finds regions of local similarity 
between sequences. The program compares nucleotide or protein sequences from the 
same or different organisms. Sequence similarity searching can be used to predict the 
location and function of protein-coding and transcription-regulation regions in genomic 
DNA. 
I have compared this data sequence using BLAST to the Brookhaven Protein Data Bank 
(PDB), the repository for protein-structure obtained by X-ray crystallography and NMR. All 
sequences in the PDB with an E-value of Blast below a certain threshold of 10 are 
considered as candidates for the template. http://blast.ncbi.nlm.nih.gov/Blast.cgi. (Table 
9) The PDB code is unique code for the crystal structure.(Table 9) This PDB code is used to 
view the crystal structure in jmol on the PDB website http://www.pdb.org. 
The PDB file is downloaded and the structure is modified to give the crystal figure using 
Molosoft. To Get the results for two representative receptors 5-HT1A and 5-HT3 following 
steps have been followed: 
1) www.ensembl.org 
a) Select human 
b) Search for serotonin receptor 
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c) By species- homosapeines 
RECEPT
OR 
 CCDS ACCESSI
ON No. 
PDB 
code 
DESCRIPTION QUERY 
COVERA
GE 
E 
VALUE 
5HT-1A ENSG00000178394  NP000515.2 3D4S A Chain A, Cholesterol 
Bound Form Of 
Human Beta2 
Adrenergic Receptor 
        88% 5e-45 
5HT-1B ENSG00000148680 7408 NP062873.1 2R4R A Chain A, Crystal 
Structure Of The 
Human Beta2 
Adrenoceptor 
66% 5.8e-
03 
5HT-2C ENSG00000147246 14564 NP000859.1 2R4R A Chain A, Crystal 
Structure Of The 
Human Beta2 
Adrenoceptor 
67% 3e-37 
5HT-2A ENSG00000102468 9405 NP000612.1 2R4R A Chain A, Crystal 
Structure Of The 
Human Beta2 
Adrenoceptor 
67% 8e-36 
5HT-4 ENSG00000164270 4291 NP955525.1 2R4R A Chain A, Crystal 
Structure Of The 
Human Beta2 
Adrenoceptor 
88% 4e-53 
5HT-5 ENSG00000157219 5936 NP076917.1 2R4R A Chain A, Crystal 
Structure Of The 
Human Beta2 
Adrenoceptor 
94% 2e-33 
5HT-6 ENSG00000158748 197 NP000862.1 2R4R A Chain A, Crystal 
Structure Of The 
Human Beta2 
Adrenoceptor 
72% 2e-42 
5HT-7 ENSG00000148680 7408 NP062873.1 2R4R A Chain A, Crystal 
Structure Of The 
Human Beta2 
Adrenoceptor 
66% 8e-42 
5HT-3 ENSG00000166736 8366 NP0011552
44 
2BG9 B Chain B, Refined 
Structure Of The 
Nicotinic 
Acetylcholine 
Receptor 
71% 3e-37 
 
Table 9: Results of Comparing this Data Sequence using BLAST to the Brookhaven Protein Data Bank 
(PDB) 
 
2) Select the receptor required 
a) External references 
b) Ref sequence peptide 
3) Use accession number and run BLAST in database select PDB proteins 
4) Get sequence producing significant alignment 
5) Click on protein 3Dstructure or 
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6) Put the PDB code on www.pdb.org  
7) View image in Jmol 
To get the crystalloid structure of serotonin receptor structure, 5-HT1A was compared to 
the data sequence using BLAST to the protein databank (PDB). The PDB code 3D4S is 
unique code for the crystal structure. This PDB code is used to view the crystal structure 
on the PDB website.(Figure 16) This showed the structure similarity to Chain A, 
Cholesterol Bound Form Of Human Beta2 Adrenergic Receptor. 
 
 
 
Figure 16: Assumed Biological Molecule for the 5HT-1A Serotonin Receptor Cholesterol bound form of 
human beta2 adrenergic receptor.301 
 
Whereas the tertiary structure for the 5-HT3 serotonin receptor shows similarity to the 
Nicotine Acetylcholine Receptor. (Figure 17) 
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Figure 17: Prediction of Tertiary Structure for 5HT3 Serotonin Receptor. Similar to Nicotine Acetylcholine 
Receptor. (Refined structure of the nicotinic acetylcholine receptor at 4A resolution.)302 
 
The PDB file is downloaded and the structure is modified to give the crystal figure using 
Molosoft. (Figure 18) showing the ligand binding sites. More the number of amino acids in 
the ligand site more the specificity of binding. Hence if there is a polymorphism in the this 
coding region it will change the function (a subtle effect of the signalling cascade)  
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Figure 18: Modified Tertiary Structure of 5-HT1A to give the crystal figure using Molosoft showing the 
ligand binding sites 
 
3.3 DISCUSSION: 
Phylogenetic analysis gives insight into how a family of related sequences has been 
derived during evolution. Our results show, with high bootstrap support, the tree of 17 
member serotonin receptor family can be divided into three main CLADS (Figure 9) 
comprising of 5-HT3 receptor subtypes, 5-HT6 and the third group of 5HT1,2,4,5,7. Each 
clad which is a group of receptors that include the most recent common ancestors of all 
of its members and descendants. Members of a clad share a common evolutionary 
history and are more related to each other. These clusters of homologues may be 
functionally related groups.  
The evolutionary relationships among the sequences are shown as branches of a tree.  
The length and nesting of these branches reflects the degree of similarity or divergence 
between any two given sequences. Sequences that are the most closely related are drawn 
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as neighbouring branches on a tree, for example, our results show that 5-HT2B is more 
related to 5-HT2A than 5-HT2C to 5-HT2A (Figure 9). Similarly 5-HT7 is related more to 5-
HT4 than 5-HT5 to 5-HT4. From the three major taxons, the branch length shows 
divergence between 5-HT1B and 5-HT1A. note that the 5-HT5 and 5-HT7 represent 
distinct classes of receptors but seems to be more closely related to the 5-HT1 receptor 
than 5-HT2. 5-ht6 also falls out of other serotonin receptor classes.  
To further emphasise the significance of our tree findings, the members of the above 
three clads also diverse in their intracellular transduction mechanisms which defines the 
receptor superfamily. The most diverged group of 5-HT3 receptors are ligand gated ion 
channel whereas 5-HT1,2,4,5,6,7  receptors are G-protein coupled receptors. Further in 
the GPCR group of receptors 5-HT1 are negatively coupled to adenylyl cyclase (↓cAMP), 
5-HT2 are coupled to protein kinase, while 5-HT4,5,6,7 are positively linked to adenylyl 
cyclase (↑cAMP).  
It has been extensively shown in the case of bioamine G protein-coupled receptors, that 
the ligand binding site is embedded in the membrane, surrounded by the seven 
transmembrane α-helices.303;304 The amino acids in receptor structures interact with the 
ligands, but change in receptor sequences during evolution to form paralogous genes has 
caused agonists or antagonists compounds to discriminate between different receptor 
class or subtypes of receptors.305    
The overall structure of a receptor protein becomes conserved and adapted to a function, 
the structure is fixed by strong functional requirements. Hence the details of the receptor 
shapes can change only through millions of year down the revolution.306 Within a gene 
family two main evolutionary mechanisms cause diversifications. Firstly, during a variety 
of duplication mechanism unrepaired point mutations cause a sequence drift leading to 
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two different but similar genes.307;308 mostly these genes result in pseudogenes and are 
eliminated over time, rarely two receptors encoded by duplicated genes exhibit different 
biological characteristics.309 These paralogous genes will form different receptor subtypes 
with their specific functions. The second type of diversification occurs between different 
species encoding the same receptor subtypes. These orthologous genes have the same 
function  showing a much higher degree of same sequence identity.310 Hence the cluster 
of the 5-HT3 receptor are paralogous genes with very different mechanism of action and 
function.  
In view of the large distance in between 5-HT3 receptors and others, the phylogenetic 
trees for the two groups were dealt with separately. The tree generated for 5-
HT1,2,4,5,6,7 confirmed the same findings as above.(Figure 10) 
By drawing the 5-HT3 receptors separately we see that there are three major 
evolutionary branches (Figure 11) 5-HT3A and 5-HT3B map closely to each other 
suggesting that they have arisen by gene duplication. 
To further analyse the putative similarities between the serotonin receptor family we 
extended the analysis by generating the TMHMM structure and produced a model 
tertiary structure. Important information regarding the intracellular transduction 
mechanism defines the receptor superfamily. From our results in predicting the TMHMM 
structures of the various serotonin receptors, the GPCR have a very similar structure 
(figure 12) compared to the ligand gated ion channel receptor 5HT3 (figure 13).  
Structurally all serotonin receptors except 5HT3, which forms a part of the cation 
channels belong to the G protein superfamily and contain the characteristic structure of 7 
hydrophobic transmembrane segments with extracellular amino terminus and 
intracellular carboxyl terminal. (Figure 19) 
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Figure 19: G protein superfamily structure containing the characteristic structure of 7 hydrophobic 
transmembrane segments with extracellular amino terminus and intracellular carboxyl terminal.   
 
The seven sequence stretches of about 25-35 residues represents the α helices, they span 
the plasma membrane enabling an extracellular ligand to exert a specific effect into the 
cell. All of these receptors (5HT 1,2,4,5,6,7) transduce extracellular signals though 
interaction with guanine nucleotide binding (G) protein. However the 5HT3 receptor 
shares the characteristic feature of the other ion channel families.(Figure 20) It has a large 
extracellular domain containing the cysteine loop, four hydrophobic transmembrane 
segments. It has a large intracellular loop between the third and fourth transmembrane 
region and a extracellular Carboxyl terminus. 
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Figure 20: Ion Channel superfamily structure containing the characteristic structure of 4 hydrophobic 
transmembrane segments with extracellular amino and carboxyl terminal.   
 
The secondary structures of the representative GPCR 5HT1A and the ionic channel 5-HT3 
receptor confirms the structure differences (Figure 6&7). 
The predicted tertiary structural model of 5-HT1A receptor has the same structure as the 
Cholesterol bound form of human beta2 adrenergic receptor (a GPCR). The 5-HT3 model 
has shown similarity to Nicotine Acetylcholine Receptor (an ion channel receptor). Great 
caution is needed when using the homology based models for detail functional and 
structural annotations since the loops and helix are often different in different receptors. 
But homology modelling of the receptors can be utilised in understanding of ligand-
protein interaction and further identification of new and potent ligands. 
Hence we have shown that serotonin receptors not only share the common ancestors but 
have several common structural features except 5HT3. 
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3.4 CONCLUSION 
It is clear from the phylogenetic tree and prediction of the serotonin receptor protein 
structure, there are two representative groups. The Serotonin receptors 5HT-1,2,4,5,6,7 
are G protein coupled receptors (GPCR’s) and have a 7 α transmembrane helices (7TMR) 
and they mediate signal transduction through the G protein. They are key controllers of 
diverse physiological process (signal transduction) hence they are major drug targets. 
GPCR play a very important role however it is very difficult to resolve their tertiary 
structure by x-ray crystallography. Hence computational methods have been developed 
to predict their structure based on their sequences. These receptors have shown 
homology to the human β-adrenergic receptor, hence may carry out functional roles 
traditionally associated with adrenergic receptors like carbohydrate metabolism, 
modulation of sensory input, memory etc.  
Whereas the 5HT-3 receptors, are far in the phylogenetic tree in spite of the common 
ancestor, hence have been dealt with separately. This fact is further emphasised by our 
protein structure predictions that unlike the others they are ligand- gated ion channel 
sharing the features of the ion channel family members. They show greater structural 
similarity to the Nicotine Acetylcholine Receptors. This is supported by the fact that they 
have a large intracellular loop between third and fourth transmembrane region. These 
receptors are channels for the conduction of both cations and anions which form the 
basis of the transfer of information at the neuronal synaptic junction. 
This analysis allows us to conclude that although close to the rest of the serotonin 
receptors in the evolution tree, 5-HT3 receptors constitute a separate family of receptors. 
Hence we hypothesize that the clad containing the 5-HT1,2,4,5,7 group of receptors 
comprises a series of homologous genes arisen by gene duplication and share common 
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structural features. We will select representative receptor types, evenly distributed in this 
CLAD of receptors to see their contribution to the development of PMDD. 
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CHAPTER 4:  
GENETICS OF PREMENSTRUAL SYNDROME: INVESTIGATION OF 
SPECIFIC SEROTONIN RECEPTORS POLYMORPHISM: 
RECRUITMENT OF STUDY PARTICIPANTS
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The chapter is the continuation from the thesis “GENETICS OF THE SEROTONERGIC 
PATHWAY IN PREMENSTRUAL DYSPHORIC DISORDER” on permission of Prof KMK Ismail 
as the clinical categorisation of the recruited patients and controls is the same.  
4.1 RECRUITMENT OF STUDY PARTICIPANTS: 
The study was conducted in University Hospital North Staffordshire, Keele University 
Hospital. The unit has a specialised PMS clinic run by Prof Obrien, Specialist nurse, Health 
assistant and research fellow (clinical scientist). The department has had a longstanding 
interest in PMS and its treatments. Many research and review articles have been 
published making enormous input into the understanding, diagnosis and management of 
this condition. The study has been funded by departmental funds. Patient referrals have 
been via GP’s directly, other units in the West Midlands and fellow consultant teams 
locally.  
ETHICS 
The study was approved by the Staffordshire and Shropshire Ethics Committee and 
informed written consent was obtained from each participant. Women were recruited 
from a specialised PMS clinic, general gynaecology clinics or following advertisement on 
the hospital intranet system.  
First Contact 
In order to achieve a successful first contact, without the need for additional attempts, 
and hence saving costs, ladies were seen by the Specialised Research Nurse on one to one 
basis for at-least 30mins consultation. Detail history and presenting symptoms were 
noted. The ladies were introduced to the study and invited to participate. An invitation 
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letter and information leaflet were given to the ladies along with the DRSP forms 
(complete daily diaries for 2 to 3 menstrual cycle) return addressed and stamped 
envelopes. The appointment could be followed by a phone call in order to confirm and 
schedule next appointment.  
The Invitation Letter and the Information Leaflet (Appendices 6) were combined together. 
This was a personal invitation to participate in the study, and was short as other relevant 
information was given in an attached information leaflet. The leaflet contains key 
information on the study in a concise form, targeted at provisional persons. It was in 
simple words, easily understandable and informative. It typically addressed:  
 WHAT ARE WE AIMING TO DO? 
 WHY ARE WE ASKING YOU FOR YOUR HELP? 
 WHO IS ORGANISING THE STUDY? 
 WHAT WILL WE BE ASKING YOU TO DO? 
 DO I HAVE TO TAKE PART? 
 WHO WILL SEE MY RECORDS AND KNOW ABOUT ME TAKING PART? 
 WILL MY EXPENSES BE PAID? 
 WHOM DO I CONTACT WITH ANY CONCERNS? 
Re-Contacts 
If the lady did not respond or did not attend further appointments, she was contacted via 
telephone call 3 attempts and a written letter with reschedule appointment date. If the 
person was not contactable, moved residence or refused the recruitment ended at that 
point. If she agreed to participated she was enrolled either as a case or controls. The 
GOPMS Recruitment Sheet (Appendices 7) was completed which included information 
like Study number, name, contact address and telephone number and Date Enrolled. The 
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GOPMS Data Sheet (Appendices 8) was also completed at this visit which included 
relevant history, presenting complaints, medication, family history and measure used for 
diagnosis.  
4.2 PARTICIPANTS: CASES/CONTROLS 
The Inclusion and exclusion criteria were very robust and can be seen in our previous 
GOPMS studies. Women were considered to be potentially suitable for inclusion in that 
study if following criteria were met: 
1. The ladies had to be white Europeans. 
2. Age group between 18 – 48 years 
3. Should have regular menstrual cycles (28 ± 4 days).  
4. These women should not be on any form of hormonal therapy, contraception or 
HRT at least for 2 months before and during the 2 cycles of symptom rating. 
Women were considered non-eligible or excluded from the above group for GOPMS study 
if: 
1. She was pregnant 
2. Planning a pregnancy 
3. Any history of existing or past relevant psychiatric disorder or 
4. If using any psychotropic medications. 
104 white European women between the ages of 18-48 were enlisted from the local 6 
population, and categorized into two groups; PMDD and controls. All subjects reported 
regular menstrual cycles (28 ± 4 days) and none was taking oral contraceptives, hormone 
replacement therapy or psychotropic drugs. Any woman known to have an existing or 
previous psychiatric disorder was excluded from the study.  
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4.3 CLINICAL CATEGORISATION: CASES/CONTROLS 
Clinical diagnosis was determined by prospective symptom rating using the daily record of 
severity of problems (DRSP) scale14, based on self-assessment reports spanning two 
consecutive menstrual cycles. Symptom ratings of menstrual cycle days 6-12 and the 
seven days immediately before the next menstrual period were used to calculate the 
mean follicular and mean luteal scores respectively, using the formula:  
 
Equation 1: Symptom rating for clinical categorisation 
Severity rating (%) = 
(mean luteal score – mean follicular score) 
X100 
mean follicular score 
 
 
Women were diagnosed with PMDD if there was a ≥200% increase in severity of one or 
more, or a ≥100% increase of two or more of the DSM-IV PMDD-defining symptoms.105;311 
According to DSM-IV to diagnose PMDD, require the presence of five out of 11 possible 
symptoms limited to the late-luteal phase of the menstrual cycle, including at least one of 
the following PMDD defining symptoms: marked depression, anxiety/tension, affective 
lability and irritability (criterion A).12  The severity of symptoms must significantly disrupt 
work performance or social functioning (criterion B). Furthermore, the disturbance must 
not be an exacerbation of symptoms of an existing psychiatric disorder (criterion C). 
The control group comprised women who reported no significant premenstrual 
symptoms, and did not meet the above criteria. 
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4.4 RESULTS OF CLINICAL CATEGORISATION  
One hundred and seven Caucasian women who fulfilled the inclusion /exclusion criteria 
for the study were recruited. Two study participants (numbers 33 and 92) failed to follow-
up hence excluded from the final analysis. One study participant was excluded as the 
blood sample was not enough to perform the experiments and on re-contact we found 
out that she had moved out of the area. Data were complete for one hundred and four 
European Caucasian women who were categorised into two groups; controls (n=51) and 
PMDD (n=53). The mean age of the control group was 36.2 years (age range 22-48 years) 
and the PMDD group had a mean age of 37.7 years (age range 27-46 years). In line with 
the DSM-IV diagnostic criteria for PMDD, Women were diagnosed with PMDD if there was 
a ≥200% increase in severity of one or more, or a ≥100% increase of two or more of the 
symptoms during the luteal phase compared to the follicular phase – in both menstrual 
cycles using the formula presented in equation 1. Otherwise they were categorized as 
controls. The follicular, luteal and percentage of difference for each of these symptoms in 
both groups are presented in Appendices 9 and Appendices 10. 
4.5 SAMPLE COLLECTION AND STORAGE 
After consent Five to ten ml of blood were taken by venupuncture and placed in ethylene 
diamine tetra-acetic acid (EDTA) tubes. These samples were collected by a research sister 
and were anonymised using the unique study number issued for each participant at time 
of recruitment. Samples were transferred to the laboratory where they were stored at -
200C for further analysis. The two researchers (VD and JM) who independently genotyped 
the samples were blind to clinical categorisation till the end of the study. 
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CHAPTER 5:  
GENETICS OF PREMENSTRUAL SYNDROME: INVESTIGATION OF 
SPECIFIC SEROTONIN RECEPTORS POLYMORPHISM: LABORATORY 
METHODOLOGY
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5.1 BACKGROUND 
5.1.1 Genetic Polymorphisms 
The human genome is the sum total of DNA molecules found within every cell except Red 
Blood Cell. Every cell in a person’s body has the same DNA. Most DNA is located in the cell 
nucleus, but a small amount of DNA can also be found in the mitochondria. The 
information in DNA is stored as a code made up of four chemical bases: adenine (A), 
guanine (G), cytosine (C), and thymine (T). Human DNA consists of about 3000 million 
bases, and more than 99% of those bases are the same in all people. Sequence, of these 
bases determines the information available and required for building and maintaining an 
organism. The information is in the form of genes. 
A gene is the basic physical and functional unit of heredity, acting as instructions to make 
molecules called proteins. Genes form only 3% of the total genome and rest of the DNA is 
non-coding but have a functional role in regulating and promoting gene expression. They 
also have a structural role in chromosome integrity segregation. The function of large 
fraction of genome is yet not known and does not depend on the sequence of the bases. 
Genes are made up of exons (coding sequence) and introns (non-coding sequence). Every 
person has two copies of each gene, most genes are the same in all people, but a small 
number of genes (less than 1% of the total) are slightly different between people. Alleles 
are forms of the same gene with small differences in their sequence of DNA bases and 
contribute to each person’s unique physical features. In some cases, different alleles may 
produce different phenotypes, as in mutations responsible for monogenic disorders; in 
others they may not have any effect. 
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Mutation is the process whereby genes change from one allelic form to another and may 
form an entirely new allele. The wildtype allele dictates the most common phenotype in a 
natural population. Genes can mutate randomly, at any time and in any cell. Mutations 
occur during normal replication, due to mutagens or due to erroneous repair following a 
exposure to a mutagen, radiation, or infection by viruses. Mutant alleles may be recessive 
or dominant. Many common mutations at the DNA level have no consequences for the 
individual’s phenotype. Mutations are revealed in an individual’s phenotype if the 
function of genes and their products are affected. Different types of mutations at the 
DNA level are: 
a) Missense mutation: This type of mutation is a change in one DNA base pair that results 
in the substitution of one amino acid for another in the protein. The amino acid 
substitution may have no affect or may render the protein non-functional 
b) Nonsense mutation: nonsense mutation is also a change in one DNA base pair forming 
a STOP codon instead of a codon specifying an amino acid. This type of mutation results in 
a shortened protein that may function improperly or not at all. 
c) Insertion: An insertion changes the number of DNA bases in a gene by adding a single 
base or a piece of DNA.  
d) Deletion: A deletion changes the number of DNA bases by removing a single base pair 
or a piece of DNA.  
e) Duplication: A duplication consists of a piece of DNA that is abnormally copied one or 
more times.  
f) Frameshift mutation: This type of mutation occurs when the addition or loss of DNA 
bases (number of base pairs are not divisible by three) changes a gene’s reading frame. A 
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frameshift mutation shifts the grouping of these bases and changes the code for amino 
acids.  
g) Repeat expansion: Nucleotide repeats are short DNA sequences that are repeated a 
number of times in a row, hence altering the function of a protein. For example, a 
trinucleotide repeat is made up of 3-base-pair sequences, and a tetranucleotide repeat is 
made up of 4-base-pair sequences.  
Genetic polymorphism is the presence of two or more allelic forms in a species (“many 
morphs”) when the alternative forms are common, i.e. wildtype alleles. Polymorphism 
may occur at the phenotypic level (Mendel’s study) or at the protein level. 
5.1.2 Types of Genetic Polymorphisms 
There are various kinds of polymorphisms: (appendices 11) 
a) Single Nucleotide Polymorphisms (SNPs): alteration in a single nucleotide in the 
DNA sequence. It may have the following function:  
i. Majority are “silent” with no known functional change. A SNP in which both 
alleles produce the same amino acid sequence are called synonymous 
polymorphism.  
ii. Alter gene expression or regulation by acting at the promoter region and 
enhancing or silencing the function. It may affect the mRNA stability or gene 
splicing. 
iii. Alter function of gene product by changing the sequence of protein, due to 
missense, nonsense polymorphism. 
b) Restriction Fragment Length Polymorphisms (RFLPs) 
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Because polymorphisms in a restriction sites translates into variability in the 
length of fragments after digestion of DNA with that restriction enzyme, these 
DNA markers are called RFLPs 
c)  Minisatellites or VNTRs (Variable Numbers of Tandem Repeats): short repeated 
segments of identical DNA at a particular locus in the genome. 
d)  Microsatellites or SSRs (Simple Sequence Repeats) 
 
5.1.3 Methods of detection of Genetic Polymorphism 
Up to date the most frequent used procedure to diagnose polymorphism is Gel 
Electrophoresis. Many new techniques are emerging that rapidly screen large number of 
samples at any one time, like the capillary array electrophoresis.312 It is sensitive and has 
the ability for automating the rapid electrophoretic separation of a number of low-
volume samples with relatively short analysis times.313;314 Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) is the newest 
procedure in use to detect microsatellite polymorphisms in couple of seconds.315 
In Gel electrophoresis the samples are loaded into a gel medium which is either agarose 
or polyacrylamide. Due to electric current the negatively charged DNA molecules migrate 
towards the positive pole at different rates depending on the size of the molecules and 
the concentration of the gel matrices. Once the molecules have been separated the 
polymorphism can be viewed either by using ethidium bromide in the agarose gel or silver 
nitrate staining in polyacrylamide gel. The other methods which are used to view these 
molecules are to use radiolabelled nucleotide during the PCR or use Laser technology 
where the primers are labelled with fluorescent dye. Computer programmes are used to 
analyse the output results. RFLF’s may be detected by using southern hybridization 
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procedure where the molecules separated are transferred to a nylon membrane, which is 
hybridised to a probe with the sequence of interest. 
 Polymorphic markers of known location in the genome are used for: 
a) Gene mapping 
b)  Association of genes to phenotypes 
c)  Genetic Identity 
d)  Population Genetics 
5.2 Laboratory Methodology 
All procedures were performed using strict laboratory protocols which adhered to the 
Control of Substances Hazardous to Health (COSHH) guidelines. 
5.2.1 Extraction of DNA from Whole Blood (Laboratory Protocol)  
Introduction: 
Isolation of DNA from whole Blood can be difficult. Erythrocytes constitute more than 
99% of blood cells; however, they lack nuclei and therefore possess no DNA. Nucleated 
blood cells are used to prepare genomic DNA. Only leukocytes (0.3% of total blood cells) 
contain nuclei and DNA.  In the DNA extraction protocol described below the cells are first 
washed, then lysed and the nuclei (left intact) are pelleted in a low speed centrifuge run. 
The nuclei are re-suspended in a small volume, and lysed with SDS and proteinase K. 
Ethanol and chloroform extractions follow to remove most of the non-nucleic acid organic 
molecules. The remaining DNA is extracted into chloroform and is subsequently 
recovered via ethanol precipitation. The DNA which is precipitated is collected on a glass 
hook, and re-suspended.  
101 
 
Equipment: 
1. Greiner v-bottomed 50 ml tubes. 
2. Centrifuge capable of accommodating 50 ml Greiner v-bottomed tubes. 
3. Micro-centrifuge. 
4. Vortex mixer. 
5. Incubator oven set at 65oC. 
6. Horizontal spiral mixer. 
7. Sterile syringe needles. 
8. Gilson P200, P1000 and P5000 pipettes. 
9. Sterile yellow, blue and large white (5 ml) Gilson pipette tips. 
10. Sterile 1.5 ml Eppendorf tubes. 
11. Sterile 5 ml Bijoux bottles. 
12. Ice bucket. 
13. Ice. 
Reagents: (appendices 12) 
1. Reagent A  
        (Contains 10 mM Tris HCL, 320 mM sucrose, 1% v/v Triton X-100.)  
2. Reagent B 
        (Contains 400mM of Tris HCL pH 8.0, 60 mM of  EDTA, 150 mM of NaCl.)  
3. 5M Sodium perchlorate 
4. Chloroform [Sigma C-2432]. Store at -20oC. 
5. Ethanol 95% or 100%. Store at -20oC. 
6. Ethanol 70%. Store at 4oC. 
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Procedure 
1. Pipette two to four ml of EDTA blood were pipetted into 45 ml of Reagent A in a 
50 ml Greiner tube. 
2. Mix the solution was mixed on a horizontal spiral mixer for 10 minutes at room 
temperature.  
3. Centrifuge at 2600 rpm for 4 minutes.  
4. Carefully decant off the lysed red cells, leaving the nuclear pellet behind. If the 
pellet is difficult to visualize, do not decant every last drop of lysed cell. The white 
cells will be in the small fraction left behind. 
5. The nuclear pellets are thoroughly re-suspended in 1.0 ml of Reagent B by 
carefully aspirating the reagent/pellet mixture up and down using a P1000 Gilson 
pipette (40 times).  
6. The solution was then vortexed. 
7. Add 250 L of 5M sodium perchlorate  
8. Vortex for 40secs 
9. spiral mixed for 15 minutes at room temperature. 
10.  Incubate at 650C for 25 minutes with occasional mixing. 
11. Cool the tubes ice and add 2.0 ml of chloroform at -20oC, using a P5000 Gilson 
pipette.  
12. The solution was then vortexed and then spiral-mixed for 10 minutes at room 
temperature.  
13. Now centrifuge at 2600 rpm for 4mins. 
14. Carefully remove the upper layers into a 1.5 ml Eppendorf tubes with each 
containing 200µl aliquots. 
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15. Micro-centrifuge at 13000 rpm for 10 minutes.  
16. Carefully remove the upper layer (~1.0 ml in 200 L aliquots) into Bijoux tube 
17. Add 2.0 ml of 95% ethanol at -20oC 
18. mixed well by inversion to precipitate the DNA.  
19. DNA was hooked out using a sterile syringe needle, and transfered to a sterile 1.5 
ml Eppendorf tube containing 1 ml of 70% ethanol.  
20. The DNA was washed by inverting the tube a few times. 
21. Micro-centrifuge at 13000 rpm for 5 minutes to pellet the DNA, then the ethanol 
decanted off.  
22. The tube was then dried and the DNA was dissolved in 0.25 - 1.0 ml water 
(depending on the pellet size) and stored at 4oC. 
5.2.2 Polymerase Chain Reaction (PCR) 
Introduction 
The polymerase chain reaction (PCR) is a relatively simple technique that amplifies a DNA 
template to produce specific DNA fragments in vitro.316 The efficiency of amplification or 
the sequence of the amplified material can then be examined for any of many purposes, 
including genotyping or the characterization of new genes, gene expression patterns, 
mutations or polymorphisms. PCR consists of repeated cycles of copying of DNA or cDNA 
templates between two oligonucleotide primers of known sequence that promote 
synthesis towards each other. 
A typical amplification reaction includes target DNA, two oligonucleotide primers, 
deoxynucleotide triphosphates (dNTPs), a thermo stable DNA polymerase, reaction buffer 
and magnesium. Once prepared, the reaction is placed in a thermal cycler, an instrument 
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that subjects the reaction to a series of different temperatures for set amounts of time. 
This series of temperature and time adjustments is referred to as one cycle of 
amplification. Each PCR cycle theoretically doubles the amount of targeted sequence 
(amplicon) exponentially in the reaction.  
Each cycle is composed of the following steps (Figure 21):  
a) Heat Lid: if the reaction is heated to temperatures >60°C before polymerization 
begins, synthesis of undesired PCR products and primer-dimer is avoided or reduced. 
b) Pause 
c) Denaturation: The initial step denatures the target DNA (single stranded DNA) by 
heating it to 95°C or higher for 3 minutes. This produces the necessary single-stranded 
DNA template for replication by the thermo stable DNA polymerase.  
d) Annealing: at 50–70°C the oligonucleotide primers can form stable associations 
(anneal) with the denatured target DNA and serve as primers for the DNA 
polymerase.  
e) Extension: the synthesis of new DNA begins as the reaction temperature is raised to 
70–74°C. Taq acts in and dNTP’S line up. 
f) The next cycle begins with a return to 94°C for denaturation. 
g) After 20–40 cycles, the amplified product may be analyzed for size, quantity, 
sequence, etc., or used in further experimental procedures. 
h) Final Extension: 72°C for 5 mins following annealing  
i) Hold: after cooling down at 26°C room temperature. 
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Figure 21: Schematic Representation Of PCR (Institute of Medical Microbiology and Hygiene, University of 
Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany)317  
 
j) Amplification efficiency is decreased because of competitive reactions, substrate 
exhaustion, polymerase inactivation and target reannealing. As the number of cycles 
increases, the amplification efficiency decreases, eventually resulting in a plateau 
effect. (Figure 22) 
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Figure 22: Amplification Efficiency Curve. The Amplification Efficiency decreases eventually resulting in a 
plateau effect as the number of cycles increases. 
Equipment  
1. Automated thermal cycler 
2. Vortex mixer 
3. Centrifuge  
4. 0.5 mL Eppendorf PCR tubes  
5. Gilson pipettes: 20 L, 200 L and 500 L 
6. Sterile yellow and blue Gilson pipette tips 
7.  
Reagents (for standard PCR procedure) (appendices 13)  
a) GoTaq DNA Polymerase: Taq DNA polymerase is isolated from Thermus aquaticus and 
catalyses the primer-dependent incorporation of nucleotides into duplex DNA in the 
5′→3′ direction in the presence of Mg2+. used to amplify PCR products of 5kb or less. 
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The fidelity of Taq DNA polymerase is slightly higher at lower pH, lower magnesium 
concentration and relatively low dNTP concentration.318;319 
Most reaction buffers consist of a buffering agent, most often a Tris-based buffer, and 
salt, commonly KCl. The buffer regulates the pH of the reaction, which affects DNA 
polymerase activity and fidelity.319 Some of the GoTaq comes colourless or coloured 
which does not require the loading dye. They may come supplied at pH 8.5 and 
contain MgCl2 at a concentration of 7.5mM for a final concentration of 1.5mM. Many 
DNA polymerases are supplied with a magnesium-free reaction buffer and a tube of 
25mM MgCl2 so that you can adjust the Mg2+ concentration to the optimal level for 
each reaction. 
b) Primers: go to www.ensemble.org follow homosapiens and search for 5HT. A 
complete genomic sequence with highlighted exon and small areas of introns given. 
Define the target region to be amplified and generally PCR primers range in length 
from 15–30 bases. Select GC content of40-60% and avoid 3 G or C residues near the 3’ 
end. the melting temperature (Tm) of the two primers should be within 5°C so that 
the primers anneal efficiently at the same temperature.  
c) MgCl2: Magnesium is a required cofactor for thermo stable DNA polymerases, and 
magnesium concentration is a crucial factor that can affect amplification success. 
Empirically determine the optimal magnesium concentration for each target because 
in the absence of adequate free magnesium, TaqDNA polymerase is inactive, whereas 
excess free magnesium reduces enzyme activity318 and may increase the level of 
nonspecific amplification.320;321  
d) dNTP‘s: Contains 100mM solutions of dATP, dCTP, dGTP and dTTP.  
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Procedure:  
Prepare master mix of 24µl for each sample using the following (table 10): 
a) Add 1µl DNA sample into 24µl master mix in a pre-labelled eppendorf PCR tubes 
b) Vortex 
c) Known positive controls (from other studies) were used for reference comparison on 
gel electrophoresis.  
d) Negative control samples contained sterile water with no DNA to confirm the integrity 
of reagent components. 
e) PCRs were performed in duplicates using both Phoenix thermal cyclers under strictly 
controlled conditions. 
Component 1 Test 
Sample (µl) 
5 Test 
Sample (µl) 
10 Test 
Sample (µl) 
15 Test 
Sample (µl) 
20 Test 
Sample (µl) 
 
Water 
 
13.9 
 
69.5 
 
139 
 
208.5 
 
278 
 
Forward 
Primer 
 
2.5 
 
12.5 
 
25 
 
37.5 
 
50 
 
Reverse 
Primer 
 
2.5 
 
12.5 
 
25 
 
37.5 
 
50 
 
10X Buffer 
 
2.5 
 
12.5 
 
25 
 
37.5 
 
50 
 
dNTP's 
(5Mm) 
 
1 
 
5 
 
10 
 
15 
 
20 
 
MgCl2 
 
1.5 
 
7.5 
 
15 
 
22.5 
 
30 
 
Taq DNA 
 
0.1 
 
0.5 
 
1 
 
1.5 
 
2 
Table 10: Master Mix Depending on the Number of Samples 
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Procedure for Phoenix Thermal Cycler (Figure 24): 
The two most commonly altered cycling parameters are annealing temperature and 
extension time. Primer sequence is a major factor that determines the optimal annealing 
temperature, which is often within 5°C of the melting temperature of the primers. Using 
an annealing temperature lower than the primer Tm (Oligonucleotide synthesis facilities 
will often provide an estimate of a primer's Tm) can result in higher yields, as the primers 
anneal more efficiently at the lower temperature. One way to calculate the annealing 
temperature is to use the formula 
TM = {2 x (total number of A & T)} + {4 x (total number of C & G)} 
For example (Figure 23): 
 
Figure 23: Example of Calculating the Annealing Temperature 
The length of the extension cycle, which may need to be optimized, depends on PCR 
product size and the DNA polymerase being used and is usually between 1-2mins. The risk 
of undesirable PCR products appearing in the reaction increases as the cycle number 
increases hence PCR typically involves 25–35 cycles of amplification. 
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Figure 24: Procedure for Phoenix Thermal Cycler 
Analyse 5μl of the PCR products by agarose gel electrophoresis. The products should be 
readily visible by UV transillumination of the ethidium bromide-stained gel. Store reaction 
products at –20°C until needed. 
Troubleshooting: 
 Thaw the magnesium solution completely prior to use and vortex the magnesium 
solution for several seconds before pipetting. 
 Cross-contamination between samples can occur and should be minimised to prevent 
carryover of RNA and DNA from one experiment to the next. Use separate work areas 
and pipettes for pre- and post-amplification steps. To reduce cross-contamination 
during pipetting use positive displacement pipettes or aerosol-resistant tips. Wear 
gloves, and change them often between different experiments and steps. 
Final hold
26°C
Final extension
72°C/ 5mins
Denaturation
94°C/ 30secs after 25-35 cycles
Extension
72°C/ 30secs Taq acts & dNTP's line up
Annealing
54°C/ 30secs primers stick
Initial Denaturation
95°C/ 3mins single standed
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 Making up a master-mix of PCR reagents reduces the number of pipetting steps and 
the likelihood of contamination. 
5.2.3 Electrophoresis of PCR products 
Electrophoresis is a technique to purify or to separate macromolecules especially proteins 
and nucleic acids. The negatively charged nucleic acids (due to their phosphate back 
bone) when placed in an electric field migrate towards the positive pole (anode). 
Proteins and nucleic acids are electrophoresed within a "gel", which is cast in the shape of 
a thin slab, with wells for loading the sample. The gel is immersed within an 
electrophoresis buffer that provides ions to carry a current and some type of buffer to 
maintain the pH at a relatively constant value.  The gel itself is composed of either 
agarose or polyacrylamide, each of which is suitable to do a particular task.  
Detection nucleic acids in agarose or acrylamide gels can be performed in several ways: 
1. The method of choice is staining with the intercalating dye, ethidiurn bromide, either 
after electrophoresis or during the run. Visualization of the DNA-dye complex by UV 
illumination322;323 
2. Staining of the gel with acridine orange and visualization of the nucleic acid-dye 
complex by UV illumination.  
3. UV shadowing 
4. Silver staining. This is the most sensitive method and provides a permanent record of 
the actual separation. A destructive method molecules can not be recovered from gel 
after staining. 
5. The gel can be blotted onto a membrane filter and the blot either exposed to X- Ray 
film or hybridized. 
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Agarose Gel Electrophoresis of PCR products  
Agarose is a polysaccharide extracted from seaweed. It is widely used for the 
fractionation of DNA by varying the concentration between 0.5 to 2%. 
Agarose gels have a large range of separation, but relatively low resolving power. By 
varying the concentration of agarose, fragments of DNA from about 200 to 50,000 bp can 
be separated using standard electrophoretic techniques. (Figure 25) 
 
 
 
 
Figure 25: Migration of a set of DNA fragments in three concentrations of agarose, The larger fragments 
are much better resolved in the 0.7% gel, while the small fragments separated best in 1.5% agarose. The 
1000 bp fragment is indicated in each lane. 
 
 
Agarose gels have the added advantage, they are extremely easy to prepare and perform: 
you simply mix agarose powder with buffer solution, melt it by heating, and pour the gel. 
It is also non-toxic. 
Reagents (Appendices 14) 
1. Tris-Borate-EDTA buffer [TBE 10X]  
2. Molecular Biology Certified  Agarose 500 g [Bio-Rad  137632D] 
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3. Ethidium Bromide* 10 mg/mL 
  Prepare a stock solution in deionised water (1 g/100mL). Aliquot into 2 ml volumes for 
use. Store the stock solution at 4oC protected from light. Store the working aliquot at 
room temperature protected from light 
4.  Gel Loading Buffer: 
0.25% w/v bromophenol blue 
0.25% w/v xylene cyanol 
40% w/v sucrose in deionised water 
Equipment: 
1. Anachem Scotlab Horizontal electrophoresis units 
2. Power supply unit 
3. Microwave oven 
4. 250ml conical flask 
5. 100ml measuring cylinder 
6. Gilson P20 pipette 
7. Sterile yellow Gilson pipette tips 
Procedure: 
Before starting it is necessary to have some idea of the sizes of DNA fragments to be 
resolved. Generally, a 1.0% or a 2.0% gel is used for the separation of fragments between 
100 and 1000 base pairs.   
1. For 100ml  2.0% agarose weigh out 2.0gm agarose into a clean flask and add 100ml 1X 
TBE buffer 
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2. Mix and dissolve by heating in a microwave oven at maximum power (~600 watts) for 
approximately 1min, (watch to avoid boiling over). The agarose solution may need 
reheating to ensure all agarose has dissolved. 
3. Allow to cool to approximately 500C and add 5µl ethidium bromide (10mg/ml) 
solution. 
4. Use autoclave tape to seal the ends of a clean dry casting tray. Position a comb at one 
end and pour the agarose solution into the mould. Leave at room temperature. 
5. When the gel has set remove the tape and comb. Place the gel and casting tray into 
the electrophoresis tank. Add sufficient 1X TBE buffer to cover the surface of the gel. 
(Figyre 26) 
6. To each 5µl DNA sample add 2µl sucrose loading buffer. Choose an appropriate size 
DNA size marker and add sufficient sucrose loading buffer. Load each sample to the 
well in the gel. (Figure 27) 
 
 
Figure 26: Agarose Gel Electrophoresis; loading sample into the well 
7. Run the gel at a suitable voltage, until separation of the products is achieved. As a 
rough guide, 150v for about 10minutes will let you see whether the PCR has worked 
and then it is down to the individual as to how much longer the gel should be run. 
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Figure 27: Electrophoresis Tank with Gel and Casting Tray in 1XTBE Buffer 
 
8. After electrophoresis the gel is removed and examined on the ultraviolet trans 
illuminator. (Figure 28) The ethidium bromide intercalates with DNA allowing PCR 
products to be visualised when exposed to ultraviolet light. Take care to position a UV 
protective shield between yourself and the trans illuminator as UV light damages 
eyesight.  
 
 
Figure 28: System for visualizing, analyzing and documenting ethidium bromide stained agarose and 
acrylamide gels 
 
9. Take a photo of your notebook and interpret the digest and PCR reactions. 
 
116 
 
Troubleshooting: 
 Agarose gel may be remelted and reused for subsequent electrophoresis of PCR 
products. Gels should be used a maximum  of five times and then disposed of by 
incineration. 
 To avoid wasting agarose the gel casting tray should be measured and the 
approximate volume of agarose gel required calculated. 
Polyacrylamide Gel Electrophoresis of PCR products 
Polyacrylamide gel electrophoresis (PAGE) provides a versatile, gentle, high resolution 
method for fractionation and physical-chemical characterization of molecules on the basis 
of size, conformation, and net charge.324 
Polyacrylamide is a cross-linked polymer of acrylamide monomers. The length of the 
polymer chains is dictated by the concentration of acrylamide used, which is typically 
between 3.5 and 20%. When this polymer is formed, it turns into a gel and electricity is 
used to pull the proteins through the gel so the entire process is called polyacrylamide gel 
electrophoresis (PAGE). 
Polyacrylamide gels have a rather small range of separation, but very high resolving 
power. In the case of DNA, polyacrylamide is used for separating fragments of less than 
about 500 bp. However, under appropriate conditions, fragments of DNA differing is 
length by a single base pair are easily resolved. In contrast to agarose, polyacrylamide gels 
are used extensively for separating and characterizing mixtures of proteins. 
Reagents: (Appendices 15) 
 
1. Stock Acrylamide/Bis 29:1 solution. (Store at 4°C). 
2. 10% Ammonium persulfate APS (10gms + 100 ml H2O) 
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3. Fixative: 10% methanol + 0.5% acetic acid ( mix 100ml methanol with 5ml acetic acid 
and make upto 1lt with deionised water and storeat room temperature). 
4. Silver stain: Silver nitrate 0.1%(1gm dissolve in 1lt H2O in a dark bottle at room 
temperature) 
5. Developer: 1.5% Sodium Hydroxide (dissolve 15gms of NaOH with 1lt deionised water 
and store room temperature) 
6. formaldehyde 
7. 1X TBE 
8. TEMED 
 
Equipment: 
1. Large plate 
2. Small plate 
3. 2 plate clamps 
4. Plate stand 
5. Gel comb 
6. 20ml syringe 
7. Biorad Protean II Rig 
8. Electrophoresis tank (Figure 29) 
9. Gilson P20 pipette 
10. Sterile yellow Gilson pipette tips 
11. 100ml cylinder 
12. clean 250ml beaker 
13. Glass or plastic dishes, at least 20 cm square and capable of holding 100 mL of 
solution. 
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Figure 29: PAGE the Polyacrylamide Electrophoresis Tank 
 
Procedure: 
a) preparing gel plates 
i. rinse the two plates and spacers and dry them thoroughly. 
ii. Place large plate flat on surface, position spacers at the side, then position the 
small plate on top. Square up and put on plate clamps. tighten slightly and place 
vertically in plate stand. Slip card in between plates and make sure it moves freely 
up and down. Tighten or loosen clamps accordingly 
iii. Check the bottom of the plates to ensure alignment is square, make sure the 
bottom of both plates and spacers are flush with one another to prevent leaking. 
Now move to clamping section of plate stand and secure 
iv. Make sure the squaretooth comb fits between the plates.  Finally, make sure the 
gel will not leak by filling the area between the plates with deionized water.  If the 
water leaks, check to see that the bottom of the plates and the spacers align and 
that the area between the plates is sealed at the bottom when placed in the 
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loading part of the apparatus.  When the gel does not leak, drain the water and 
dry the area between the plates with a paper towel.    
b) preparing the polyacrylamide gel 
i. To prepare 8% gel, to 30ml 1X TBE add 10ml of acrylamide. (40%, 29:1) in a 100ml 
cylinder then poured into a clean 250ml beaker. Then add 40 µl of TEMED (starts 
acting as catalyst). Then add 400µl of 10% APS (initiation of catalyst process). 
ii. Using a sterile large syringe carefully pour the gel between the glass plates.  Pour 
against the large back plate one side at an angle of 45° with a constant flow to 
prevent bubble formation.  If any bubbles are noticeable, gently tap the glass plate 
to remove the bubble.  Pour until the gel is about a centimetre away from the top 
and then stop. Put any remaining gel solution into a carefully labelled container 
and use it as a polymerization control. 
iii. Insert the squaretooth comb with 15, 20 or 25 teeth into the gel so that the wells 
are submerged in the gel solution, but leaving a bit of air in the top to prevent 
bubble formation and to allow for the addition of extra gel as the result of leakage 
prior to polymerization. 
iv. Allow the gel to set for at least an hour, using the polymerization control to verify 
that the gel polymerized between the plates.   
v. Flush out the wells using syringe containing 1X TBE although water is as good 
alternative if 1X TBE is not available. 
vi. Once the gel has set place the completed gel in the electrophoresis rig. Place the 
rig holding the gels in the electrophoresis tank and fill the top of the rig with 
1XTBE buffer. 
c) sample preparation 
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2 µl of loading dye were added to 5 µL PCR product (briefly spin to mix) and the 
samples loaded into the wells under the buffer, using a Gilson  P10 pipette. 
d) sample loading and electrophoresis 
i. Assemble the entire electrophoresis apparatus.  Fill both the top and bottom 
chambers of the apparatus with ~300 mL of 1X TBE buffer, ensuring the platinum 
wires of the apparatus are submerged at both ends. 
ii. The samples are loaded into the wells under the buffer. 
iii. The central cooling core was then lowered into the lower buffer chamber. 
iv. The hose tubing attached to the core cooling ports and water supply switched on. 
v. Connect the leads to a power supply.  Turn on the power supply, ensuring that DC 
power is on.  Press start on the power supply.  Adjust the settings to 
approximately ~25 - 30milliamps and ~800 volts for 1- 11/2 hrs.   
e) Visualisation of PCR Products using Silver Nitrate Staining (Table 11) 
i. Once the gel has run to experimental specifications, cut off the power source and 
disconnect the leads.   
ii. Empty the buffer chambers of the apparatus. Take unit out of the tank and unclip 
the plates. Remove the clamps and gently remove the spacers and the top plate 
off. Cut off the top of the gel with the spacer. 
iii. To remove the gel from the plate turn upside down over the tray and loosen 
corner of the gel with spacer gel should pop off the plate. Do not use fingers. 
iv. Place acrylamide gel into the container with 100ml of fixative. Incubate at room 
temperature for 6mins on the shaker. 
v. Remove and wash the fixative 
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vi. Overlay gel with 100ml of Silver Nitrate staining solution. Incubate at room 
temperature for 20mins on the shaker. 
vii. Remove stain and wash. 
viii. To 100mls of developer add 250µls formaldehyde, and place on the gel. Incubate 
at the room temperature on the mixture until the bands are visualised. 
ix. Wash and then dry the backside of the plate with a paper towel and doc the gel on 
it. Use UV-Transilluminator to print an image of the electrophoresis patterns. 
 
Step Solution Duration 
A Fixative 6 min 
B deionized water (repeat twice) 2 x 2 min 
C staining solution with AgNO3 20 min 
D deionized water 10 sec 
E developer solution (4-10˚C) 45-60 min (until bands are visible) 
F deionized water 2 min 
Table 11: Silver Nitrate Staining of the PCR Product 
 
Troubleshooting: 
 if the gel begins to leak from the bottom of the plates, use the syringe to take up 
whatever leaks and return it to the rest of the gel at the top. Keep repeating the 
process until the gel has set and hence stops leaking. 
 When adding the comb often it is best to place it on one side then the other as this 
will stop the air bubbles being trapped into the gel. 
 Wet rubber seal on electrophoresis rig to give a better seal between the gel plates 
and rig. 
 When handling acrylamide wear gloves as it is a neurotoxin. 
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5.3 Polymorphism Studied 
Five Key Polymorphisms were studied in 5HT1A (C-1019G), 5HT1B (A-161T), 5HT2A (102T/C), 
5HT2C (Cys23-Ser23) and 5HT7 (Pro-257-Leu) receptors. These receptors and genes were 
selected according to the following criteria: involvement of the receptors in the function 
of serotonin; representative of the common receptor protein structure and equally 
spread around the evolutionary tree; they have been studied and shown to be linked to 
various other psychiatric diseases in a variety of different population groups with 
significant results.  
5.4 Polymerase Chain Reaction 
Genomic DNA was isolated from peripheral blood leucocytes using the technique 
mentioned in 5.2.1, once again as the samples from our old studies in the laboratory were 
contaminated. Once DNA was extracted GAPDH was performed to all the samples. 
 5.4.1 Glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH): 
The GAPDH gene, also known as “housekeeping gene”325;326 is often stably and 
constitutively expressed at high levels in most tissues and cells and hence used as a 
control. GAPDH has been proven time and time to be the best housekeeping genes for 
study.327;328 When performing GAPDH strict conditions (drugs and chemicals) has to be 
maintained as many factors can influence the housekeeping gene expression.329;330  
GAPDH reaction condition included initial denaturation at 95°C for 3mins, then primer 
annealing/ primer extension/ denaturation at 58/74/94°C, 30secs/cycle for 30 cycles. 
Final extension was set at 74°C for 5mins. PCR product was run in 1% agarose gel and the 
electrophoresis conditions included standard 110volts for 1hr30mins. 
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This test presented data describing the expression of DNA for GAPDH in all the samples 
extracted from whole blood of both controls and cases (Figure 30).  
 
Figure 30: Glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH) 
5.4.2 Selection of primers:  
To Select primers we obtained the protein and nucleotide sequence from the site 
www.ensembl.org. and then Primer picked using PRIMER 3 software from the website 
http://www.frodo.wi.mit.edu and the general rules to design these primers applied. 
These primers include the target region to be amplified and the general rules to design 
these primers are as following: 
a. Length should be between 15-30bp. 
b. GC content should be between 40-60% 
c. Avoid three G or C residues near the 3’ primer end to avoid nonspecific primer 
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annealing. 
d. The melting temperature (TM) should be between 52 -58°C 
e. The difference in the melting temperature (TM) of the two primers should not be more 
than 5°C  
Oligonucleotides (Primers) are received in dry ice from Operon Biotechnologies. To Make 
100 µM Spin the primers at 100rpm for 5mins before opening and then re-suspend in a 
sterile buffered solution i.e TE at pH 8.0, vortex and then spiral mix. To make working 
primer concentration of 5µM, dilute stock primers in the ratio of 1:20 (5µl stock +95µl of 
water). Store at -20°C and to use again thaw at room temperature on ice for some time 
and then spiral mix before use.  
The primers for 5-HT1A (appendices 16) penultimate nucleotide at the 3’ end of the 
reverse primer was deliberately altered from a thymine (T) to an adenine (A, underlined 
below), to introduce BseGI restriction site in the G allele. The forward and reverse primer 
sequences were 5’-GTAAGGCTGGACTGTTAGATG-3’ and 5’-
GGAAGAAGACCGAGTGTGTCAT-3’ respectively.  
Since the polymorphism is not detectable as a conventional RFLP331 a PCR forward primer 
for 5-HT2C (appendices 19) that introduces a base substitution close to the codon of 
interest was used to create an artificial restriction site with two allelic form. The 3rd last 
nucleotide at the 3’ end of the forward primer has been changed from Adenine (A) to 
Cytosine (C). The forward and reverse primer sequences were        5’-
GGCCTATTGGTTTGGCCAT-3’ and 5’-GCCATGATCACAAGGATG-3’ respectively.  
The primers for 5-HT1B (appendices 17), 5-HT2A (appendices 18), 5HT7 (appendices 20) 
receptors containing the polymorphisms were designed and general rules applied 
accordingly. (Table 12)  
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Receptor 
Polymorphisms 
Oligonucleotide Primer Sequences Length Tm GC% 
 
5-HT1A (C-1019G) 
Forward 
5’-GAGTAAGGCTGGACTGTTAGATG-3’ 
23 57.2 47.8 
Reverse  
5’-GGAAGAAGACCGAGTGTGTCAT-3’ 
 
22 59.7 50.0 
 
5-HT1B (A161T) 
Forward  
5’- CTCAAGCAGTACTTCACCCTCC-3’ 
22 60.3 54.5 
Reverse  
5’- GTTCCTCCATGGCTCTCCTCG-3’ 
 
21 65.5 61.9 
 
5-HT2A (102T/C) 
Forward  
5’-GAGCAGAAACTATAACCTGTT-3’ 
21 54.6 38 
Reverse  
5’-CAAGTGACATCAGGAAATAG-3’ 
 
20 56 45 
 
5-HT2C(Cys23-Ser23) 
Forward  
5’-GGCCTATTGGTTTGGCCAT-3’ 
19 59.7 47 
Reverse  
5’-GCCATGATCACAAGGATG-3’ 
 
18 55.5 50 
 
5-HT7 (Pro-279-Leu) 
Forward  
5’-CCTCCATCACCTTACCTCCA-3’ 
20 62.4 55 
Reverse  
5’-GGTGGCTGCTTTCTGTTCTC-3’ 
 
20 62.4 55 
Table 12: Oligonucleotide primer sequences for the chosen receptor polymorphisms. 
5.4.3 Amplification 
Genomic regions encompassing each of the six polymorphic sites were amplified in 
duplicate by Polymerase Chain Reaction. Water, PCR buffer, MgCl2, TaqDNA polymerase 
was mixed as required by the protocol for PCR (Table 10). PCR conditions were optimised 
accordingly for each polymorphism (Table13).  
Each 25µl reaction mixture contained approximately 100ng DNA, 1x Taq DNA polymerase 
buffer containing1.5mmol/L MgCl2, 12.5pmol of each forward and reverse primer, 5nmol 
of dNTP's, and 0.5 units of Taq DNA polymerase. PCR cycling parameters are listed in 
table 13 and the PCR product sequence for each polymorphisms site of interest is 
included in Table 14. 
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Each set of amplification was done in duplicate and was accompanied by a negative and 
positive control. The PCR reaction mixture was then incubated in a thermocycler. 
 
Receptor 
Polymorphism 
PCR   Conditions PCR 
Product 
Size 
 
5-HT1A (C-1019G) 
Step Temp Time No of 
Cycles 
 
 
169 1.Initial denaturation 950C 3mins  
35 
2.Denaturation 940C 30secs 
   Primer annealing 59.50C 1min 30sec 
   Primer extension 720C 30secs 
 
5-HT1B (A161T) 
 
1.Initial denaturation 950C 3mins  
 
35 
 
 
360 
 
2.Denaturation 940C 30secs 
   Primer annealing 630C 30secs 
   Primer extension 720C 30secs 
 
5-HT2A (102T/C) 
1.Initial denaturation 950C 3mins  
 
36 
 
412 2.Denaturation 940C 30sec 
   Primer annealing 540-C 30sec 
   Primer extension 720C 30sec 
 
5-HT2C (Cys23-
Ser23) 
1.Initial denaturation 960C 5min  
 
36 
 
182 2.Denaturation 940C 30sec 
   Primer annealing 500C 1min30sec 
   Primer extension 720C 1min 
 
5-HT7 (Pro-279-Leu) 
1.Initial denaturation 960C 5min  
 
35 
 
350 2.Denaturation 940C 30sec 
Primer annealing 600C 1min 
Primer extension 720C 1min 
Table 13: Amplification of the genotypic fragments containing the polymorphic sites was studied using 
optimised conditions and the standard methods 
 
5.4.4 Detection: 
5µl of each amplified product will then be analysed by gel ectrophoresis using 1-2% 
agarose in the presence of Ethidium Bromide by UV illumination. The amplified product 
gave the required sizes (table 13) 
Which was compared using a molecular weight marker ( Generuler 50/100bp DNA 
Ladder). If positive signal is obtained the samples were treated with endonucleases as 
required. (Figures 31-35) 
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Receptor Product Sequence 
 
 
5-HT1A 
 
GAGTAAGGCTGGACTGTTAGATGATAACGGAGGTACCGTTTTGTTGT
TGTTGTCGTCGTTGTTCGTTTGTTTTTGGAGACGGAGTCTCGCTCTG
TCGCCCAGGCTGGAGTGCAATGGCGCGAGAACGGAGGTAGCTTTTT
AAAAAGGAAGAC▼↕ACACTCGGTCTTCTTCC 
                   T 
 
 
 
 
5-HT1B 
 
CTCAAGCAGTACTTCACCCTCCTGCACTAGACGCCTCCAGGGAGCT
GGAGCGGAGCAGGGCTCGGTGGGCCAGCTCTTAGCAACCCAGGTC
TAAGACCCGGTGTGGAGAGGAACAACCACAGACGCGGCGGCTTAGC
TAGGCGCTCTGGAAGTGCAGGGGAGGCGCCCGCCTGCCTTGGCTG
CCGCACCCATG▼ACCTCTAGTTTCAGCTGTGAACCTGGGCGGAGGA
ATAATTGAGGAACTCACGGAACTATCAACTGGGGACAAACCTGCGAT
CGCCACGGTCCTTCCGCCCTCTCCTTCGTCCGCTCCATGCCCAAGA
GCTGCGCTCCGGAGCTGGGGCGAGGAGAGCCATGGAGGAAC 
 
 
5-HT2A 
 
GAGCAGAAACTATAACCTGTTAGTCCTTCTACACCTCATCTGCTACAAGT
TCTGGCTTAGACATGGATATTCTTTGTGAAGAAAATACTTCTTTGAGCTC
AACTACGAACTCCCTAATGCAATTAAATGATGACACCAGGCTCTACAGTA
ATGACTTTAACTCC▼GGAGAAGCTAACACTTCTGATGCATTTAACTGGA
CAGTCGACTCTGAAAATCGAACCAACCTTTCCTGTGAAGGGTGCCTCTC
ACCGTCGTGTCTCTCCTTACTTCATCTCCAGGAAAAAAACTGGTCTGCTT
TACTGACAGCCGTAGTGATTATTCTAACTATTGCTGGAAACATACTCGTC
ATCATGGCAGTGTCCCTAGAGAAAAAGCTGCAGAATGCCACCAACTATT
TCCTGATGTCACTTG        
 
 
5-HT2C 
                                        C 
GGCCTATTGGTTTGGCAATG▼TGATATTTCTGTGAGCCCAGTAGCAGC        
TATAGTAACTGACATTTTCAATACCTCCGATGGTGGACGCTTCAAATTCC
CAGACGGGGTACAAAACTGGCCAGCACTTTCAATCGTCATCATAATAAT
CATG▼ACAATAGGTGGCAACATCCTTGTGATCATG▼GC 
 
 
5-HT7 
 
CCTCCATCACCTTACCTCCACTCTTTGGATGGGCTCAGAATGTAAAT
GATGATAAGGTGTGCTTGATCAGCCAGGACTTTGGCTATACGATTTA
CTCTACCGCAGTGGCATTTTATATCCCCATGTCCGTCATGCTTTTCAT
GTACTACCAGATTTACAAGGCTGCCAGGAAGAGTGCTGCCAAACACA
AGTTTCCTGGCTTCCC▼TCGAGTGGAGCCAGACAGCGTCATCGCCC
TGAATGGCATAGTGAAGCTCCAGAAGGAGGTGGAAGAGTGTGCAAA
CCTTTCGAGACTCCTCAAGCATGAAAGGAAAAACATCTCCATCTTTAA
GCGAGAACAGAAAGCAGCCACC 
 
Table 14: PCR Product Sequence for each Polymorphism of interest. 
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5.5 Restriction Enzyme Digest 
The PCR products were digested with the restriction endonucleases to selectively cleave 
the DNA strands at various restriction sites, also known as DNA fragmentation to obtain 
and note the required polymorphisms. All restriction digests were incubated in 
duplicates, in a total reaction volume of 20 µl, containing 3-5µl of PCR product, 1X 
reaction buffer and one or two units of the respective restriction endonuclease. 
Wherever possible, pairs of complementary restriction enzymes were used in separate 
digests reactions, each of which targeted a different allele. The cleaved variants have 
been shown in the table after each enzyme. The conditions were optimized accordingly 
depending on the enzyme properties. The products were analysed on 2-4% agarose gel or 
8-10% polyacrylamide gels for electrophoresis and compared with a molecular weight 
marker (Generuler of 100bp/50bp/25bp DNA ladder) (Table 15) 
Endonucleases were ordered from FERMENTAS Life Sciences, they arrived with the 
buffers, enzyme information including recommended conditions for use and storage 
requirements. 5-HT1A(C-1019G) PCR products was incubated at 55°C overnight with BseGI 
with the cleavage site 5’-GGATGNN↓-3’ and 3’-CCTAC↑NN-5’ were analysed on 4% 
agarose gel at 120volts for 2hrs.(Figure 31) 5-HT1B(A-161T) Amplicons were digested at 
37°C for 4 hours using NIaIII (cleavage sites 5’---CATG↓---3’ and 3’---↑GTAC---5’) and 
analysed on 2% agarose gel.(Figure 32)  5-HT2A(102T/C) products were digested with MspI 
at 37°C for 4 hours and analysed on 2% agarose gel on 110volts for 2 hours.(Figure 33) For 
5-HT2C(CYS23-Ser23) 10 units of NIaIII enzyme with 5µl of sample was left overnight in the 
water bath at 37°C and then analysed by using 8% polyacrylamide gel electrophoresis at 
30mA, 210 volts for 2 hours. Silver Nitrate staining was performed as explained in section 
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5.2.3 and (table 11). Polyarylamide gel was used for 5-HT2C(CYS23-Ser23) due to small 
product basepair size for both wild and polymorphic samples.(Figure 34) 5-HT7(Pro-279-
Leu) PCR products of 35obp were digested with the XhoI in various repeatd different 
conditions to confirm the results and there was uniformly no difference in the digested 
product results, but we were sure that the enzyme was definitely working. After 
standardising the conditions all samples were digested at 37°C under water bath for 3 
hours and were analysed on 3% agarose gel.(Figure 35). Genotypes were independently 
determined by two researchers (VD and JM), without prior knowledge of clinical group 
status. 
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Receptor 
Polymorphism 
Enzyme Cleavage Site Electrophoresis                                      
Gel             Temp              Time 
Product 
5-HT1A (C-
1019G) 
BseG1 5’-GGATGNN↓-3’       
3’-CCTAC↑NN-5’ 
4% Agarose  55°C 4hrs Wild Type:  169 
Polymorphism: 152+17 
5-HT1B (A161T) NlaIII 5’---CATG↓---3’      
3’---↑GTAC---5’ 
2% Agarose 37°C 4hrs Wild Type: 312+41+7 
Polymorphism: 192+120+41+7  
5-HT2A (102T/C) Msp I 5’---C↓CGG---3’     
3’---GGC↑C---5’ 
2% Agarose 37°C 4hrs Wild Type: 410 
Polymorphism: 163+247 
5-HT2C(Cys23-
Ser23) 
NlaIII 5’---CATG↓---3’      
3’---↑GTAC---5’ 
 8% PAGE 37°C Overnight Wild Type:  (150+146)+30+(2+6) 
Polymorphism: (20+16)+130+30+(2+6) 
5-HT7(Pro-279-
Leu) 
Xho I 5’--C↓TCGAG--3’   
5’--GAGCT↑C--3’ 
3% Agarose 37°C 3hrs Wild Type: 145+205 
Polymorphism: 350 
 
Table 15: Restriction endonucleases to fragment DNA and expected products to recognize the polymorphisms 
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Figure 31: Schematic presentation of the 5-HT1A receptor, PCR product and BseG1  Enzyme digest to 
demonstrate Genotypes 
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Figure 32: Schematic presentation of the 5-HT1B receptor, PCR product and NIaIII  Enzyme digest to 
demonstrate Genotypes 
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Figure 33: Schematic presentation of the 5-HT2A receptor, PCR product and MspI  Enzyme digest to 
demonstrate Genotypes 
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Figure 34: Schematic presentation of the 5-HT2C receptor, PCR product and NIaIII  Enzyme digest to 
demonstrate Genotypes 
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Figure 35: Schematic presentation of the 5-HT7  receptor, PCR product and XhoI  Enzyme digest to 
demonstrate Genotypes 
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5.6 Sequencing 
To check and confirm our results of PCR and endonuclease function, selected samples of 
each receptor (5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C, and 5-HT7) forward and reverse strands of 
wild, polymorphic and heterozygous genotype were verified by direct DNA sequencing to 
Cambridge geneservice. The data files sent to us were in the ABI format. These were 
opened and reviewed using a freely downloadable software called “ Finch TV”. This 
software can be accessed by clicking on the following link. 
http://www.geospiza.com/Products/finchtv.shtml . The sequencing confirmed our results 
and hence the polymorphisms for each receptor. (Figures 36-40) 
From the sequencing results we can confirm the working primer for 5-HT1A where the 
penultimate nucleotide at the 3’ ends of the reverse primer was deliberately altered from 
a thymine (T) to an adenine (A).  Similarly in 5-HT2C the 3rd last nucleotide at the 3’ end of 
the forward primer has been changed from Adenine (A) to Cytosine (C) to create a 
restriction site for the action of the endonuclease.  
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Figure 36: Sequencing snapshots for 5HT1A showing and confirming 3 different genotypes in both 
forward and reverse complements 
 
5HT 1A (Ensembl sequence) 
GAGTAAGGCTGGACTGTTAGATGATAACGGAGGTACCGTTTTGTTGTTGTTGTCGTCGTTGTTCGTTTGTTTTTGG 
AGACGGAGTCTCGCTCTGTCGCCCAGGCTGGAGTGCAATGGCGCGAGAACGGAGGTAGCTTTTTAAAAAGGATGACA
CACTCGGTCTTCTTCC 
5HT 1A (94) Forward & Reverse  C/C 
 
5HT1A (98) Forward & REVERSE : G/C 
 
5HT1A (99) Forward & Reverse : G/G 
 
138 
 
Figure 37: Sequencing snapshots for 5HT1B showing and confirming 3 different genotypes in both forward 
and reverse complements 
 
5HT 1B (Ensembl sequence) 
CTCAAGCAGTACTTCACCCTCCTGCACTAGACGCCTCCAGGGAGCTGGAGCGGAGCAGGGCTCGGTGGGCCAGCTCT
TAGCAACCCAGGTCTAAGACCCGGTGTGGAGAGGAACAACCACAGACGCGGCGGCTTAGCTAGGCGCTCTGGAAGTG
CAGGGGAGGCGCCCGCCTGCCTTGGCTGCCGCACCCATGACCTCTAGTTTCAGCTGTGAACCTGGGCGGAGGAATAA
TTGAGGAACTCACGGAACTATCAACTGGGGACAAACCTGCGATCGCCACGGTCCTTCCGCCCTCTCCTTCGTCCGCT
CCATGCCCAAGAGCTGCGCTCCGGAGCTGGGGCGAGGAGAGCCATGGAGGAAC 
 
5HT 1B (14) Forward & Reverse  A/A 
 
5HT1B (105) Forward & REVERSE : T/C 
 
5HT1B (98) Forward & Reverse : T/T 
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Figure 38: Sequencing snapshots for 5HT2A showing and confirming 3 different genotypes in both 
forward and reverse complements 
5HT 2A (Ensembl sequence) 
GAGCAGAAACTATAACCTGTTAGTCCTTCTACACCTCATCTGCTACAAGTTCTGGCTTAGACATGGATATTCTTTGTGAAG
AAAATACTTCTTTGAGCTCAACTACGAACTCCCTAATGCAATTAAATGATGACACCAGGCTCTACAGTAATGACTTTAACT
CCGGAGAAGCTAACACTTCTGATGCATTTAACTGGACAGTCGACTCTGAAAATCGAACCAACCTTTCCTGTGAAGGGTGCC
TCTCACCGTCGTGTCTCTCCTTACTTCATCTCCAGGAAAAAAACTGGTCTGCTTTACTGACAGCCGTAGTGATTATTCTAA
CTATTGCTGGAAACATACTCGTCATCATGGCAGTGTCCCTAGAGAAAAAGCTGCAGAATGCCACCAACTATTTCCTGATGT
CACTTG 
5HT 2A (03) Forward & Reverse  C/C 
 
5HT2A (96) Forward & REVERSE : C/T 
 
5HT2A (92) Forward & Reverse : T/T 
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Figure 39: Sequencing snapshots for 5HT2C showing and confirming 3 different genotypes in both forward 
and reverse complements 
 
5HT 2C (Ensembl sequence) 
GGCCTATTGGTTTGGCCATGTGATATTTCTGTGAGCCCAGTAGCAGCTATAGTAACTGACATTTTCAATACCT
CCGATGGTGGACGCTTCAAATTCCCAGACGGGGTACAAAACTGGCCAGCACTTTCAATCGTCATCATAATAAT
CATGACAATAGGTGGCAACATCCTTGTGATCATGGC 
5HT 2C (30) Reverse:  G/G 
 
5HT2C (96) Forward & Reverse: G/C 
 
5HT2C (33) Forward & Reverse : G/G 
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Figure 40: Sequencing snapshots for 5HT7 showing and confirming 3 different genotypes in both forward 
and reverse complements 
5HT 7 (Ensembl sequence) 
CCTCCATCACCTTACCTCCACTCTTTGGATGGGCTCAGAATGTAAATGATGATAAGGTGTGCTTGATCAGCCAGGACTTTGGC
TATACGATTTACTCTACCGCAGTGGCATTTTATATCCCCATGTCCGTCATGCTTTTCATGTACTACCAGATTTACAAGGCTGCCA
GGAAGAGTGCTGCCAAACACAAGTTTCCTGGCTTCCCTCGAGTGGAGCCAGACAGCGTCATCGCCCTGAATGGCATAGTGAA
GCTCCAGAAGGAGGTGGAAGAGTGTGCAAACCTTTCGAGACTCCTCAAGCATGAAAGGAAAAACATCTCCATCTTTAAGCGA
GAACAGAAAGCAGCCACC 
5HT 7 (76) Reverse:  C/C 
 
5HT7 (102) Forward & Reverse: C/T 
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5.7 Statistical Analysis 
The frequency of the mutant alleles responsible for a monogenic disorder in a population 
is specified by the Hardy-Weinbuerg Distribution, which states that : 
p2 +2pq +q2 = 1 
where p is the allele frequency of the more common allele and q the frequency of the less 
common allele. The equation is only true if certain conditions are met , such as mating is 
random and there is no migration into or from the population. 
Hardy-Weinberg equilibrium for genotype frequencies was tested in both patients and 
controls using chi-square tests (χ2). Simple chi-square tests of independence were also 
performed to confirm the presence or absence of allele or genotype associations. Odds 
ratios (OR) with 95% confidence intervals (CI) were estimated for the effects of high-risk 
genotypes and alleles. 
To account for low frequencies in some groups, Fisher exact p tests were used to compare 
genotype and allelic distribution between the PMDD and control group. Stat Xact -4 
software was used for initial analysis of 5-HT1A results. This was further confirmed and 
for rest of the receptors on line calculator was used Kirkman, T.W. (1996) “Statistics to 
Use” http://www.physics.csbsju.edu/stats/  
Statistical significance was considered at exact p values of <0.05. Odds ratio were 
calculated to determine whether a particular genotype or allele was associated with an 
increased risk of PMDD. 
In the end a stepwise logistic analysis was performed to see any evidence of a specific 
association between any genotype and clinical category. 
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CHAPTER 6: 
GENETICS OF PREMENSTRUAL SYNDROME: INVESTIGATION OF 
SPECIFIC SEROTONIN RECEPTORS POLYMORPHISM: RESULT
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6.1 CLINICAL CATEGORISATION  
One hundred and four white European women from Stoke on Trent in the United 
Kingdom were identified and categorized into two groups. The group diagnosed with 
Premenstrual Dysphoric Disorder if there was a ≥200% increase in severity of one or 
more, or a ≥100% increase of two or more of the symptoms during the luteal phase 
compared to the follicular phase  during the two menstrual cycles, this group included 
fifty three cases, PMDD (n=53), with mean age 37.7 years (range 27-46 years). The other 
arm included fifty one ladies in the control group (n=51), with mean age 36.2 years (range 
22-48 years). 
6.2 POLYMORPHISM STUDIED  
Five Key Polymorphisms were studied in 5HT1A (C-1019G), 5HT1B (A-161T), 5HT2A (102T/C), 
5HT2C (Cys23-Ser23) and 5HT7 (Pro-257-Leu) receptors. These receptors and genes were 
selected according to the following criteria: involvement of the receptors in the function 
of serotonin; representative of the common receptor protein structure and equally 
spread around the evolutionary tree; they have been studied and shown to be linked to 
various other psychiatric diseases in a variety of different population groups with 
significant results.  
6.2.1 Receptor 5-HT 1A (C-1019G): 
C-1019G (identity number: rs6295 G/C) is the most investigated gene variation (SNP) on 
5-HT1A receptor which is present on chromosome 5q11.2-q13.332 A functional variant in 
the promoter region of the gene consists of a C to G substitution located at nucleotide 
position 
145 
 
92,928 (GDB: AC008965), and is 1019 base pairs (bp) downstream of the transcription 
initiation site.333  
YEAR AUTHER DISORDER Yes/No OUTCOME 
2003 Lemonde et 
al334 
Major depression 
& suicide 
Yes G (-1019) allele depresses 5-HT1A 
autoreceptor expression 
predisposing to suicide & depression. 
2003 Strobe et al Anxiety- and 
depression 
Yes Does play a role in the development 
and modulation of anxiety- and 
depression-related personality traits. 
2004 Chen TJ et 
al335 
Major Depression Yes findings suggest that this 5-HT1A 
polymorphism may affect AEP P2 
latency in a gender-dependent 
manner 
2004 Serretti A et 
al336;337 
Antidepressant 
response in 
depression 
Yes 5HT1A- C/C variants influence the 
antidepressant efficacy in bipolar 
subjects. 
2004 Huang et al338 Depression and 
substance abuse 
Yes An association seen between the 
polymorphism and schizophrenia, 
substance abuse and panic disorder 
2004 Rothe C et 
al339 
Panic disorder 
and Agrophobia 
Yes Significant association of the G allele 
in patients with panic disorder with 
agrophobia. 
2004 Lemonde et 
al340 
Antidepressant 
response 
Yes C-1019G 5-HT1A gene polymorphism 
is a potential marker for 
antidepressant response. 
2006 Yu YW et al341 Fluoxetine 
response in major 
depressive 
disorder 
Yes Female patients with -1019c/c 
showed a better response to 
fluoxetine. 
2008 Wu et al342 Major depressive 
disorder 
yes 5-HTR1A C (-1019) G polymorphism is 
probably associated with MDD and it 
is likely to be the susceptible gene 
locus for the female and late-onset 
MDD. 
2008 Le François B 
et al343 
Mental Illness Yes There is an association of the G(-
1019) allele with increased raphe 5-
HT1A binding potential, increased 
amygdala reactivity to emotional 
stimuli, and reduced amygdala 
volume, particularly in disease states, 
suggests a functional role for the C(-
1019)G site in 5-HT1A receptor dys-
regulation and predisposition to 
mental illness. 
Table 16: Studies Reporting Association Between 5-HT1A (C-1019G) Polymorphism and Several Diseases 
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This C(-1019)G polymorphism sits within a 26 bp palindromic region, which in humans 
binds two repressors known as Deaf-1 and He5.334 The polymorphism has been reported 
to be involved in modulating the rate of transcription of the 5-HT1A gene. The G allele 
fails to bind to these repressors, with a consequent upregulation of 5-HT1A autoreceptor 
expression and a reduction of serotonergic neurotransmission.344 Several studies have 
reported an association between the (-1019)G allele and major depression, panic disorder 
and suicide, and a decreased response to SSRIs in both Caucasian and Chinese subjects. 
(Table 16) Since low serotonin has also been implicated in the pathogenesis of PMDD, we 
postulated that women carrying at least one G allele would be at increased risk of 
premenstrual dysphoria. 
6.2.2 Receptor 5-HT 1B (A-161T) 
HTR1B is a presynaptic and postsynaptic receptor; it is located within the region of 6q13-
26. 5-HT1B is a single exon gene (does not have introns). A-161T polymorphism (rs130058 
SNP) located on the Chromosome 6:78173281 (forward strand) has been described in the 
5’UTR.345 It is a regulatory region and is on the binding site for the transcription factor AP-
1, hence affecting the AP-1 binding activity and gene expression.  
A-161T has been shown to modify transcriptional activity in choriocarcinoma and colon 
adenocarcinoma cell lines.346 A-161T has been associated in a population-based study 
with alcohol dependence in Chinese Han,346 and A-161 has been associated significantly in 
a family-based study of schizophrenia.345 Since HTR1B is involved in modulating the 
effects of serotonin (and indirectly other neurotransmitters) and A-161T has been shown 
to be functional,347 it may affect the brain function in PMDD and response to drugs. (Table 
17) 
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YEAR  AUTHER DISORDER Yes/No OUTCOME 
2002 Sun et al346 Alcohol 
dependence 
Yes  The HTR1B A-161T polymorphism 
may be valuable both as a functional 
and as an anonymous genetic marker 
for HTR1B. 
2003 Duan et al347 Function of the 
polymorphism 
Yes T-261G and A-161T exhibit opposing 
effect on gene expression 
2004 Duan et al348 schizophrenia No  HTR1B gene does not plays a major 
role in the etiopathogenesis of 
schizophrenia in Chinese Han 
population 
2004 Hong et al349 Attempted suicide, 
aggressive 
behaviour and 
schizophrenia 
No This genetic polymorphism does not 
play a major role in the pathogenesis of 
schizophrenic disorders 
2004 Tsai350 MDD No It does not play a major role in the 
susceptibility to MDD, nor related to 
suicidal attempt or the therapeutic 
response to fluoxetine in MDD. 
2005 Li et al351 Attention Deficit 
Hyperactivity 
Disorder 
Yes Found a trend towards excess 
transmission of the 861G allele 
and the 861G/161A haplotype in 
ADHD-I. 
2009 Lee et al352 Anxiety/depressio
n alcoholism 
yes 5HT1B gene A-161T polymorphisms 
might be one of the common genetic 
factors between the ANX/DEP ALC 
and antisocial ALC subgroups. 
2010 Jin-Xia Caoa et 
al353 
Alcohol 
dependence 
Yes A161Tpolymorphism was associated 
with alcohol dependence 
Table 17: Studies Reporting Association Between 5-HT1B (A-161T) Polymorphism and Several Diseases 
 
6.2.3 Receptor 5-HT 2A (102T/C) 
The human 5-HT2A receptor gene consists of three exons spanning more than 20 kb354 
and is located on chromosome 13q14-21.355 The silent C/T(102) polymorphism on exon 1 
does not alter the 34TH amino acid (serine) sequence of the 5-HT2A receptor but the T and 
C allele quantitatively differ in their expression and function.356 
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YEAR AUTHER DISORDER Yes/No OUTCOME 
1996 Ozaki et al357 Seasonal affective 
disorder 
Yes There was significant linkage 
disequilibrium bet 102-T/C and 516-T/C 
both in SAD patients and controls 
1996 Erdmann et 
al358 
Schizophrenia Yes There is an association of the non-coding 
polymorphism 102T/C with the 
development of schizophrenia. 
1997 Zhang HY et 
al359 
Mood disorder Yes The C allele frequency  was higher in 
depressed patient 
1998 Holmes et al360 Psychosis in 
Alzheimer’s 
disease 
Yes It is associated with psychotic symptoms 
in AD but are clinically silent until the 
onset of the neurodegenerative process. 
2001 Du. L et al361 Depression & 
Suicide 
Yes Showed this polymorphism was 
significantly associated with suicide 
ideation in depressed patient 
2001 Arias B et al362 Seasonal pattern 
to major 
depression 
Yes Variation may play a role in the 
development of major depression with 
seasonal pattern 
2001 Arias B et al363 Suicidal 
behaviour in 
Depressed 
Yes I increased risk of suicidality conferred by 
5-HT(2A)-C allele. 
2003 Robertson et 
al364 
Bipolar affective 
puerperal 
psychosis 
No It does not appear to play a role in the 
development of bipolar affective puerperal 
psychosis. 
2003 Rocchi et al365 Psychosis in 
Alzheimer disease 
Yes A significant association between C/C 
genotype and psychotic symptoms in AD. 
2003 Holmes C et 
al366 
Depression in 
Alzheimer’s  
Yes Homozygous carriers of 5-HT2A 
C102allele were5 times more likely to 
have major depressive illness. 
2003 Inada et al367 Panic disorder Yes HTR2A plays an important role in the 
pathogenesis of panic disorder 
 
2004 Lam LC et 
al368 
Alzheimer’s 
disease 
Yes Certain symptoms in AD are associated 
with receptor polymorphism. 
2005 Maron E et 
al369 
Major Depression 
& Panic disorder 
Yes Pure PD was associated with the 5HT2A 
polymorphism 
2005 Zalsman G370 Family based 
association study  
of suicide in 
adolescents 
No It is unlikely to be associated with suicidal 
behaviour in adolescent suicide behaviour. 
 
Table 18: Studies Reporting Association Between 5-HT2A (102T/C) Polymorphism and Several Diseases 
 
 
Over representation of the 102C allele has been shown to cause lower expression of the 
5-HT2A receptor than the T allele,356 and has been linked to many psychiatric disorders 
including schizophrenia.371;372 (Table 18) The silent polymorphism contributing to the 
genetic disposition of disorder suggests that a functional mutation in a regulatory region 
of the gene is in linkage disequilibrium with the 102T/C variant.253;358  
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6.2.4 Receptor 5-HT 2C (Cys23-Ser23) 
5-HT2C receptor is on the long arm of the X chromosomw. 5-HT2C is widely spread in the brain 
and is involved in the regulation, production and secretion of hormones like ACTH,257 Oxytocin373 
and Prolactin.374 A structural variant of the serotonin 2C (5-HT2C) on exon 2, receptor gene 
(68G/C), gives rise to a cysteine to serine substitution in the N terminal extracellular domain of 
the receptor protein (cys23ser). The site of Cys23-Ser23 substitution is within the first 
hydrophobic region of the human 5-HT2C receptor.331 This substitution may alter the protien 
folding by altering the disulphide bonds.331 Ser23 appears to be an abundant candidate allele 
capable of directly influencing inter-individual variation in behaviour and susceptibility to mental 
disorder.375 (Table 19) 
6.2.5 Receptor 5-HT 7(Pro-279-Leu) 
The 5-HT7 gene (HTR7), cloned in 1993376;377, locates in human chromosome 10q21-24378 and 
contains three exons and one alternative splice exon. A Cytosine to Thymidine polymorphism 
leading to Proline to leucine amino acid substitution on 279 position in the third intracellular loop 
of the receptor protein has been studied in various disorders.379;380 (Table 20) This point 
substitution changes the protein and affects the G-protein coupling sufficient to modify the 
function of the receptor. 
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YEAR AUTHER DISORDER Yes/No OUTCOME 
1996 Gutierrez et 
al381 
Bipolar affective 
disorder  
Yes The Ser23 allele may increase the 
susceptibility to bipolar affective 
disorder in women. 
 
1997 Oruc et al382 Bipolar disorder Yes Variations in these genes may be 
responsible for a minor increase in 
susceptibility for bipolar disorder in 
women. 
 
1997 Ebstein et 
al383 
Human personality 
trait of reward 
dependence 
Yes It has been shown to be related to the 
personality trait of reward dependence 
1998 Holmes et 
al360 
Psychosis in 
Alzheimer’s disease 
Yes It is associated with psychotic 
symptoms in AD but are clinically 
silent until the onset of the 
neurodegenerative process. 
 
2000 Evans et al384  Impulsivity Yes Cys23Ser is related to the 
impulsiveness and deliberate self-
harm. 
 
2000 Segman et 
al385 
Tardive dyskinesia 
in Chronic 
schizophrenia 
Yes Significant excess of Ser23 allele in 
females with TD in schizophrenia 
2001 Lerer B et 
al386 
Affective disorder Yes This variation does have a role in 
major affective disorder 
 
2001 Gutierrez et 
al387 
Bipolar affective 
disorder 
Yes Only a slight increase of s-Ser23 
haplotype was found in the subgroup 
of bipolar women with family history 
of psychiatric illness 
 
2003 Holmes C et 
al366 
Depression in 
Alzheimer’s disease 
Yes Homozygous or hemizygous carrier of 
5-HT2C Ser were 12 times more likely 
to have major depressive illness. 
 
2003 Johann et 
al388 
Alcohol 
dependence with 
attention Deficit 
disorder.  
No This polymorphism does not 
contribute to the supposed common 
genetic predisposition of ADHD and 
alcohol dependence 
 
Table 19: Studies Reporting Association Between 5-HT2c (Cys23-Ser23) Polymorphism and Several 
Diseases 
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YEAR  AUTHER DISORDER Yes/No OUTCOME 
1995 Gelernter et 
al378 
Tourette syndrome No Excluded genetic linkage between this 
locus and Tourette syndrome under a 
reasonable set of assumptions. 
1996 Erdmann J et 
al379 
Bipolar affective 
disorder & 
schizophrenia 
No Does not play a major role in the 
development of bipolar affective 
disorder and schizophrenia 
1998 Pesonen et 
al380 
Alcoholics Yes The 5-HT7Leu279 allele may be a 
predisposing allele in a subgroup of 
alcoholic offenders with multiple 
behavioral problems. 
1999 Hinney et al389 Obesity, 
underweight or 
anorexia nervosa 
No None of the association tests revealed 
nominal P-values below 0.3. 
2003 Kiel et al390 Psychiatric 
diseases 
Yes This may have relevance for the action 
of new drugs which affect psychiatric 
diseases like schizophrenia. 
Table 20: Studies Reporting Association Between 5-HT7 (Pro-297-Leu) Polymorphism and Several Diseases 
 
6.3 GENOTYPES 
DNA was extracted successfully from whole blood in all 104 samples. The GAPDH or 
housekeeping genes were identified in all above samples. 
All experiments were done in duplicates and each genotyping was individually analysed 
by two researchers and assessors with aim to achieve 100% agreement. If there was any 
discrepancy with the result the experiment was performed again. We were blinded to the 
clinical categorisation during the course of the experiments until the time for analysing 
the data. 
We achieved 100% agreement between the two assessors. The genotype distribution of 
the tested polymorphisms is shown in (table 21) for the controls and (table 22) for the 
PMDD group. 
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Patient ID 
Code 
5HT  
7 
5-HT 
1A 
5-HT 
1B 
5-HT 
2A 
5-HT 
2C 
1 C/C G/C A/T T/C C/C 
2 C/C G/G A/T C/C C/C 
6 C/C C/C T/T C/C C/C 
9 C/C G/C A/T T/C C/C 
12 C/C G/C A/T C/C C/C 
18 C/C G/C A/T C/C C/C 
23 C/C G/G A/T T/C C/S 
24 C/C G/G A/T T/T C/S 
26 C/C G/C A/T T/C C/C 
27 C/C C/C A/A T/T C/C 
30 C/C G/C A/A T/C C/C 
32 C/C G/G A/A T/C C/C 
35 C/C G/C A/T T/T C/C 
37 C/C G/G A/A C/C C/C 
38 C/C G/C A/A T/C C/S 
39 C/C G/C A/A T/T C/C 
41 C/C C/C A/A T/T C/C 
43 C/C G/C A/T C/C C/C 
46 C/C G/G A/T T/T C/C 
49 C/C C/C A/T T/C C/C 
50 C/C G/G A/A T/C C/S 
51 C/C G/G A/A T/C C/C 
54 C/C G/G A/T T/C C/S 
55 C/C G/G A/T T/C C/C 
 
Table 21: Control group – genotypes 
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Patient ID 
Code 
5-HT 
7 
5-HT 
1A 
5-HT 
1B 
5-HT 
2A 
5-HT 
2C 
56 C/C G/C A/A T/C C/C 
57 C/C G/C A/T T/C C/C 
58 C/C G/G A/T C/C C/C 
59 C/C G/G A/A C/C C/C 
61 C/C G/G A/T C/C C/C 
62 C/C G/G A/A C/C C/C 
63 C/C G/C T/T C/C C/C 
65 C/C G/G A/A T/C C/C 
66 C/C C/C A/A T/C C/C 
73 C/C C/C A/A T/C C/S 
74 C/C G/G A/T C/C C/C 
86 C/C G/G T/T T/C C/C 
88 C/C G/C A/A T/C C/S 
89 C/C G/C A/T T/T C/C 
90 C/C G/C A/A C/C C/C 
94 C/C C/C A/A T/T C/C 
95 C/C G/G A/A T/C C/C 
96 C/C C/C A/A T/C S/S 
97 C/C G/C A/T T/C C/C 
98 C/C G/C T/T T/C C/C 
99 C/C G/G A/T T/C C/S 
100 C/C G/C A/T C/C C/C 
102 T/C G/C A/A T/C C/C 
103 C/C G/C A/A C/C C/S 
104 C/C G/G T/T T/T C/S 
105 C/C G/C A/T C/C C/S 
106 C/C C/C A/A C/C C/S 
 
Table 21: Control group – genotypes (Continued) 
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Patient ID 
Code 
5HT  
7 
5-HT 
1A 
5-HT 
1B 
5-HT 
2A 
5-HT 
2C 
3  C/C G/C A/A C/C C/S                             
4  C/C C/C A/T C/C C/C 
5  C/C C/C A/T C/C C/C 
7 C/C C/C A/T C/C C/C 
8 C/C C/C A/A C/C C/C 
10  C/C G/G A/T C/C C/C 
11  C/C G/C A/T T/C C/C 
13  C/C C/C A/T C/C C/C 
14  C/C G/C A/A T/T C/C 
15  C/C G/C A/T T/T C/S 
16  C/C G/G A/A T/C C/C 
17  C/C G/C A/T T/C C/S 
19  C/C C/C A/T C/C C/S 
20  C/C C/C A/A T/T C/S 
21 C/C G/G A/T C/C C/C 
25 C/C G/C T/T T/T C/C 
28  C/C C/C A/A T/C C/C 
29 C/C G/C A/T T/T C/C 
31  C/C G/G A/T T/C C/S 
34  C/C C/C A/T T/C S/S 
36 C/C G/C A/T T/T C/C 
40  C/C G/C T/T T/C C/S 
42 C/C G/C A/A C/C C/C 
44  C/C G/G A/A C/C C/C 
45 C/C G/C A/T T/C C/C 
47 C/C G/C A/A T/C C/S 
48 C/C G/C A/A T/C C/C 
 
Table 22: PMDD group – genotypes 
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Patient ID 
Code 
5-HT 
7 
5-HT 
1A 
5-HT 
1B 
5-HT 
2A 
5-HT 
2C 
52 C/C G/C A/T T/C C/C 
53  C/C G/C A/A T/C C/C 
60 C/C G/G A/A T/C C/C 
64 C/C C/C A/T C/C C/S 
67 C/C G/C A/A T/C C/S 
68 C/C C/C T/T T/T C/C 
69 C/C G/G T/T C/C C/C 
70 C/C G/C A/T C/C C/C 
71 C/C G/G A/A T/C C/C 
72 C/C G/C A/A T/C C/S 
75  C/C C/C A/T T/C C/C 
76 C/C G/G A/A T/T C/S 
77 C/C C/C A/A T/C C/C 
78  C/C G/C A/A C/C C/S 
79 C/C G/C A/A C/C C/S 
80  C/C C/C A/A T/C C/C 
81 C/C C/C A/T C/C C/C 
82  C/C C/C A/A T/C C/C 
83 C/C G/C A/A T/C C/C 
84 C/C G/C A/A T/T C/C 
85 C/C G/G A/A T/C C/C 
87 C/C C/C A/A T/C C/C 
(91 C/C G/C A/A T/T C/C 
(93 C/C G/C A/A T/T C/C 
101 C/C C/C A/T T/C C/C 
107 C/C G/G A/T T/C C/C 
 
Table 22: PMDD group – genotypes (continued) 
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Our results of PCR and endonuclease function, were checked and confirmed on selected 
samples of each receptor (5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C, and 5-HT7). Both forward and 
reverse strands of wild, polymorphic and heterozygous genotype were verified by direct 
DNA sequencing. The genotype distribution and allelic frequencies in the PMDD and 
control groups is shown in (table 22) and (table 23) respectively. 
The frequency of the mutant alleles responsible for a monogenic disorder in a population 
is specified by the Hardy-Weinbuerg Distribution. The equation is only true if certain 
conditions are met. Such as mating is random and there is no migration into or from the 
population. Hence it follows the principle stating that in an infinitely large, randomly 
mating population in which selection, migration, and mutation do not occur, the 
frequencies of alleles and genotypes do not change from generation to generation and 
this should equate to 1. 
All genotype distributions conformed to the Hardy-Weinberg equilibrium, except for 5-
HT7 in the Control cohort (χ2 = 1.05,1 df). This deviation was attributed to the complete 
absence of the T/T genotype in women diagnosed with premenstrual dysphoria or 
Control. In 5-HT7 the amino acid substitution proline279- leucine is due to a cytosine(836) 
to thymidine DNA base substitution. The allele frequency of this polymorphism is low in 
all women genotyped and the only subject with the Leu279 variant is heterozygous. The 
detailed characteristics of the individuals with Leu279, was a healthy control in the control 
group.  Hence Leu279 allele did not associate significantly to PMDD (P=.306). 
All 5-HT1A genotypes conformed to the Hardy-Weinberg equilibrium (Controls χ2 1=0.46, 
PMDD χ2 1=0.32). Compared to the postulated ‘high risk’ G/G genotype, there was a 
marked overrepresentation of the C/C genotype in the PMDD group (odds ratio [OR] 3.63, 
95% confidence intervals [CI] 1.22-10.78; χ2 1=5.61, exact p=0.034). Dichotomising 
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genotypes into presence or absence of the C allele showed that presence of at least one C 
allele was associated with a 2.5-fold increased risk of PMDD (OR 2.46, 95% CI 1.03-5.88; 
χ2 1=4.23, exact p=0.053), when compared with the control group. Similarly, allelic 
distributions showed significant association of the C variant with PMDD (χ2 1=6.3, exact 
p=0.013). 
A stepwise logistic regression analysis of all other receptor genotypes showed no 
statistically significant association between any genotype and clinical category, and there 
were no statistically significant allelic distribution profiles between the PMDD and control 
groups (Table 22) and (Table 23).  
GENOTYPE GENOTYPE 
CODE 
CONTROLS 
(N = 51) 
PMDD 
(N=53) 
χ2  
 
DF p 
5HT-1A     
 
5.66 
 
 
2 
 
 
0.059 
G/C 27 22(43%) 24(45%) 
G/G 28 20(39%) 11(21%) 
C/C 29 9(18%) 18(34%) 
       
5HT-1B     
 
0.512 
 
 
2 
 
 
0.774 
A/T 30 23(45%) 21(40%) 
T/T 31 5(10%) 4(8%) 
A/A 32 23(45%) 27(52%) 
       
5HT-2A     
 
0.162 
 
 
2 
 
 
0.992 
T/C 33 25(49%) 25(47%) 
C/C 34 17(33%) 17(32%) 
T/T 35 9(18%) 11(21%) 
       
5-HT-7     
 
1.05 
 
 
1 
 
 
0.306 
C/C 36 50(98%) 53(100%) 
T/C 37 1(2%) 0 
T/T 38 0 0 
       
5-HT-2C     
 
0.115 
 
 
2 
 
 
0.994 
G/G 39 38(75%) 38(72%) 
G/C 40 12(23%) 14(26%) 
C/C 41 1(2%) 1(2%) 
Table 22: Genotypic frequencies, 2 and exact p values for each polymorphism  
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RECEPTOR ALLELS CONTROLS 
(N=51) 
PMDD 
(N=53) 
χ2 
 
DF P EXACT p 
5HT1A C-
1019G 
   6.3 1 0.12 0.13 
G 62(61%) 46(43%) 
C 40(39%) 60(57%) 
        
5HT1B A-161T    0.489 1 0.485 0.544 
A 69(68%) 75(72%) 
T 33(32%) 29(28%) 
        
5HT2A T102C    0.193 1 0.661 0.676 
T 59(58%) 57(55%) 
C 43(42%) 47(45%) 
        
5HT2C Cys23-
Ser23 
   0.789 1 0.779 0.845 
G 88(86%) 90(85%) 
C 14(14%) 16(15%) 
        
5HT7 Pro-279-
Leu 
   1.041 1 0.307 - 
C 101(99%) 106(100%) 
T 1(1%) 0(0%) 
Table 23: Allelic frequencies, 2 and exact p values for each polymorphism 
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CHAPTER 7:  
GENETICS OF PREMENSTRUAL SYNDROME: INVESTIGATION OF 
SPECIFIC SEROTONIN RECEPTORS POLYMORPHISM: DISCUSSION 
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7.1 DISCUSSION 
The genetic basis of susceptibility to PMDD has been widely studied through candidate 
gene approach. The success of this depends on the choice of a good candidate which may 
be hampered by incomplete knowledge of the role of individual gene products within a 
complex biological system. In this study we have tried to find a relationship between the 
various serotonin receptors and their subtypes by identifying their primary, secondary 
and tertiary structural similarity and done a Phylogenetic analysis to determine which 
genes are likely to have equivalent or diverse functions. We have also described five 
various nucleotide polymorphisms in candidate serotonin receptor genes involved in 
serotonin response. The genes analysed were 5HT1A, 5HT1B, 5HT2A, 5HT2C and 5HT7. These 
genes were selected according to the following criteria: involvement of the genes in the 
function of serotonin; representative of the common receptor protein structure and 
equally spread around the evolutionary tree; they have been studied and shown to be 
linked to various other psychiatric diseases in a variety of different population groups 
with significant results. Several authors have reported on the similarities and associations 
between PMS / PMDD and affective disorders for example anxiety, panic disorder, major 
depression and the seasonal affective disorder.391-396 Drugs active at these receptors are 
used in the treatment of many of the aforementioned mental disorders, depression and 
PMDD. These polymorphisms have been previously described and their suitability for 
genotyping assessed. The functional significance for some polymorphisms is not known 
even though some may be non-functional, others may be of unrecognised physiological 
importance. Even then they may serve as a useful indicator of the involvement of other 
unidentified liked allelic variants of the same gene in the disease pathogenesis.  
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This is the first reported genotypic analysis of 5HT1A (C-1019G), 5HT1B (A-161T), 5HT2A 
(T102C), 5HT2C (Cys23Ser) and 5HT7 (Pro279Leu)  
The serotonin-1A (5-HT1A) receptor is expressed on serotonin neurons as an 
autoreceptor where it regulates the activity of the entire serotonin system. Over-
expression of the 5-HT1A autoreceptor has been implicated in reducing serotonergic 
neurotransmission,397-399 and is associated with major depression and suicide, whereas 
post synaptic 5-HT1A receptors are reduced in depression400-403 and anxiety.404-407 5-HT1A 
is a receptor protein with seven hydrophobic transmembrane domains, typical of G-
protein coupled receptors and inhibits adenylyl cyclase activity, inactivate calcium 
channels, and activate potassium channels.408 The 5HT1A receptor is an intronless gene 
located on human chromosome 5q11.2-13C. 
The 5-HT1A C(–1019)G polymorphism is located in a transcriptional regulatory region and 
the sequence is within a 26-bp palindrome, a possible site of protein-DNA interactions. 
We studied the C(-1019)G polymorphism in PMDD. In our study there was a significant 
excess of the C/C genotype and C allele in the PMDD group compared to controls. Our 
finding is in stark contrast to previous studies of this marker in psychiatric disorders, 
which showed the G/G genotype and the G allele to be significantly associated with major 
depression, suicide, panic disorders and agoraphobia.409;410  
Given that mood disorders and PMDD share several key symptoms such as irritability, 
depression, anxiety and affect lability, and the fact that SSRIs comprise standard 
treatment for both pathologies, our results were unexpected. However, there are two 
crucial differences between the psychological symptoms of premenstrual dysphoria and 
those of other mood disorders. First, PMDD symptoms are cyclical, occurring exclusively 
during the luteal-phase of ovulatory cycles, then dissipating during menses; in contrast to 
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the chronicity of symptoms in major depression.  Second, the therapeutic response to 
SSRIs is more immediate in PMDD; in most cases within one menstrual cycle after starting 
treatment 411. This characteristic has led to targeted luteal-phase SSRI therapy, which has 
been shown to be as effective as continuous treatment throughout the menstrual cycle 
412;413. In contrast, a lag of 3-6 weeks is required before SSRIs achieve their maximum 
effect in mood disorders. Recent studies of the C(-1019)G polymorphism in major 
depression have reported that female patients with the C/C genotype showed a better 
response to SSRIs than those with the G variant414;415. This improved response was 
independent from clinical variables (p=0.036)416. Although the functional characteristics 
of the C/C genotype do not explain why it would increase susceptibility to PMDD, it may 
provide insight into the rapid and effective response to SSRIs. Our control group C(-
1019)G data did not concur with that of any white Caucasian study reported to date. 
However, there does appear to be a wide variation in genotype and allelic frequencies for 
this marker between different white Caucasian control groups, even within the same 
country409;417-419. Thus, our C(-1019)G data may represent a local genotypic anomaly. Our 
original PMDD study 420 which genotyped eight polymorphic markers of serotonin 
metabolism used the same cohort of women as presented here. The allelic frequencies in 
the control group concurred with those in other European Caucasian studies for all 
polymorphisms except the serotonin transporter (5-HTT) VNTR-2, which showed an 
excess of the 12-repeat allele compared to other reports. Thirdly, the association 
between the C(-1019)G marker and premenstrual dysphoria may be affected by sample 
size. Our study population is relatively small, nevertheless the control group statistics 
from our previous study indicate that the numbers are sufficient to provide reliable initial 
data for the C(-1019)G polymorphism.  
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5-HT1B is a receptor found both presynaptic and postsynaptic regions. It is widely 
distributed in the basal ganglia, hippocampus, and cortex. Studies have shown marked 
behavioural changes interestingly in both overexpression and in knockout mice.421;422 The 
5-HT1B receptors localized presynaptically on serotonergic terminals inhibit the release of 
5-HT hence inhibitory autoreceptors, and postsynaptically on other nerve endings, where 
they inhibit the release of various neurotransmitters.423  
The human 5-HT1B gene is located on chromosome 6q14.1. The 5-HT1B does not have 
introns hence has a single exon, and is implicated to harbour a schizophrenia 
susceptibility gene (SCZD5).424 We looked at the A-161T polymorphism which has been 
described in the 5’UTR of 5-HT1B gene as it is a good candidate variant for association 
studies due to being functional.347 A-161T has been shown to be associated with alcohol 
dependence and schizophrenia.345;346 Based on the above, we hypothesize that A-161T 
polymorphism in the HTR1B gene may relate to the aetiology of PMDD. 
We found no significant differences in allele (χ2=0.489; df=1; Exact P=0.544) and genotype 
(χ2=0.512; df=2; p=0.774) frequencies between the patient or control groups, although at 
this polymorphic site the A allele frequency was seen more than the T allele both in 
controls (frequency 0.68 vs 0.32) and study types(frequency 0.72 vs 0.38). 
The 5-HT1B receptor is involved in modulating the release of serotonin and other 
neurotransmitters, especially dopamine, so the altered expression of the 5-HT1B receptor 
may lead to a disturbance in the central nervous system, which may be a factor in the 
development of PMDD. Because PMDD is a disorder that affects neurobehavioral 
features, it is likely some other polymorphism in 5-HT1B may lead to dysregulation the 
receptor in turn leading to suboptimal regulation of more than one neurotransmitter; this 
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ultimately may manifest as symptoms of the PMDD. Hence further studies are needed to 
investigate the other polymorphisms. 
A cDNA that encodes HTR2A has been isolated, and the gene is localized on chromosome 
13 q14-q21.425;426 The cDNA shows an MspI polymorphic site at position T102C.427 5HT2A 
receptor is of great interest as various neuroleptic agents and antidepressant bind with 
high affinity to this receptor.428 5HT2 receptors have seven transmembrane domains that 
share amino acid identity with each other and with other members of the G-protein 
coupled receptor superfamily. 
 Statistically significant association between the silent T102C polymorphism in the 5HT2A 
receptor gene and multiple psychiatric disorders has been reported suggesting genetic 
predisposition to these conditions may be affected by a functional 5HT2A variant that is in 
linkage disequilibrium with 102T/C.358;429 Hence we wanted to look for similar association 
in our study group with PMDD 
We found no significant differences in allele (χ2=0.193; df=1; Exact P=0.0676) and 
genotype (χ2=0.162; df=2; p=0.992) frequencies between the patient or control groups, 
although at this polymorphic site the TCTG allele frequency was seen more than the TCCG 
allele both in controls(frequency 0.58 vs 0.42) and study types(frequency 0.55 vs 0.45). 
Even though in other studies with white European population; the TCCG allele is more 
prevalent in the normal population (frequency 0.6 versus 0.4).358;427;429;430 In spite of the 
fact that all patients in this study were white European, it is still possible that stratification 
occurred. 
We have failed to replicate the association between T102C polymorphism in 5HT2A and 
other psychiatric conditions.371;429;431 Association studies in unrelated individuals are 
designed to detect the coincidence of a polymorphic marker and disease states, the 
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association exists either because the mutation studied is pathogenetic or because it is in 
linkage disequilibrium with the causative mutation- i.e. it has not been separated by 
recombination in the time since the mutation occurred.432 The fact that the C to T 
mutation does not change the amino acid composition of the receptor suggests that the 
linkage disequilibrium is the more likely possibility in the significant studies, the marker 
being in close proximity to the causative mutation.433  Failure to replicate significant 
results in small size samples also points to a minor gene effect. 
The serotonin (5-HT)2C receptor is distributed widely throughout the brain, but is densely 
expressed in regions implicated in anxiety, mood, drug-induced hallucinogenesis, reward, 
neuroendocrine regulation, and appetite.434 The HTR2C gene is located on chromosome 
Xq24.  A Cys–Ser polymorphism at amino acid 23 in the first hydrophobic region of HTR2C 
has been identified.435 Allele frequencies in unrelated Caucasians in other studies were 
0.13 and 0.87 for 5HT2CSer and 5HT2CCys respectively.435;436  This coding SNP was choosen 
to study because an in vitro study showed that the Ser23 is more active than the Cys23.436 
We found no significant differences in allele (χ2=0.789; df=1; Exact P=0.845) and genotype 
(χ2=0.115; df=2; p=0.994) frequencies between the patient or control groups, although at 
this polymorphic site the Cys23 allele frequency was seen more than the Ser23 allele both 
in controls(frequency 0.88 vs 0.14) and study types(frequency 0.85 vs 0.15). This finding is 
consistent the other studies which have shown that the frequencies of the Cys23 and 
Ser23 alleles in unrelated Caucasians are 0.87 and 0.13, respectively.435;436 We also 
noticed that the homozygous for Ser23/Ser23 in both controls and PMDD group was just 
2% compared to the wild type Cys23/Cys23 (controls 75%, PMDD 72%) and heterozygous 
form Cyst23/Ser23 (controls 23%, PMDD 26%). Hence there is more transmission of Cys23 
allele and Cys23/Ser23 haplotype in our female population.   
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In our study, no association between the Cys23Ser polymorphism and PMDD was found. 
This is in contrast to Arzu Gunes et.al.437, who reported that the Ser23 allele was more 
frequent among male schizophrenic patients with Antipsychotic-induced extrapyramidal 
side effects (EPS). Segman et al. has also reported a similar significant association 
between the Cys23Ser polymorphism and tardive dyskinesia, with patients with 
dyskinesia having a higher frequency of the 23Ser allele.385 
Since the HTR2C gene is located on the X chromosome, the gender distribution may have 
influenced the allele frequency calculations in previous studies showing positive 
association between Cys23Ser polymorphism and various mood disorders.  
Taking the advantage of the X chromosome and PMDD in females it may be significant to 
look into the relationship between other polymorphism on 5-HT2C, or may be functional 
studies looking into interaction between various 5-HT2C and MAOA genes.  
The gene encoding the 5HT7 receptor has been localised to human chromosome 10q.438 
Based on its sequence it has a structure of seven hydrophobic transmembrane helices 
separated by three extracellular and three intracellular loops.269;376;379 Studies have 
evaluated the contribution of the genetic variation of the serotonin 5HT7 receptor to the 
development of schizophrenia and bipolar affective disorders.268;379;439 
A cytosine to thymidine (C → T) polymorphism, leading to a proline to leucine amino acid 
substitution at position 279 (pro279leu) in the third intracellular loop of the receptor 
protein was genotyped in our study.379  It has been postulate that the most likely 
consequence of the Pro279Leu point substitution is a change in local protein structure, 
which would affect G-protein coupling. Such an alteration at the molecular level could be 
sufficient to modify the function of the 5-HT7 receptor. In various studies the Leu279 
variant has been found in similar frequencies in all groups,379 whereas our study has 
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shown that not only the Pro279 genotype (frequency of 0.98 in controls and 1.00 in study 
group) but the C allele frequency is much more prevalent compared to the T allele 
(frequency 0.99 vs 0.01 in controls and 1.0 vs 0.0 in study group) which was seen in only 
one control candidate in the hetrozygous form (this has been confirmed by sequencing). 
Hence the allele frequency of this polymorphism is very low and the subject with the 
leucine variant is heterozygous who was in the control group. A similar finding was seen 
in a study by Pesonen et. al 1998440 where The allele frequency of this polymorphism is 
low (0.004 in all Finns genotyped) and all the subjects with the Leu279 variant are 
heterozygous that is 6 out of the 752 Finns and 0 from other Caucasians. Another study 
with Han Chinese population showed the complete absence of the Pro279Leu 
polymorphism in their study.441  The frequencies of this polymorphism in Western 
individuals are also rather low (around or smaller than 1%)379;442 
The expression of mRNA for the 5-HT7 receptor in the midline hypothalmus, thalamic and 
limbic structures indicates a role in affective behaviour and receptor might be a target of 
antipsychotic agents.390 Further the functional studies of  Pro279Leu variation are of 
interest because the third intracellular loop of the receptor in which it is located plays an 
important role in G protein coupling hence strongly influences cAMP formation and may 
modify signal transduction.390 The low leu279 allele frequency in our study limits the 
statistical power of the association analysis of this receptor, indicating that presence of 
this variant is not causally related to the development PMDD. Even the ambitious 
conscious effort to prove that PMDD is different to other psychiatric disorder may be 
impossible with this variant because of almost absence of the homozygous form in our 
study group. As our study group was only females and relatively small, there may be a link 
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between the presence of this allele and gender which may require further studies in 
males and females in larger population.    
One after another monogenic diseases are being successfully mapped within the human 
genome, however in diseases with a complex mode of transmission like PMDD and other 
Psychiatric disorders linkage studies with DNA Markers have been far less conclusive than 
hoped. Rational strategies for the advancement of psychopharmacology are dependent 
on furthering our currently sparse knowledge of the patho-physiologic basis of PMDD. To 
this end, human genetic approaches offer a promising alternative to traditional 
biochemical and neurophysiologic investigations as twin, family, and adoption studies all 
support the heritability of many psychiatric syndromes. Unfortunately, attempts to first 
map (i.e., localize a unique region of DNA shared by patients with a particular disorder) 
and then identify genes predisposing to PMDD have been frustrated by the complexity of 
the genetic mechanisms underlying behavioural phenotypes. With single gene disorders 
(also referred to as mendelian disorders) there is a simple, direct relationship between 
variation in a single gene and the phenotype that results. In contrast, the relationship 
between phenotype and genotype is not straightforward for complex genetic traits. In 
this setting, multiple different susceptibility genes and environmental factors interact in 
varying combinations within individuals who appear to have clinically indistinguishable 
phenotypes. This means that in any given sample of patients diagnosed with 
premenstrual dysphoric disorder, the number of individuals actually sharing a disease 
gene or genes in common might be very small such that the ‘‘effective’’ sample size does 
not provide enough power to detect the responsible genes.  
We have tried to reduce genetic heterogeneity in the patient sample by studying 
genetically isolated populations and by narrowing the affected phenotype under study 
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based on criteria of severity and robust Another approach is to greatly expand the sample 
size and number of DNA markers used in genetic association studies to increase the 
power to detect multiple possible genes contributing to disease in subsets of the sample. 
More often than not, results are not reproducible from study to study, in large part 
because of the heterogeneous nature of psychiatric diseases, the absence of a specific 
diagnostic laboratory test, and the modest numbers of patients in many studies. 
Some commonly studied polymorphisms, such as the C103T variant in the 5-HT2A 
receptor, are silent (i.e., do not change the genetic code), whereas other polymorphisms, 
such as the 5-HT2C receptor Cys23Ser allele, produce mutant proteins with no apparent 
alterations in functional properties. The clinical importance of such a subtle genetic 
variant may require analysis of other related genes in tandem.  
Methods for detecting genetic polymorphisms are advancing rapidly and now allow 
simultaneous genotyping of several nucleotide polymorphisms. 
 
7.2 SUMMARY 
PMS/PMDD remains a matter of concern due to controversies in its definition, diagnostic 
criteria, aetiology, pathophysiology and effective treatment modalities. According to the 
American Psychiatric Association (APA) Diagnostic and Statistical manual (DSM-IV) fourth 
edition the prevalence of PMDD is 3-8%. Recently International Society for Premenstrual 
Disorders (ISPMD) group has developed an international universally acceptable 
multidisciplinary agreement regarding definition, quantification and clinical trial design of 
premenstrual disorders (PMD). The impact of the disease on quality of life, marital and 
parental social adjustment is similar to the impact of major depressive disorder (MDD). 
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The global burden of the disease can be calculated by using the number of years of 
healthy lost to disability. The most elaborate diagnostic criteria for PMDD is APA DSM-IV 
criteria but this has some unsolved issues too. There is currently no accepted objective 
means of assessing PMS and clinical diagnosis relies predominantly on the subjective self-
reporting of symptomatology. There is very little doubt as to the direct relationship 
between the trigger caused by the normal ovarian cycle and CNS sensitivity to these 
hormonal changes.  
Genetic factors are also pertinent to the aetiology of PMDD as shown by family and twin 
studies. A wide range of therapeutic pharmacological and nonpharmacological 
interventions have been tested in the treatment of premenstrual symptoms. 
Continuous research is being conducted worldwide to find the aetiology of PMDD. Many 
studies have identified various abnormalities in the serotonin system in women with PMS 
and PMDD. These include abnormal levels of whole blood serotonin, serotonin platelet 
uptake, abnormal responses to serotonergic probes and exacerbation of premenstrual 
symptoms after tryptophan depletion.  
This is the first study linking the 5HT1A C(-1019) allele and PMDD. There was a marked 
over-representation of the C/C genotype of 5-HT1A C(-1019)G polymorphism in the 
PMDD  group. The presence of at least one C allele was associated with a 2.5-fold 
increased risk of PMDD. There were no significant associations between the other tested 
genotypes, allelic distribution and clinical category. These findings do not support a major 
role for common polymorphisms in contributing to susceptibility to PMDD. 
A combination of genetics, neurotransmitter’s pathology, endocrinology and imaging may 
help and lead us to the cause, diagnosis and management of this disorder. The Serotonin 
receptor gene polymorphisms not studied as yet are the potential areas for continued 
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investigation. However, preliminary data from our study and previously investigated 
polymorphisms by our group do not indicate that the genetic approach provides a robust 
diagnostic tool for PMDD.  
Until an objective means (molecular and / or imaging) of diagnosing for PMS is agreed, 
diagnosis is likely to relay on daily questionnaires such as the DRSP which most closely 
relates to the symptom factors within DSM IV PMDD.  
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Appendices 1: Protein sequences for Serotonin Receptors (FASTA format) 
Protein sequences for Serotonin Receptors     (FASTA format) 
 
1. 5-hydroxytryptamine receptor 1A; Short=5-HT1A 
>gi|231454|sp|P08908.3|5HT1A_HUMAN  
422 aa 
MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAAIALERSLQNV 
ANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVLCCTSSILHLCAIALDRYWAITD 
PIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPEDRSDPDACTISKDHGYTIYSTFGAFYIPLLL 
MLVLYGRIFRAARFRIRKTVKKVEKTGADTRHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGA 
VRQGDDGAALEVIEVHRVGNSKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGII 
MGTFILCWLPFFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCKFC 
RQ 
2. 5-hydroxytryptamine receptor 1B; Short=5-HT1B 
>gi|112821|sp|P28222.1|5HT1B_HUMAN  
390 aa 
MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNCSAKDYIYQDSISLPWKVLLVMLLALITLATTLSNAFV 
IATVYRTRKLHTPANYLIASLAVTDLLVSILVMPISTMYTVTGRWTLGQVVCDFWLSSDITCCTASILHL 
CVIALDRYWAITDAVEYSAKRTPKRAAVMIALVWVFSISISLPPFFWRQAKAEEEVSECVVNTDHILYTV 
YSTVGAFYFPTLLLIALYGRIYVEARSRILKQTPNRTGKRLTRAQLITDSPGSTSSVTSINSRVPDVPSE 
SGSPVYVNQVKVRVSDALLEKKKLMAARERKATKTLGIILGAFIVCWLPFFIISLVMPICKDACWFHLAI 
FDFFTWLGYLNSLINPIIYTMSNEDFKQAFHKLIRFKCTS 
3. 5-hydroxytryptamine receptor 1D; Short=5-HT1D 
>gi|112819|sp|P28221.1|5HT1D_HUMAN  
377aa 
MSPLNQSAEGLPQEASNRSLNATETSEAWDPRTLQALKISLAVVLSVITLATVLSNAFVLTTILLTRKLH 
TPANYLIGSLATTDLLVSILVMPISIAYTITHTWNFGQILCDIWLSSDITCCTASILHLCVIALDRYWAI 
TDALEYSKRRTAGHAATMIAIVWAISICISIPPLFWRQAKAQEEMSDCLVNTSQISYTIYSTCGAFYIPS 
VLLIILYGRIYRAARNRILNPPSLYGKRFTTAHLITGSAGSSLCSLNSSLHEGHSHSAGSPLFFNHVKIK 
LADSALERKRISAARERKATKILGIILGAFIICWLPFFVVSLVLPICRDSCWIHPALFDFFTWLGYLNSL 
INPIIYTVFNEEFRQAFQKIVPFRKAS 
4. 5-hydroxytryptamine receptor 1E; Short=5-HT1E 
>gi|112822|sp|P28566.1|5HT1E_HUMAN  
365aa 
MNITNCTTEASMAIRPKTITEKMLICMTLVVITTLTTLLNLAVIMAIGTTKKLHQPANYLICSLAVTDLL 
VAVLVMPLSIIYIVMDRWKLGYFLCEVWLSVDMTCCTCSILHLCVIALDRYWAITNAIEYARKRTAKRAA 
LMILTVWTISIFISMPPLFWRSHRRLSPPPSQCTIQHDHVIYTIYSTLGAFYIPLTLILILYYRIYHAAK 
SLYQKRGSSRHLSNRSTDSQNSFASCKLTQTFCVSDFSTSDPTTEFEKFHASIRIPPFDNDLDHPGERQQ 
ISSTRERKAARILGLILGAFILSWLPFFIKELIVGLSIYTVSSEVADFLTWLGYVNSLINPLLYTSFNED 
FKLAFKKLIRCREHT 
5. 5-hydroxytryptamine receptor 1F; Short=5-HT1F 
>gi|398967|sp|P30939.1|5HT1F_HUMAN  
366aa 
MDFLNSSDQNLTSEELLNRMPSKILVSLTLSGLALMTTTINSLVIAAIIVTRKLHHPANYLICSLAVTDF 
LVAVLVMPFSIVYIVRESWIMGQVVCDIWLSVDITCCTCSILHLSAIALDRYRAITDAVEYARKRTPKHA 
GIMITIVWIISVFISMPPLFWRHQGTSRDDECIIKHDHIVSTIYSTFGAFYIPLALILILYYKIYRAAKT 
LYHKRQASRIAKEEVNGQVLLESGEKSTKSVSTSYVLEKSLSDPSTDFDKIHSTVRSLRSEFKHEKSWRR 
QKISGTRERKAATTLGLILGAFVICWLPFFVKELVVNVCDKCKISEEMSNFLAWLGYLNSLINPLIYTIF 
NEDFKKAFQKLVRCRC 
6. 5-hydroxytryptamine receptor 2A; Short=5-HT-2 
>gi|543727|sp|P28223.2|5HT2A_HUMAN  
471aa 
MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGCLSPSCLSLLH 
LQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIADMLLGFLVMPVSMLTILYGYR 
WPLPSKLCAVWIYLDVLFSTASIMHLCAISLDRYVAIQNPIHHSRFNSRTKAFLKIIAVWTISVGISMPI 
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PVFGLQDDSKVFKEGSCLLADDNFVLIGSFVSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLAS 
FSFLPQSSLSSEKLFQRSIHREPGSYTGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFITNIMAVICK 
ESCNEDVIGALLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYK 
SSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV 
7. 5-hydroxytryptamine receptor 2B; Short=5-HT2B 
>gi|1168220|sp|P41595.1|5HT2B_HUMAN  
481aa 
MALSYRVSELQSTIPEHILQSTFVHVISSNWSGLQTESIPEEMKQIVEEQGNKLHWAALLILMVIIPTIG 
GNTLVILAVSLEKKLQYATNYFLMSLAVADLLVGLFVMPIALLTIMFEAMWPLPLVLCPAWLFLDVLFST 
ASIMHLCAISVDRYIAIKKPIQANQYNSRATAFIKITVVWLISIGIAIPVPIKGIETDVDNPNNITCVLT 
KERFGDFMLFGSLAAFFTPLAIMIVTYFLTIHALQKKAYLVKNKPPQRLTWLTVSTVFQRDETPCSSPEK 
VAMLDGSRKDKALPNSGDETLMRRTSTIGKKSVQTISNEQRASKVLGIVFFLFLLMWCPFFITNITLVLC 
DSCNQTTLQMLLEIFVWIGYVSSGVNPLVYTLFNKTFRDAFGRYITCNYRATKSVKTLRKRSSKIYFRNP 
MAENSKFFKKHGIRNGINPAMYQSPMRLRSSTIQSSSIILLDTLLLTENEGDKTEEQVSYV 
8. 5-hydroxytryptamine receptor 2C; Short=5-HT-2C 
>gi|112816|sp|P28335.1|5HT2C_HUMAN  
458aa 
MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSIVIIIIMTIGG 
NILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVWPLPRYLCPVWISLDVLFSTA 
SIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVWAISIGVSVPIPVIGLRDEEKVFVNNTTCVLN 
DPNFVLIGSFVAFFIPLTIMVITYCLTIYVLRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANP 
NQDQNARRRKKKERRPRGTMQAINNERKASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLL 
NVFVWIGYVCSGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTN 
EPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV 
9. 5-hydroxytryptamine receptor 3A; Short=5-HT3A 
>gi|1168222|sp|P46098.1|5HT3A_HUMAN  
Full=Serotonin-gated ion channel receptor 
478aa 
MLLWVQQALLALLLPTLLAQGEARRSRNTTRPALLRLSDYLLTNYRKGVRPVRDWRKPTTVSIDVIVYAI 
LNVDEKNQVLTTYIWYRQYWTDEFLQWNPEDFDNITKLSIPTDSIWVPDILINEFVDVGKSPNIPYVYIR 
HQGEVQNYKPLQVVTACSLDIYNFPFDVQNCSLTFTSWLHTIQDINISLWRLPEKVKSDRSVFMNQGEWE 
LLGVLPYFREFSMESSNYYAEMKFYVVIRRRPLFYVVSLLLPSIFLMVMDIVGFYLPPNSGERVSFKITL 
LLGYSVFLIIVSDTLPATAIGTPLIGVYFVVCMALLVISLAETIFIVRLVHKQDLQQPVPAWLRHLVLER 
IAWLLCLREQSTSQRPPATSQATKTDDCSAMGNHCSHMGGPQDFEKSPRDRCSPPPPPREASLAVCGLLQ 
ELSSIRQFLEKRDEIREVARDWLRVGSVLDKLLFHIYLLAVLAYSITLVMLWSIWQYA 
10. 5-hydroxytryptamine receptor 3B; Short=5-HT3B 
>gi|74705987|sp|O95264.1|5HT3B_HUMAN  
451aa 
MLSSVMAPLWACILVAAGILATDTHHPQDSALYHLSKQLLQKYHKEVRPVYNWTKATTVYLDLFVHAILD 
VDAENQILKTSVWYQEVWNDEFLSWNSSMFDEIREISLPLSAIWAPDIIINEFVDIERYPDLPYVYVNSS 
GTIENYKPIQVVSACSLETYAFPFDVQNCSLTFKSILHTVEDVDLAFLRSPEDIQHDKKAFLNDSEWELL 
SVSSTYSILQSSAGGFAQIQFNVVMRRHPLVYVVSLLIPSIFLMLVDLGSFYLPPNCRARIVFKTSVLVG 
YTVFRVNMSNQVPRSVGSTPLIGHFFTICMAFLVLSLAKSIVLVKFLHDEQRGGQEQPFLCLRGDTDADR 
PRVEPRAQRAVVTESSLYGEHLAQPGTLKEVWSQLQSISNYLQTQDQTDQQEAEWLVLLSRFDRLLFQSY 
LFMLGIYTITLCSLWALWGGV 
11. RecName: Full=5-hydroxytryptamine receptor 3C; Short=5-HT3C 
>gi|166198366|sp|Q8WXA8.2|5HT3C_HUMAN  
447aa 
MEGGWPARQSALLCLTVSLLLQGRGDAFTINCSGFDQHGVDPAVFQAVFDRKAFRPFTNYSIPTRVNISF 
TLSAILGVDAQLQLLTSFLWMDLVWDNPFINWNPKECVGINKLTVLAENLWLPDIFIVESMDVDQTPSGL 
TAYISSEGRIKYDKPMRVTSICNLDIFYFPFDQQNCTFTFSSFLYTVDSMLLGMDKEVWEITDTSRKVIQ 
TQGEWELLGINKATPKMSMGNNLYDQIMFYVAIRRRPSLYIINLLVPSSFLVAIDALSFYLPAESENRAP 
FKITLLLGYNVFLLMMNDLLPASGTPLISVYFALCLSLMVVSLLETVFITYLLHVATTQPPPMPRWLHSL 
LLHCTSPGRCCPTAPQKGNKGLGLTLTHLPGPKEPGELAGKKLGPRETEPDGGSGWTKTQLMELWVQFSH 
AMDTLLFRLYLLFMASSILTVIVLWNT 
12. RecName: Full=5-hydroxytryptamine receptor 3D; Short=5-HT3D 
>gi|74712683|sp|Q70Z44.1|5HT3D_HUMAN  
454aa 
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MQKHSPGPPALALLSQSLLTTGNGDTLIINCPGFGQHRVDPAAFQAVFDRKAIGPVTNYSVATHVNISFT 
LSAIWNCYSRIHTFNCHHARPWHNQFVQWNPDECGGIKKSGMATENLWLSDVFIEESVDQTPAGLMASMS 
IVKATSNTISQCGWSASANWTPSISPSMDRARAWRRMSRSFQIHHRTSFRTRREWVLLGIQKRTIKVTVA 
TNQYEQAIFHVAIRRRCRPSPYVVNFLVPSGILIAIDALSFYLPLESGNCAPFKMTVLLGYSVFLLMMND 
LLPATSTSSHASLVAPLALMQTPLPAGVYFALCLSLMVGSLLETIFITHLLHVATTQPLPLPRWLHSLLL 
HCTGQGRCCPTAPQKGNKGPGLTPTHLPGVKEPEVSAGQMPGPGEAELTGGSEWTRAQREHEAQKQHSVE 
LWVQFSHAMDALLFRLYLLFMASSIITVICLWNT 
13. RecName: Full=5-hydroxytryptamine receptor 3E; Short=5-HT3-E 
>gi|162416113|sp|A5X5Y0.1|5HT3E_HUMAN  
456aa 
MEGSWFHRKRFSFYLLLGFLLQGRGVTFTINCSGFGQHGADPTALNSVFNRKPFRPVTNISVPTQVNISF 
AMSAILDVNEQLHLLSSFLWLEMVWDNPFISWNPEECEGITKMSMAAKNLWLPDIFIIELMDVDKTPKGL 
TAYVSNEGRIRYKKPMKVDSICNLDIFYFPFDQQNCTLTFSSFLYTVDSMLLDMEKEVWEITDASRNILQ 
THGEWELLGLSKATAKLSRGGNLYDQIVFYVAIRRRPSLYVINLLVPSGFLVAIDALSFYLPVKSGNRVP 
FKITLLLGYNVFLLMMSDLLPTSGTPLIGVYFALCLSLMVGSLLETIFITHLLHVATTQPPPLPRWLHSL 
LLHCNSPGRCCPTAPQKENKGPGLTPTHLPGVKEPEVSAGQMPGPAEAELTGGSEWTRAQREHEAQKQHS 
VELWLQFSHAMDAMLFRLYLLFMASSIITVICLWNT 
14. 5-hydroxytryptamine receptor 4; Short=5-HT4 
>gi|12644029|sp|Q13639.2|5HT4R_HUMAN  
 
MDKLDANVSSEEGFGSVEKVVLLTFLSTVILMAILGNLLVMVAVCWDRQLRKIKTNYFIVSLAFADLLVS 
VLVMPFGAIELVQDIWIYGEVFCLVRTSLDVLLTTASIFHLCCISLDRYYAICCQPLVYRNKMTPLRIAL 
MLGGCWVIPTFISFLPIMQGWNNIGIIDLIEKRKFNQNSNSTYCVFMVNKPYAITCSVVAFYIPFLLMVL 
AYYRIYVTAKEHAHQIQMLQRAGASSESRPQSADQHSTHRMRTETKAAKTLCIIMGCFCLCWAPFFVTNI 
VDPFIDYTVPGQVWTAFLWLGYINSGLNPFLYAFLNKSFRRAFLIILCCDDERYRRPSILGQTVPCSTTT 
INGSTHVLRDAVECGGQWESQCHPPATSPLVAAQPSDT 
15. 5-hydroxytryptamine receptor 5A; Short=5-HT5A 
>gi|1345607|sp|P47898.1|5HT5A_HUMAN  
357aa 
MDLPVNLTSFSLSTPSPLETNHSLGKDDLRPSSPLLSVFGVLILTLLGFLVAATFAWNLLVLATILRVRT 
FHRVPHNLVASMAVSDVLVAALVMPLSLVHELSGRRWQLGRRLCQLWIACDVLCCTASIWNVTAIALDRY 
WSITRHMEYTLRTRKCVSNVMIALTWALSAVISLAPLLFGWGETYSEGSEECQVSREPSYAVFSTVGAFY 
LPLCVVLFVYWKIYKAAKFRVGSRKTNSVSPISEAVEVKDSAKQPQMVFTVRHATVTFQPEGDTWREQKE 
QRAALMVGILIGVFVLCWIPFFLTELISPLCSCDIPAIWKSIFLWLGYSNSFFNPLIYTAFNKNYNSAFK 
NFFSRQH 
16. 5-hydroxytryptamine receptor 6; Short=5-HT6 
>gi|1703010|sp|P50406.1|5HT6R_HUMAN  
440aa 
MVPEPGPTANSTPAWGAGPPSAPGGSGWVAAALCVVIALTAAANSLLIALICTQPALRNTSNFFLVSLFT 
SDLMVGLVVMPPAMLNALYGRWVLARGLCLLWTAFDVMCCSASILNLCLISLDRYLLILSPLRYKLRMTP 
LRALALVLGAWSLAALASFLPLLLGWHELGHARPPVPGQCRLLASLPFVLVASGLTFFLPSGAICFTYCR 
ILLAARKQAVQVASLTTGMASQASETLQVPRTPRPGVESADSRRLATKHSRKALKASLTLGILLGMFFVT 
WLPFFVANIVQAVCDCISPGLFDVLTWLGYCNSTMNPIIYPLFMRDFKRALGRFLPCPRCPRERQASLAS 
PSLRTSHSGPRPGLSLQQVLPLPLPPDSDSDSDAGSGGSSGLRLTAQLLLPGEATQDPPLPTRAAAAVNF 
FNIDPAEPELRPHPLGIPTN 
17. 5-hydroxytryptamine receptor 7; Short=5-HT7 
>gi|8488960|sp|P34969.2|5HT7R_HUMAN  
479aa 
MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLSEVTASPAPTWDAPPDNASGC 
GEQINYGRVEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLIVSLALADLSVAVAVMPFVSV 
TDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDRYLGITRPLTYPVRQNGKCMAKMILSVWLLS 
ASITLPPLFGWAQNVNDDKVCLISQDFGYTIYSTAVAFYIPMSVMLFMYYQIYKAARKSAAKHKFPGFPR 
VEPDSVIALNGIVKLQKEVEECANLSRLLKHERKNISIFKREQKAATTLGIIVGAFTVCWLPFFLLSTAR 
PFICGTSCSCIPLWVERTFLWLGYANSLINPFIYAFFNRDLRTTYRSLLQCQYRNINRKLSAAGMHEALK 
LAERPERPEFVLRACTRRVLLRPEKRPPVSVWVLQSPDHHNWLADKMLTTVEKKVMIHD 
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Appendices 2: Anotated Aligned Receptor sequences using CHROMA 
Anotated Aligned Serotonin Receptor sequences using 
CHROMA 
 
 
5HT2A           
MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFN(21)LSCEGCLSPSCLSLLH----LQE 
5HT2C           MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAI----
VTDIFNTSDGGRFKFP----DGV 
5HT2B           -MALSYRVSELQSTIPEHILQSTFVHVISSNWS----
GLQTESIPEEMKQIVE----EQG 
5HT1B           MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNC----SAKDYIYQDSISLPW-
------- 
5HT1D           ----------MSPLNQSAEGLPQEASNRSLNAT-----ETSEAWDPRTLQAL-
------- 
5HT1E           --------------------------MNITNCT----TEASMAIRPKTITE--
------- 
5HT1F           ---------------------MDFLNSSDQNLT----SEELLNRMPS------
------- 
5HT1A           ----------------MDVLSPGQGNNTTSPPA----
PFETGGNTTGISDVTV----SY- 
5HT5A           ---------MDLPVNLTSFSLSTPSPLETNHSL----GKDDLRPSSPLLSVF-
------- 
5HT7R           
MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLSEVT(22)YGR 
5HT3A           -MLLWVQQALLAL-LLPTLLAQG-EARRSRNTT----RPALLRLSDYLLTNY-
------- 
5HT3B           -----MLSSVMAPLWACILVAAGILATDTHHPQ----DSALYHLSKQLLQKY-
------- 
5HT3C           MEGGWPARQSALLCLTVSLLLQGRGDAFTINCS----
GFDQHGVDPAVFQAVF----D-- 
5HT3E           MEGSWFHRKRFSFYLLLGFLLQGRGVTFTINCS----
GFGQHGADPTALNSVF----N-- 
5HT3D           MQKHSPGPPALAL-LSQSLLTTGNGDTLIINCP----
GFGQHRVDPAAFQAVF----D-- 
5HT4R           ------------------------MDKLDANVS----SEEGFGSVE-------
------- 
5HT6            -------------------MVPEPGPTANSTPA----WGAGPPSAPGG-----
------- 
Consensus/80%   
........................h...s.pss........h..ss.h............ 
 
 
5HT2A           --KNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNA-
TNYFLMSLAIADMLLGF---LV 
5HT2C           --QNWPALSIVIIIIMTIGGNILVIMAVSMEKKLHNA-
TNYFLMSLAIADMLVGL---LV 
5HT2B           NKLHWAALLILMVIIPTIGGNTLVILAVSLEKKLQYA-
TNYFLMSLAVADLLVGL---FV 
5HT1B           --KVLLVMLLALITLATTLSNAFVIATVYRTRKLHTP-
ANYLIASLAVTDLLVSI---LV 
5HT1D           --KISLAVVLSVITLATVLSNAFVLTTILLTRKLHTP-
ANYLIGSLATTDLLVSI---LV 
5HT1E           --KMLICMTLVVITTLTTLLNLAVIMAIGTTKKLHQP-
ANYLICSLAVTDLLVAV---LV 
5HT1F           --KILVSLTLSGLALMTTTINSLVIAAIIVTRKLHHP-
ANYLICSLAVTDFLVAV---LV 
5HT1A           --QVITSLLLGTLIFCAVLGNACVVAAIALERSLQNV-
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ANYLIGSLAVTDLMVSV---LV 
5HT5A           --GVLILTLLGFLVAATFAWNLLVLATILRVRTFHRV-
PHNLVASMAVSDVLVAA---LV 
5HT7R           VEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQP-
SNYLIVSLALADLSVAV---AV 
5HT3A           --RKGVRPVRDWRKPTTVSIDVIVYAILNVDEKNQVL-
TTYIWYRQYWTDEFLQWNPEDF 
5HT3B           --HKEVRPVYNWTKATTVYLDLFVHAILDVDAENQIL-
KTSVWYQEVWNDEFLSWNSSMF 
5HT3C           --RKAFRPFTNYSIPTRVNISFTLSAILGVDAQLQLL-
TSFLWMDLVWDNPFINWNPKEC 
5HT3E           --RKPFRPVTNISVPTQVNISFAMSAILDVNEQLHLL-
SSFLWLEMVWDNPFISWNPEEC 
5HT3D           --RKAIGPVTNYSVATHVNISFTLSAIWNCYSRIHTF-NCHH—
ARPWHNQFVQWNPDEC 
5HT4R           --
KVVLLTFLSTVILMAILGNLLVMVAVCWDRQLRKIKTNYFIVSLAFADLLVSV---LV 
5HT6            --SGWVAAALCVVIALTAAANSLLIALICTQPALRNT-
SNFFLVSLFTSDLMVGL---VV 
Consensus/80%   
..p.hh..hhsh.hhhsh.hshhlhhhl.hppplp...ssabbhsbshsDbblth...bs 
 
 
5HT2A           MPVSMLTILYGYRWPLPSKLCAVWIYLD------------------------
VLFSTASI 
5HT2C           MPLSLLAILYDYVWPLPRYLCPVWISLD------------------------
VLFSTASI 
5HT2B           MPIALLTIMFEAMWPLPLVLCPAWLFLD------------------------
VLFSTASI 
5HT1B           MPISTMYTVTG-RWTLGQVVCDFWLSSD------------------------
ITCCTASI 
5HT1D           MPISIAYTITH-TWNFGQILCDIWLSSD------------------------
ITCCTASI 
5HT1E           MPLSIIYIVMD-RWKLGYFLCEVWLSVD------------------------
MTCCTCSI 
5HT1F           MPFSIVYIVRE-SWIMGQVVCDIWLSVD------------------------
ITCCTCSI 
5HT1A           LPMAALYQVLN-KWTLGQVTCDLFIALD------------------------
VLCCTSSI 
5HT5A           MPLSLVHELSGRRWQLGRRLCQLWIACD------------------------
VLCCTASI 
5HT7R           MPFVSVTDLIGGKWIFGHFFCNVFIAMD------------------------
VMCCTASI 
5HT3A           DNITKLSIPTDSIW-
VPDILINEFVDVGKSPNIPYVYIRHQGEVQNYKPLQVVTACSLDI 
5HT3B           DEIREISLPLSAIW-
APDIIINEFVDIERYPDLPYVYVNSSGTIENYKPIQVVSACSLET 
5HT3C           VGINKLTVLAENLW-
LPDIFIVESMDVDQTPSGLTAYISSEGRIKYDKPMRVTSICNLDI 
5HT3E           EGITKMSMAAKNLW-
LPDIFIIELMDVDKTPKGLTAYVSNEGRIRYKKPMKVDSICNLDI 
5HT3D           GGIKKSGMATENLW-LSDVFIEES--VDQTPAGLMA------------
SMSIVKATSNTI 
5HT4R           MPFGAIELVQD-IWIYGEVFCLVRTSLD------------------------
VLLTTASI 
5HT6            MPPAMLNALYG-RWVLARGLCLLWTAFD------------------------
VMCCSASI 
Consensus/80%   
hsbs.h.hhh..bW.bsphbh..bhshD........................l.hs*hsI 
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5HT2A           MHL------CAISLDRYVAI-QNP---IHHSRFNSRT-----KAFLKIIAVW-
TISVGIS 
5HT2C           MHL------CAISLDRYVAI-RNP---IEHSRFNSRT-----KAIMKIAIVW-
AISIGVS 
5HT2B           MHL------CAISVDRYIAI-KKP---IQANQYNSRA-----TAFIKITVVW-
LISIGIA 
5HT1B           LHL------CVIALDRYWAI-TDA---VEYSAKRTPK-----RAAVMIALVW-
VFSISIS 
5HT1D           LHL------CVIALDRYWAI-TDA---LEYSKRRTAG-----HAATMIAIVW-
AISICIS 
5HT1E           LHL------CVIALDRYWAI-TNA---IEYARKRTAK-----RAALMILTVW-
TISIFIS 
5HT1F           LHL------SAIALDRYRAI-TDA---VEYARKRTPK-----HAGIMITIVW-
IISVFIS 
5HT1A           LHL------CAIALDRYWAI-TDP---IDYVNKRTPR-----RAAALISLTW-
LIGFLIS 
5HT5A           WNV------TAIALDRYWSI-TRH---MEYTLRTRKC-----VSNVMIALTW-
ALSAVIS 
5HT7R           MTL------CVISIDRYLGI-TRP---LTYPVRQNGK-----CMAKMILSVW-
LLSASIT 
5HT3A           YNFPFDVQNCSLTFTSWLHT-IQD---
INISLWRLPEKVKSDRSVFMNQGEWELLGVL-- 
5HT3B           YAFPFDVQNCSLTFKSILHT-VED---
VDLAFLRSPEDIQHDKKAFLNDSEWELLSVSST 
5HT3C           FYFPFDQQNCTFTFSSFLYT-VDS(4)MDKEVWEITD---
TSRKVIQTQGEWELLGINKA 
5HT3E           FYFPFDQQNCTLTFSSFLYT-VDS(4)MEKEVWEITD---
ASRNILQTHGEWELLGLSKA 
5HT3D           SQ-------
CGWSASANWTPSISP(4)ARAWRRMSRSFQIHHRTSFRTRREWVLLGIQKR 
5HT4R           FHL------CCISLDRYYAICCQP---LVYRNKMTPL-----RIALMLGGCW-
VIPTFIS 
5HT6            LNL------CLISLDRYLLI-LSP---LRYKLRMTPL-----RALALVLGAW-
SLAALAS 
Consensus/80%   
bpb......Cslsbspabhh.hps...hpb..bpp.......+.hhbh.h.W.hlth..s 
 
 
5HT2A           MPIPVFGL---------QDDSKVF---KEGSCLLADD---
NFVLIGSFVSFFIPLTIMVI 
5HT2C           VPIPVIGL---------RDEEKVFV--NNTTCVLNDP---
NFVLIGSFVAFFIPLTIMVI 
5HT2B           IPVPIKGI----------ETDVDNP—
NNITCVLTKERFGDFMLFGSLAAFFTPLAIMIV 
5HT1B           LPPFF--W---------RQAKA-EE--EVSECVVNTDHI-
LYTVYSTVGAFYFPTLLLIA 
5HT1D           IPPLF--W---------RQAKA-QE--EMSDCLVNTSQI-
SYTIYSTCGAFYIPSVLLII 
5HT1E           MPPLF--W---------RSHRRLSP--PPSQCTIQHDHV-
IYTIYSTLGAFYIPLTLILI 
5HT1F           MPPLF--W---------RHQG--TS--RDDECIIKHDHI-
VSTIYSTFGAFYIPLALILI 
5HT1A           IPPML-GW---------RTPED-RS--DPDACTISKDH—
GYTIYSTFGAFYIPLLLMLV 
5HT5A           LAPLLFGW-----------GETYSE--GSEECQVSREP—
SYAVFSTVGAFYLPLCVVLF 
5HT7R           LPPLF-GW---------AQNVN-----DDKVCLISQDF—
GYTIYSTAVAFYIPMSVMLF 
5HT3A           --PYFREF(5)NYYAEMKFYVVIRR—
RPLFYVVSLLLPSIFLMVMDIVGFYLPPNSGER 
5HT3B           YSILQSSA---GGFAQIQFNVVMRR—
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HPLVYVVSLLIPSIFLMLVDLGSFYLPPNCRAR 
5HT3C           TPKMSMGN---NLYDQIMFYVAIRR—
RPSLYIINLLVPSSFLVAIDALSFYLPAESENR 
5HT3E           TAKLSRGG---NLYDQIVFYVAIRR—
RPSLYVINLLVPSGFLVAIDALSFYLPVKSGNR 
5HT3D           TIKVTVAT---
NQYEQAIFHVAIRRRCRPSPYVVNFLVPSGILIAIDALSFYLPLESGNC 
5HT4R           FLPIMQGW(5)IDLIEKRKFNQ-NS--NSTYCVFMVNK—
PYAITCSVVAFYIPFLLMVL 
5HT6            FLPLLLGW---------HELGHARPP-VPGQCRLLASL—
PFVLVASGLTFFLPSGAICF 
Consensus/80%   
h..hh..h...............p...ps..hhlp......ahlh.shhtFalP...h.. 
 
 
5HT2A           TYFLTIKSLQKEATLCV----SDLGTRAKLAS----------
FSFLPQSSLSSEKLFQR- 
5HT2C           TYCLTIYVLRRQALMLL----HGHTEEPPGLS----------
LDFLKCCKRNTAEEENS- 
5HT2B           TYFLTIHALQKKAYLVK------NKPPQRLTW--
LTVSTVFQRDETPCSSPEKVAMLDG- 
5HT1B           LYGRIYVEARSRILKQT-----PNRTGKRLTR--------
AQLITDSPGSTSSVTSINS- 
5HT1D           LYGRIYRAARNRILN------PPSLYGKRFTT----------
AHLITGSAGSSLCSLNS- 
5HT1E           LYYRIYHAAKSLYQKRG----SSRHLSNRSTD----SQ----
NSFASCKLTQTFCVSDF- 
5HT1F           LYYKIYRAAKTLYHKRQ----ASRIAKEEVNG-----
QVLLESGEKSTKSVSTSYVLEK- 
5HT1A           
LYGRIFRAARFRIRKTV(15)PAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQG 
5HT5A           VYWKIYKAAKFRVGSRK---------------------------
TNSVSPISEAVEVKD- 
5HT7R           MYYQIYKAARKSAAKHK----FPGFPR---------------
VEPDSVIALNGIVKLQK- 
5HT3A           VSFKITLLLGYSVFLII----VSDTLPATAIG----TPL-
IGVYFVVCMALLVISLAETI 
5HT3B           IVFKTSVLVGYTVFRVN----MSNQVPRSVGS-----
TPLIGHFFTICMAFLVLSLAKSI 
5HT3C           APFKITLLLGYNVFLLM----MNDLLPASGTP-------
LISVYFALCLSLMVVSLLETV 
5HT3E           VPFKITLLLGYNVFLLM----MSDLLPTSGTP-------
LIGVYFALCLSLMVGSLLETI 
5HT3D           APFKMTVLLGYSVFLLM----
MNDLLPATSTS(13)TPLPAGVYFALCLSLMVGSLLETI 
5HT4R           AYYRIYVTAKEHAHQ--------------------------------
IQMLQRAGASSE- 
5HT6            TYCRILLAARKQAVQVA--------------------------
SLTTGMASQASETLQV- 
Consensus/80%   
h.hphh.hh..phhb................................s.sh.s...hpp. 
 
 
5HT2A           ------------SIHREPGSY-------------TGRR---------------
----TMQ 
5HT2C           ------------ANPNQDQNA------RRRKKKERRPRG--------------
----TMQ 
5HT2B           -------SRKDKALPNSGDET------LMRRTSTIGKK---------------
----SVQ 
5HT1B           ------------RVPDVPSES----GSPVYVNQVKVRVSDALLEK--------
----KKL 
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5HT1D           ------------SLHEGHSHSAG---SPLFFNHVKIKLADSALER--------
----KRI 
5HT1E           ------------STSDPTTEF------EKFHASIRIPPFDNDLD---HPGER-
----QQI 
5HT1F           ------------SLSDPSTDF------DKIHSTVRSLRSEFKHE---KSWRR-
----QKI 
5HT1A           DDGAALEVIEVHRVGNSKEHL------PLPSEAGPTPCAPASFE---
RKNERNAEAKRKM 
5HT5A           ------------SAKQPQMVF------TVRHATVTFQPEG-------------
----DTW 
5HT7R           ---------------------------EVEECANLSRLLKHERK---------
----NIS 
5HT3A           FIVRLVHKQD---
LQQPVPAWLR(9)LLCLREQSTSQRPPATSQ(4)DDCSAMGNHCSHM 
5HT3B           VLVKFLHDEQRGGQEQPFLCL----------------RGDTDAD---------
----RPR 
5HT3C           FITYLLHVAT--TQPPPMPRWLH---SLLLHCTSPGRCCPTAPQ---
KGNKGLGLTLTHL 
5HT3E           FITHLLHVAT--TQPPPLPRWLH---SLLLHCNSPGRCCPTAPQ---
KENKGPGLTPTHL 
5HT3D           FITHLLHVAT--TQPLPLPRWLH---SLLLHCTGQGRCCPTAPQ---
KGNKGPGLTPTHL 
5HT4R           ------------SRPQSADQH--------------------------------
----STH 
5HT6            -----------PRTPRPGVES------------ADSRRL--------------
----ATK 
Consensus/80%   
................s..p.....................................p.b 
 
 
5HT2A           SISNE-----QKACKVLGIVFFLFVVM-----WCPFFITNIMAVI-
CKESCNEDVIGALL 
5HT2C           AINNE-----RKASKVLGIVFFVFLIM-----WCPFFITNILSVL-
CEKSCNQKLMEKLL 
5HT2B           TISNE-----QRASKVLGIVFFLFLLM-----WCPFFITNITLVL-C-
DSCNQTTLQMLL 
5HT1B           MAARE-----RKATKTLGIILGAFIVC-----WLPFFIISLVMPI-CKDACW—
FHLAIF 
5HT1D           SAARE-----RKATKILGIILGAFIIC-----WLPFFVVSLVLPI-CRDSCW—
IHPALF 
5HT1E           SSTRE-----RKAARILGLILGAFILS-----WLPFFIKELIVGL-S--IYT—
VSSEVA 
5HT1F           SGTRE-----RKAATTLGLILGAFVIC-----WLPFFVKELVVNV-C-DKCK—
ISEEMS 
5HT1A           ALARE-----RKTVKTLGIIMGTFILC-----WLPFFIVALVLPF-CESSCH—
MPTLLG 
5HT5A           REQKE-----QRAALMVGILIGVFVLC-----WIPFFLTELISPL-C--SCD—
IPAIWK 
5HT7R           IFKRE-----QKAATTLGIIVGAFTVC-----WLPFFLLSTARPFICGTSCS-
CIPLWVE 
5HT3A           GGPQD(4)PRDRCSPPPPPREASLAVCGL---LQELSSIRQFLEK--------
-RDEIRE 
5HT3B           VEPRA-----QRAVVTESSLYGEHLAQPG(5)WSQLQSISNYLQT--------
-QDQTDQ 
5HT3C           PGPKE---PGELAGKKLGPRETEPDGGSG---WTKTQLMEL------------
------- 
5HT3E           PGVKE---PEVSAGQMPGPAEAELTGGSE---WTRAQREH-------------
-EAQKQH 
5HT3D           PGVKE---PEVSAGQMPGPGEAELTGGSE---WTRAQREH-------------
-EAQKQH 
5HT4R           RMRTE-----TKAAKTLCIIMGCFCLC-----WAPFFVTNIVDPF-I--DYT—
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VPGQVW 
5HT6            HSRKA-----LKASLTLGILLGMFFVT-----WLPFFVANIVQAV-C--DC--
-ISPGLF 
Consensus/80%   
...pE.....p+As.h.G.hbs.bhhh.....Wh.bb..p.h.................. 
 
 
5HT2A           
NVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYKSS 
5HT2C           
NVFVWIGYVCSGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRE 
5HT2B           
EIFVWIGYVSSGVNPLVYTLFNKTFRDAFGRYITCNYRATKSVKTLRKRSSKIYFRNPMA 
5HT1B           DFFTWLGYLNSLINPIIYTMSNEDFKQAFHKLIRFKCTS--------------
------- 
5HT1D           DFFTWLGYLNSLINPIIYTVFNEEFRQAFQKIVPFRKAS--------------
------- 
5HT1E           DFLTWLGYVNSLINPLLYTSFNEDFKLAFKKLIRCREHT--------------
------- 
5HT1F           NFLAWLGYLNSLINPLIYTIFNEDFKKAFQKLVRCRC----------------
------- 
5HT1A           AIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCKFCRQ-------------
------- 
5HT5A           SIFLWLGYSNSFFNPLIYTAFNKNYNSAFKNFFSRQH----------------
------- 
5HT7R           
RTFLWLGYANSLINPFIYAFFNRDLRTTYRSLLQCQYRNINRKLSAAGMHEALKLAERPE 
5HT3A           VARDWLRV-GSVLDKLLFHIYL-LAVLAYSITLVMLWSIWQYA----------
------- 
5HT3B           QEAEWLVL-LSRFDRLLFQSYL-FMLGIYTITLCSLWALWGGV----------
------- 
5HT3C           ----WVQF-SHAMDTLLFRLYL-LFMASSILTVIVLWNT--------------
------- 
5HT3E           SVELWLQF-SHAMDAMLFRLYL-LFMASSIITVICLWNT--------------
------- 
5HT3D           SVELWVQF-SHAMDALLFRLYL-LFMASSIITVICLWNT--------------
------- 
5HT4R           
TAFLWLGYINSGLNPFLYAFLNKSFRRAFLIILCCDDERYRRPSILGQTVPCSTTTINGS 
5HT6            
DVLTWLGYCNSTMNPIIYPLFMRDFKRALGRFLPCPRCPRERQASLASPSLRTSHSGPRP 
Consensus/80%   
phb.Wl.a.sShbsslla.ha...ab.tb.bhl.h.b....................... 
 
 
5HT2A           QLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV---- 
5HT2C           LNVNIYRHTNEPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV----- 
5HT2B           ENSKFFKKHGIRNGINPAMYQSPMRLRSSTIQSSSIILLDTLLLTENEG(10) 
5HT1B           ----------------------------------------------------- 
5HT1D           ----------------------------------------------------- 
5HT1E           ----------------------------------------------------- 
5HT1F           ----------------------------------------------------- 
5HT1A           ----------------------------------------------------- 
5HT5A           ----------------------------------------------------- 
5HT7R           RPEFVLRACTRRVLLRPEKRPPVSVWVLQSPDHHNWLADKMLTTVEKKVMIHD 
5HT3A           ----------------------------------------------------- 
5HT3B           ----------------------------------------------------- 
5HT3C           ----------------------------------------------------- 
5HT3E           ----------------------------------------------------- 
5HT3D           ----------------------------------------------------- 
5HT4R           THVLRDAVECGGQWESQCHPPATSPLVAAQPSDT------------------- 
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5HT6            GLSLQQVLPLPLPPDSDSDSDAGSGGSSGLRLTAQLLLPGEATQDPPLP(29) 
Consensus/80%   ..................................................... 
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Appendices 3: Anotated Aligned Serotonin Receptor5-HT 1,2,4,5,6,7 
sequences using CHROMA 
 
Anotated Aligned Serotonin Receptor5-HT 1,2,4,5,6,7 sequences 
using CHROMA  
 
 
5HT2A           MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFN(21)LSCEGCLSPSCLSLLH----
LQE 
5HT2C           MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAI----VTDIFNTSDGGRFKFP----
DGV 
5HT2B           -MALSYRVSELQSTIPEHILQSTFVHVISSNWS----GLQTESIPEEMKQIVE----
EQG 
5HT1B           MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNC----SAKDYIYQDSISLPW-----
--- 
5HT1D           ----------MSPLNQSAEGLPQEASNRSLNAT-----ETSEAWDPRTLQAL-----
--- 
5HT1E           --------------------------MNITNCT----TEASMAIRPKTITE------
--- 
5HT1F           ---------------------MDFLNSSDQNLT----SEELLNRMPS----------
--- 
5HT1A           ----------------MDVLSPGQGNNTTSPPA----PFETGGNTTGISDVTV----
SY- 
5HT5A           ---------MDLPVNLTSFSLSTPSPLETNHSL----GKDDLRPSSPLLSVF-----
--- 
5HT7            
MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLSEVT(22)YGR 
5HT4            ------------------------MDKLDANVS----SEEGFGSVE-----------
--- 
5HT6            -------------------MVPEPGPTANSTPA----WGAGPPSAPGG---------
--- 
Consensus/80%   
........................h...ss..s.........s..s.h............ 
 
 
5HT2A           --KNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNA-
TNYFLMSLAIADMLLGFLVMPV 
5HT2C           --QNWPALSIVIIIIMTIGGNILVIMAVSMEKKLHNA-
TNYFLMSLAIADMLVGLLVMPL 
5HT2B           NKLHWAALLILMVIIPTIGGNTLVILAVSLEKKLQYA-
TNYFLMSLAVADLLVGLFVMPI 
5HT1B           --KVLLVMLLALITLATTLSNAFVIATVYRTRKLHTP-
ANYLIASLAVTDLLVSILVMPI 
5HT1D           --KISLAVVLSVITLATVLSNAFVLTTILLTRKLHTP-
ANYLIGSLATTDLLVSILVMPI 
5HT1E           --KMLICMTLVVITTLTTLLNLAVIMAIGTTKKLHQP-
ANYLICSLAVTDLLVAVLVMPL 
5HT1F           --KILVSLTLSGLALMTTTINSLVIAAIIVTRKLHHP-
ANYLICSLAVTDFLVAVLVMPF 
5HT1A           --QVITSLLLGTLIFCAVLGNACVVAAIALERSLQNV-
ANYLIGSLAVTDLMVSVLVLPM 
5HT5A           --GVLILTLLGFLVAATFAWNLLVLATILRVRTFHRV-
PHNLVASMAVSDVLVAALVMPL 
5HT7            VEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQP-
SNYLIVSLALADLSVAVAVMPF 
5HT4            --
KVVLLTFLSTVILMAILGNLLVMVAVCWDRQLRKIKTNYFIVSLAFADLLVSVLVMPF 
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5HT6            --SGWVAAALCVVIALTAAANSLLIALICTQPALRNT-
SNFFLVSLFTSDLMVGLVVMPP 
Consensus/80%   
..phhhshhlshlhhhThhhNhbVlhsl.hp+pLpps.sNYblhSLAhsDbbVtllVMPb 
 
 
5HT2A           SMLTILYGYRWPLPSKLCAVWIYLDVLFSTASIMHLCAISLDRYVAI-
QNPIHHSRFNSR 
5HT2C           SLLAILYDYVWPLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAI-
RNPIEHSRFNSR 
5HT2B           ALLTIMFEAMWPLPLVLCPAWLFLDVLFSTASIMHLCAISVDRYIAI-
KKPIQANQYNSR 
5HT1B           STMYTVTG-RWTLGQVVCDFWLSSDITCCTASILHLCVIALDRYWAI-
TDAVEYSAKRTP 
5HT1D           SIAYTITH-TWNFGQILCDIWLSSDITCCTASILHLCVIALDRYWAI-
TDALEYSKRRTA 
5HT1E           SIIYIVMD-RWKLGYFLCEVWLSVDMTCCTCSILHLCVIALDRYWAI-
TNAIEYARKRTA 
5HT1F           SIVYIVRE-SWIMGQVVCDIWLSVDITCCTCSILHLSAIALDRYRAI-
TDAVEYARKRTP 
5HT1A           AALYQVLN-KWTLGQVTCDLFIALDVLCCTSSILHLCAIALDRYWAI-
TDPIDYVNKRTP 
5HT5A           SLVHELSGRRWQLGRRLCQLWIACDVLCCTASIWNVTAIALDRYWSI-
TRHMEYTLRTRK 
5HT7            VSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDRYLGI-
TRPLTYPVRQNG 
5HT4            GAIELVQD-
IWIYGEVFCLVRTSLDVLLTTASIFHLCCISLDRYYAICCQPLVYRNKMTP 
5HT6            AMLNALYG-RWVLARGLCLLWTAFDVMCCSASILNLCLISLDRYLLI-
LSPLRYKLRMTP 
Consensus/80%   
thlh.l....W.bsphhC.lalthDlhhsTtSIbpLCsItLDRYbtI.ppslpas.bp*. 
 
 
5HT2A           TKAFLKIIAVWTISVGISMPIPVFGL----QDDSKVF--KEGSCLLADD---
NFVLIGSF 
5HT2C           TKAIMKIAIVWAISIGVSVPIPVIGL----RDEEKVFV-NNTTCVLNDP---
NFVLIGSF 
5HT2B           ATAFIKITVVWLISIGIAIPVPIKGI-----ETDVDNP-
NNITCVLTKERFGDFMLFGSL 
5HT1B           KRAAVMIALVWVFSISISLPPFF--W----RQAKA-EE-EVSECVVNTDHI-
LYTVYSTV 
5HT1D           GHAATMIAIVWAISICISIPPLF--W----RQAKA-QE-EMSDCLVNTSQI-
SYTIYSTC 
5HT1E           KRAALMILTVWTISIFISMPPLF--W----RSHRRLSP-PPSQCTIQHDHV-
IYTIYSTL 
5HT1F           KHAGIMITIVWIISVFISMPPLF--W----RHQG--TS-RDDECIIKHDHI-
VSTIYSTF 
5HT1A           RRAAALISLTWLIGFLISIPPML-GW----RTPED-RS-DPDACTISKDH—
GYTIYSTF 
5HT5A           CVSNVMIALTWALSAVISLAPLLFGW------GETYSE-GSEECQVSREP—
SYAVFSTV 
5HT7            KCMAKMILSVWLLSASITLPPLF-GW----AQNVN----DDKVCLISQDF—
GYTIYSTA 
5HT4            LRIALMLGGCWVIPTFISFLPIMQGW(11)RKFNQ-NS-NSTYCVFMVNK—
PYAITCSV 
5HT6            LRALALVLGAWSLAALASFLPLLLGW----HELGHARPPVPGQCRLLASL—
PFVLVASG 
Consensus/80%   
.pthhbIhhsWhlthhISbss.b..b.....p........s..Chl.ps...saslbt*h 
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5HT2A           VSFFIPLTIMVITYFLTIKSLQKEATLCV----SDLGTRAKLAS---------
FSFLPQS 
5HT2C           VAFFIPLTIMVITYCLTIYVLRRQALMLL----HGHTEEPPGLS---------
LDFLKCC 
5HT2B           AAFFTPLAIMIVTYFLTIHALQKKAYLVK------NKPPQRLTW-
LTVSTVFQRDETPCS 
5HT1B           GAFYFPTLLLIALYGRIYVEARSRILKQT-----PNRTGKRLTR-------
AQLITDSPG 
5HT1D           GAFYIPSVLLIILYGRIYRAARNRILN------PPSLYGKRFTT---------
AHLITGS 
5HT1E           GAFYIPLTLILILYYRIYHAAKSLYQKRG----SSRHLSNRSTD---SQ----
NSFASCK 
5HT1F           GAFYIPLALILILYYKIYRAAKTLYHKRQ----ASRIAKEEVNG----
QVLLESGEKSTK 
5HT1A           
GAFYIPLLLMLVLYGRIFRAARFRIRKTV(15)PAPQPKKSVNG(4)RNWRLGVESKAGG 
5HT5A           GAFYLPLCVVLFVYWKIYKAAKFRVGSRK--------------------------
TNSVS 
5HT7            VAFYIPMSVMLFMYYQIYKAARKSAAKHK----FPGFPR--------------
VEPDSVI 
5HT4            VAFYIPFLLMVLAYYRIYVTAKEHAHQ------------------------------
-IQ 
5HT6            LTFFLPSGAICFTYCRILLAARKQAVQVA-------------------------
SLTTGM 
Consensus/80%   
sAFalPhhlblhhYhbhbbsh+pphhb..............................ss. 
 
 
5HT2A           SLSSEKLFQR-----SIHREPGSY----------TGRR---------------
TMQSISN 
5HT2C           KRNTAEEENS-----ANPNQDQNA---RRRKKKERRPRG--------------
TMQAINN 
5HT2B           SPEKVAMLDGSRKDKALPNSGDET---LMRRTSTIGKK---------------
SVQTISN 
5HT1B           STSSVTSINS-----RVPDVPSES-GSPVYVNQVKVRVSDALLEK--------
KKLMAAR 
5HT1D           AGSSLCSLNS-----SLHEGHSHSAGSPLFFNHVKIKLADSALER--------
KRISAAR 
5HT1E           LTQTFCVSDF-----STSDPTTEF---EKFHASIRIPPFDNDLD-HPGER---
QQISSTR 
5HT1F           SVSTSYVLEK-----SLSDPSTDF---DKIHSTVRSLRSEFKHE-KSWRR---
QKISGTR 
5HT1A           ALCANGAVRQ(12)HRVGNSKEHL---PLPSEAGPTPCAPASFE-
RKNER(5)RKMALAR 
5HT5A           PISEAVEVKD-----SAKQPQMVF---TVRHATVTFQPEG-------------
DTWREQK 
5HT7            ALNGIVKLQK-----------------EVEECANLSRLLKHERK---------
NISIFKR 
5HT4            MLQRAGASSE-----SRPQSADQH-----------------------------
STHRMRT 
5HT6            ASQASETLQV----PRTPRPGVES---------ADSRRL--------------
ATKHSRK 
Consensus/80%   
..p.....p.........p...p..............................p.b...p 
 
 
5HT2A           EQKACKVLGIVFFLFVVMWCPFFITNIMAVI-
CKESCNEDVIGALLNVFVWIGYLSSAVN 
5HT2C           ERKASKVLGIVFFVFLIMWCPFFITNILSVL-
CEKSCNQKLMEKLLNVFVWIGYVCSGIN 
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5HT2B           EQRASKVLGIVFFLFLLMWCPFFITNITLVL-C-
DSCNQTTLQMLLEIFVWIGYVSSGVN 
5HT1B           ERKATKTLGIILGAFIVCWLPFFIISLVMPI-CKDACW—
FHLAIFDFFTWLGYLNSLIN 
5HT1D           ERKATKILGIILGAFIICWLPFFVVSLVLPI-CRDSCW—
IHPALFDFFTWLGYLNSLIN 
5HT1E           ERKAARILGLILGAFILSWLPFFIKELIVGL-S--IYT—
VSSEVADFLTWLGYVNSLIN 
5HT1F           ERKAATTLGLILGAFVICWLPFFVKELVVNV-C-DKCK—
ISEEMSNFLAWLGYLNSLIN 
5HT1A           ERKTVKTLGIIMGTFILCWLPFFIVALVLPF-CESSCH—
MPTLLGAIINWLGYSNSLLN 
5HT5A           EQRAALMVGILIGVFVLCWIPFFLTELISPL-C--SCD—
IPAIWKSIFLWLGYSNSFFN 
5HT7            EQKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCS-
CIPLWVERTFLWLGYANSLIN 
5HT4            ETKAAKTLCIIMGCFCLCWAPFFVTNIVDPF-I--DYT—
VPGQVWTAFLWLGYINSGLN 
5HT6            ALKASLTLGILLGMFFVTWLPFFVANIVQAV-C--DC---
ISPGLFDVLTWLGYCNSTMN 
Consensus/80%   
EpKAsphLGIlbhhFhlhWhPFFlhplh.sb.C..sC...h...l.shbhWlGYhsShlN 
 
 
5HT2A           
PLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYKSSQLQMGQKKNSKQDA 
5HT2C           
PLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTNEPVI 
5HT2B           
PLVYTLFNKTFRDAFGRYITCNYRATKSVKTLRKRSSKIYFRNPMAENSKFFKKHGIRNG 
5HT1B           PIIYTMSNEDFKQAFHKLIRFKCTS--------------------------------
--- 
5HT1D           PIIYTVFNEEFRQAFQKIVPFRKAS--------------------------------
--- 
5HT1E           PLLYTSFNEDFKLAFKKLIRCREHT--------------------------------
--- 
5HT1F           PLIYTIFNEDFKKAFQKLVRCRC----------------------------------
--- 
5HT1A           PVIYAYFNKDFQNAFKKIIKCKFCRQ-------------------------------
--- 
5HT5A           PLIYTAFNKNYNSAFKNFFSRQH----------------------------------
--- 
5HT7            
PFIYAFFNRDLRTTYRSLLQCQYRNINRKLSAAGMHEALKLAERPERPEFVLRACTRRVL 
5HT4            
PFLYAFLNKSFRRAFLIILCCDDERYRRPSILGQTVPCSTTTINGSTHVLRDAVECGGQW 
5HT6            
PIIYPLFMRDFKRALGRFLPCPRCPRERQASLASPSLRTSHSGPRPGLSLQQVLPLPLPP 
Consensus/80%   
PllYshFNcsa+pAF.pblppp...................................... 
 
 
5HT2A           KTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV-------- 
5HT2C           EKASDNEPGIEMQVENLELPVNPSSVVSERISSV--------- 
5HT2B           INPAMYQSPMRLRSSTIQSSSIILLDTLLLTENEGDKTE(6)- 
5HT1B           ------------------------------------------- 
5HT1D           ------------------------------------------- 
5HT1E           ------------------------------------------- 
5HT1F           ------------------------------------------- 
5HT1A           ------------------------------------------- 
5HT5A           ------------------------------------------- 
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5HT7            LRPEKRPPVSVWVLQSPDHHNWLADKMLTTVEKKVMIHD---- 
5HT4            ESQCHPPATSPLVAAQPSDT----------------------- 
5HT6            DSDSDSDAGSGGSSGLRLTAQLLLPGEATQDPPLPTRAA(25) 
Consensus/80%   ........................................... 
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Appendices 4: Anotated Aligned Serotonin Receptor5-HT3 sequences using 
CHROMA 
Anotated Aligned Serotonin Receptor5-HT3 sequences using 
CHROMA  
 
 
 
5HT3A           -MLLWVQQALLAL-LLPTLLAQGE-ARRSRNTTRPALLRLSDYLLTNY—
RKGVRPVRDW 
5HT3B           ----MLSSVMAPL-WACILVAAGILATDTHHPQDSALYHLSKQLLQKY—
HKEVRPVYNW 
5HT3C           
MEGGWPARQSALLCLTVSLLLQGRGDAFTINCSGFDQHGVDPAVFQAVFDRKAFRPFTNY 
5HT3E           
MEGSWFHRKRFSFYLLLGFLLQGRGVTFTINCSGFGQHGADPTALNSVFNRKPFRPVTNI 
5HT3D           MQKHSPGPPALAL-
LSQSLLTTGNGDTLIINCPGFGQHRVDPAAFQAVFDRKAIGPVTNY 
Consensus/80%   
.b..b..p..hsL.Lh.sLLhpGphssb*bNsss.tba.lsshhbpsh..RKshRPVpNa 
 
 
5HT3A           
RKPTTVSIDVIVYAILNVDEKNQVLTTYIWYRQYWTDEFLQWNPEDFDNITKLSIPTDSI 
5HT3B           
TKATTVYLDLFVHAILDVDAENQILKTSVWYQEVWNDEFLSWNSSMFDEIREISLPLSAI 
5HT3C           
SIPTRVNISFTLSAILGVDAQLQLLTSFLWMDLVWDNPFINWNPKECVGINKLTVLAENL 
5HT3E           
SVPTQVNISFAMSAILDVNEQLHLLSSFLWLEMVWDNPFISWNPEECEGITKMSMAAKNL 
5HT3D           SVATHVNISFTLSAIWNCYSRIHTFNCH--
HARPWHNQFVQWNPDECGGIKKSGMATENL 
Consensus/80%   *.sTpVsIsbhlpAILsVs.p.plLs*alWbpbsWss.FlpWNPc-
hssIpKb*bsscsl 
 
 
5HT3A           
WVPDILINEFVDVGKSPNIPYVYIRHQGEVQNYKPLQVVTACSLDIYNFPFDVQNCSLTF 
5HT3B           
WAPDIIINEFVDIERYPDLPYVYVNSSGTIENYKPIQVVSACSLETYAFPFDVQNCSLTF 
5HT3C           
WLPDIFIVESMDVDQTPSGLTAYISSEGRIKYDKPMRVTSICNLDIFYFPFDQQNCTFTF 
5HT3E           
WLPDIFIIELMDVDKTPKGLTAYVSNEGRIRYKKPMKVDSICNLDIFYFPFDQQNCTLTF 
5HT3D           WLSDVFIEESVD--QTPAGLMA------------SMSIVKATSNTISQ-------
CGWSA 
Consensus/80%   WlPDIbI.E.hDl.p*Psh.hsYlpppGplp..KPbpVs*hCsL-
Ia.FPFD.QNC*bTF 
 
 
5HT3A           TSWLHTIQDINIS-----LWRLPEKV--
KSDRSVFMNQGEWELLGVLPYFREFSMESSNY 
5HT3B           KSILHTVEDVDLA-----FLRSPEDI--QHDKKAFLNDSEWELLSVSSTYSILQS-
SAGG 
5HT3C           SSFLYTVDSMLLGMDKE-VWEITDTS-----RKVIQTQGEWELLGINKATPKMSM-
GNNL 
5HT3E           SSFLYTVDSMLLDMEKE-VWEITDAS-----RNILQTHGEWELLGLSKATAKLSR-
GGNL 
5HT3D           SANW--TPSISPSMDRARAWRRMSRSFQIHHRTSFRTRREWVLLGIQKRTIKVTV-
ATNQ 
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Consensus/80%   *SbLaTlpsb.lt.....hWcbs-
ps.....RpsbbsptEWELLGlpphh.cb*..tsNb 
 
 
5HT3A           YAEMKFYVVIRR--
RPLFYVVSLLLPSIFLMVMDIVGFYLPPNSGERVSFKITLLLGYSV 
5HT3B           FAQIQFNVVMRR--
HPLVYVVSLLIPSIFLMLVDLGSFYLPPNCRARIVFKTSVLVGYTV 
5HT3C           YDQIMFYVAIRR--
RPSLYIINLLVPSSFLVAIDALSFYLPAESENRAPFKITLLLGYNV 
5HT3E           YDQIVFYVAIRR--
RPSLYVINLLVPSGFLVAIDALSFYLPVKSGNRVPFKITLLLGYNV 
5HT3D           
YEQAIFHVAIRRRCRPSPYVVNFLVPSGILIAIDALSFYLPLESGNCAPFKMTVLLGYSV 
Consensus/80%   
YsQbbFaVsIRR..RP.hYVlsLLlPShFLhslDhlSFYLPspS.sRssFKbTlLLGYsV 
 
 
5HT3A           FLIIVSDTLPATAIG----TPL-IGVYFVVCMALLVISLAETIFIVRLVHKQDL--
QQ-P 
5HT3B           FRVNMSNQVPRSVGS----TPL-
IGHFFTICMAFLVLSLAKSIVLVKFLHDEQRGGQEQP 
5HT3C           FLLMMNDLLPASG------TPL-ISVYFALCLSLMVVSLLETVFITYLLHVATT—
QPPP 
5HT3E           FLLMMSDLLPTSG------TPL-IGVYFALCLSLMVGSLLETIFITHLLHVATT—
QPPP 
5HT3D           FLLMMNDLLPATSTS(13)TPLPAGVYFALCLSLMVGSLLETIFITHLLHVATT—
QPLP 
Consensus/80%   
FLlbMsDbLPs*t......TPL.IGVYFslCbtLbVhSLhETIFIs+LLHs.sp..Q..P 
 
 
5HT3A           VPAWLR(9)LLCLREQSTSQRPPATSQATKT--
DDCSAMGNHCSHMGGPQD(4)PRDRCS 
5HT3B           ---------FLCLRGDTDADRPRVEPRAQRAVVTESSLYGEHLAQPGTLKE------
--- 
5HT3C           MPRWLH---SLLLHCTSPGRCCPTAPQ------KGNKGLGLTLTHLPGPKE---
PGELAG 
5HT3E           LPRWLH---SLLLHCNSPGRCCPTAPQ------KENKGPGLTPTHLPGVKE---
PEVSAG 
5HT3D           LPRWLH---SLLLHCTGQGRCCPTAPQ------KGNKGPGLTPTHLPGVKE---
PEVSAG 
Consensus/80%   
hP.WL+....LhL+ss*stcpsPssPQ......c.spt.Gbp.*HbsGsKE...P...st 
 
 
5HT3A           
PPPPPREASLAVCGLLQELSSIRQFLEKRDEIREVARDWLRVGSVLDKLLFHIYLLAVLA 
5HT3B           --------------
VWSQLQSISNYLQTQDQTDQQEAEWLVLLSRFDRLLFQSYLFMLGI 
5HT3C           KKLGPRETEPDGGSGWTKTQ--------------
LMELWVQFSHAMDTLLFRLYLLFMAS 
5HT3E           QMPGPAEAELTGGSEWTRAQR-----
EHEAQKQHSVELWLQFSHAMDAMLFRLYLLFMAS 
5HT3D           QMPGPGEAELTGGSEWTRAQR-----
EHEAQKQHSVELWVQFSHAMDALLFRLYLLFMAS 
Consensus/80%   
...sP.Esp.ssst.W*chQp.....pppsp.pp.hcbWlpbtpsbD.LLF+lYLLbbtt 
 
 
5HT3A           YSITLVMLWSIWQYA 
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5HT3B           YTITLCSLWALWGGV 
5HT3C           SILTVIVLWNT---- 
5HT3E           SIITVICLWNT---- 
5HT3D           SIITVICLWNT---- 
Consensus/80%   .hITllsLWsh.... 
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Appendices 5: FASTA Results for Serotonin Receptor 5-HT 
1A,1B,2A,2C,3A,4,5,6,7 
FASTA Results for Serotonin Receptor 5-HT 
1A,1B,2A,2C,3A,4,5,6,7 
 
>sp|P08908|5HT1A_HUMAN 5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3 
MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAAIALERSLQNVANYLIGSLA
VTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISL
TWLIGFLISIPPMLGWRTPEDRSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGAD
TRHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHRVGNSKEHLPLPSEAGPT
PCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILCWLPFFIVALVLPFCESSCHMPTLLGAIINWLGYSNS
LLNPVIYAYFNKDFQNAFKKIIKCKFCRQ 
 
>sp|P28222|5HT1B_HUMAN 5-hydroxytryptamine receptor 1B OS=Homo sapiens GN=HTR1B PE=1 SV=1 
MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNCSAKDYIYQDSISLPWKVLLVMLLALITLATTLSNAFVIATVYRTR
KLHTPANYLIASLAVTDLLVSILVMPISTMYTVTGRWTLGQVVCDFWLSSDITCCTASILHLCVIALDRYWAITDAVEYS
AKRTPKRAAVMIALVWVFSISISLPPFFWRQAKAEEEVSECVVNTDHILYTVYSTVGAFYFPTLLLIALYGRIYVEARSRI
LKQTPNRTGKRLTRAQLITDSPGSTSSVTSINSRVPDVPSESGSPVYVNQVKVRVSDALLEKKKLMAARERKATKTL
GIILGAFIVCWLPFFIISLVMPICKDACWFHLAIFDFFTWLGYLNSLINPIIYTMSNEDFKQAFHKLIRFKCTS 
 
>sp|P28223|5HT2A_HUMAN 5-hydroxytryptamine receptor 2A OS=Homo sapiens GN=HTR2A PE=1 SV=2 
MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGCLSPSCLSLLHLQEKNW
SALLTAVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIADMLLGFLVMPVSMLTILYGYRWPLPSKLCAVWIYLDVLF
STASIMHLCAISLDRYVAIQNPIHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLADDNFVLIGS
FVSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSEKLFQRSIHREPGSYTGRRTMQSISNEQ
KACKVLGIVFFLFVVMWCPFFITNIMAVICKESCNEDVIGALLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQY
KENKKPLQLILVNTIPALAYKSSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV 
 
>sp|P28335|5HT2C_HUMAN 5-hydroxytryptamine receptor 2C OS=Homo sapiens GN=HTR2C PE=1 SV=1 
MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSIVIIIIMTIGGNILVIMAVSME
KKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVWPLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEH
SRFNSRTKAIMKIAIVWAISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIYVLRRQA
LMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTMQAINNERKASKVLGIVFFVFLI
MWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVCSGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRV
AATALSGRELNVNIYRHTNEPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV 
 
>sp|P50406|5HT6R_HUMAN 5-hydroxytryptamine receptor 6 OS=Homo sapiens GN=HTR6 PE=1 SV=1 
MVPEPGPTANSTPAWGAGPPSAPGGSGWVAAALCVVIALTAAANSLLIALICTQPALRNTSNFFLVSLFTSDLMVGLV
VMPPAMLNALYGRWVLARGLCLLWTAFDVMCCSASILNLCLISLDRYLLILSPLRYKLRMTPLRALALVLGAWSLAAL
ASFLPLLLGWHELGHARPPVPGQCRLLASLPFVLVASGLTFFLPSGAICFTYCRILLAARKQAVQVASLTTGMASQAS
ETLQVPRTPRPGVESADSRRLATKHSRKALKASLTLGILLGMFFVTWLPFFVANIVQAVCDCISPGLFDVLTWLGYCN
STMNPIIYPLFMRDFKRALGRFLPCPRCPRERQASLASPSLRTSHSGPRPGLSLQQVLPLPLPPDSDSDSDAGSGGS
SGLRLTAQLLLPGEATQDPPLPTRAAAAVNFFNIDPAEPELRPHPLGIPTN 
 
>sp|P34969|5HT7R_HUMAN 5-hydroxytryptamine receptor 7 OS=Homo sapiens GN=HTR7 PE=1 SV=2 
MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLSEVTASPAPTWDAPPDNASGCGEQIN
YGRVEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLIVSLALADLSVAVAVMPFVSVTDLIGGKWIFGHFFCN
VFIAMDVMCCTASIMTLCVISIDRYLGITRPLTYPVRQNGKCMAKMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQ
DFGYTIYSTAVAFYIPMSVMLFMYYQIYKAARKSAAKHKFPGFPRVEPDSVIALNGIVKLQKEVEECANLSRLLKHERK
NISIFKREQKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCSCIPLWVERTFLWLGYANSLINPFIYAFFNRDLRTTY
RSLLQCQYRNINRKLSAAGMHEALKLAERPERPEFVLRACTRRVLLRPEKRPPVSVWVLQSPDHHNWLADKMLTTV
EKKVMIHD 
 
5HT3A 
MLLWVQQALLALLLPTLLAQGEARRSRNTTRPALLRLSDYLLTNYRKGVRPVRDWRKPTTVSIDVIVYAILNVDEKNQ
VLTTYIWYRQYWTDEFLQWNPEDFDNITKLSIPTDSIWVPDILINEFVDVGKSPNIPYVYIRHQGEVQNYKPLQVVTAC
SLDIYNFPFDVQNCSLTFTSWLHTIQDINISLWRLPEKVKSDRSVFMNQGEWELLGVLPYFREFSMESSNYYAEMKF
YVVIRRRPLFYVVSLLLPSIFLMVMDIVGFYLPPNSGERVSFKITLLLGYSVFLIIVSDTLPATAIGTPLIGKAPPGSRAQS
GEKPAPSHLLHVSLASALGCTGVYFVVCMALLVISLAETIFIVRLVHKQDLQQPVPAWLRHLVLERIAWLLCLREQSTS
QRPPATSQATKTDDCSAMGNHCSHMGGPQDFEKSPRDRCSPPPPPREASLAVCGLLQELSSIRQFLEKRDEIREVA
RDWLRVGSVLDKLLFHIYLLAVLAYSITLVMLWSIWQYA 
 
5HT4 
MDKLDANVSSEEGFGSVEKVVLLTFLSTVILMAILGNLLVMVAVCWDRQLRKIKTNYFIVSLAFADLLVSVLVMPFGAIE
LVQDIWIYGEVFCLVRTSLDVLLTTASIFHLCCISLDRYYAICCQPLVYRNKMTPLRIALMLGGCWVIPTFISFLPIMQG
WNNIGIIDLIEKRKFNQNSNSTYCVFMVNKPYAITCSVVAFYIPFLLMVLAYYRIYVTAKEHAHQIQMLQRAGASSESRP
QSADQHSTHRMRTETKAAKTLCIIMGCFCLCWAPFFVTNIVDPFIDYTVPGQVWTAFLWLGYINSGLNPFLYAFLNKS
FRRAFLIILCCDDERYRRPSILGQTVPCSTTTINGSTHVLRDAVECGGQWESQCHPPATSPLVAAQPSDT 
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Appendices 6: GOPMS Information Leaflet 
Women & Children’s Division 
Maternity Building 
Newcastle Road 
Stoke on Trent 
ST4 6QG 
Email: gail.chapman@uhns.nhs.uk 
GENETICS OF PREMENSTRUAL SYNDROME 
INVITATION TO TAKE PART IN RESEARCH INTO THE ROLE GENETICS 
PLAY IN PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC 
DISORDER. 
 
We would like to invite you take part in a research study. Before you decide 
whether or not you wish to take part it is important that you understand why we are 
doing the study and how you will be involved if you do take part. Please read the 
following information carefully. Discuss it with your partner and relatives if you 
wish. Ask if there is anything you do not understand or if you would like more 
information. You will be given as much time as want to make a decision and at any 
point you can change your mind.  
 
WHAT ARE WE AIMING TO DO? 
Premenstrual symptoms (PMS) affects 95% women during their reproductive 
years. Approximately 5% suffer from the more severe disorder, this is called 
premenstrual dysphoric disorder. In previous studies oestrogen and progesterone 
(hormones from the ovary) levels have been taken from women with and those 
without PMS, no differences have been shown. However, we do know that PMS 
occurs during the progesterone part of the cycle. In a research setting, serotonin (a 
brain hormone) levels have been shown to be lower during this part of the cycle in 
women with PMS and remain normal in women without PMS. By understanding 
which genes cause this, it may be possible to improve treatment, or even prevent 
the occurrence. 
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WHY ARE WE ASKING YOU FOR YOUR HELP? 
PMS, as you are aware, is very disruptive to family life and relationships; this will 
be the main reason most of you have come to see us for advice on PMS. We are  
looking for women with and without the disorder so we can detect any difference in 
their genes. 
 
We are seeking help from 100 women with varying degrees of the condition, so 
that we may understand why there are theses differences. 
 
The white cells in your blood carry a complete set of your genes which we can 
study. 
We would like to store some of these white blood cells in the laboratory because 
we believe it will take some years and experiments to fully understand the cause of 
premenstrual syndrome. For every new test or experiment on the white cells a new 
application will be made to the Ethic Committee for their approval before we can 
start. These tests will only be carried out for premenstrual syndrome and no other 
condition. 
 
WHO IS ORGANISING THE STUDY? 
Professor O’Brien is the Professor of Obstetrics and Gynaecology with Keele 
University and North Staffordshire Hospital (NHS) Trust. He has a longstanding 
interest in PMS and its treatments He will be leading a team consisting of research 
doctor, sister and clinical scientist. The study is being funded by departmental 
funds. 
 
WHAT WILL WE BE ASKING YOU TO DO? 
Some of you will have already been screened to define how severe you have the 
disease. For those of you who have not, we will ask you to complete daily diaries 
for 2 to 3 menstrual cycle, to measure the severity of your condition. 
 
We will be asking you to donate a 30ml blood sample – one large syringe full, this 
will be taken through a needle from a vein in your arm. This usually causes only 
brief discomfort and occasionally a small bruise. We also need a 10ml sample of 
urine, this is like a specimen you would give for a pregnancy test. The sample will 
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be used to study the genes which we think differ in PMS and serotonin levels.  We 
will ask some questions about your medical history, as well assess any other 
mood disorders you may have.  
 
DO I HAVE TO TAKE PART? 
Your taking part in this study is voluntary. If you would prefer not to take part you 
do not need to give a reason. You may also withdraw form the study at any time. 
This will not affect your medical treatment. We cannot guarantee to discover 
anything that will be of directly benefit you. Neither you nor the researchers will 
benefit financially from this research. 
 
WHO WILL SEE MY RECORDS AND KNOW ABOUT ME TAKING PART? 
The Research Doctors and Sister are the only ones who need to see your records 
and no other health professional needs to be made aware of your participation. 
The  
information collected about you during the course of the study will be kept 
confidential. The result of the genetic testing on named individuals will not be 
available to any of the researchers, and the results of tests performed on your 
genes will not be divulged to you. 
 
WILL MY EXPENSES BE PAID? 
You will be offered payment for all reasonable additional expenses for taking part 
in the study, such as travelling expenses. 
 
WHOM DO I CONTACT WITH ANY CONCERNS? 
If you have any problems, concerns or other questions about this study, you 
should preferably first contact Gail Chapman, Research Sister on 01782 552449, 
where there is a “PMS Hotline” if you wish to leave a message or Professor 
O’Brien, via his secretary, on 01782 552472 at Academic Department of Obstetric 
and Gynaecology, Maternity Unit, City General Hospital, Newcastle Rd, Stoke on 
Trent. ST4 6QG.Alternatively you may contact Dave Crowley, Chief Executive, on 
01782 715444, North Staffordshire Hospital (NHS) Trust, City General Hospital, 
Newcastle Rd, Stoke on Trent. ST4 6QG. 
 
220 
 
Appendices 7: GOPMS RECRUITMENT SHEET 
GOPMS 
Recruitment Sheet 
 
Study No  ……..….     Subject Initials  
 
 
DOB      /     /           
   
 
 
Name…………………………………….. 
 
 
Address……………………………………. 
 
………………………………………………. 
 
…………………………………………………. 
 
 
Post Code…………….. 
 
 
 
Date Enrolled ………/………/……… 
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Appendices 8: GOPMS DATA SHEET 
GOPMS 
Data Sheet 
 
Study No  ……..….     Subject Initials  
 
 
DOB      /     /           
   
 
Measure used to confirm diagnosis 
 
DRSP      SYMPTOMETRICS Device 
 
COPE      VAS 
 
Other      (Specify:…………………………………………………………) 
 
 
 
Diagnosis    PMDD   Control 
 
 
 
Symptoms predominately  Physical   Psychological 
 
 
Years of Problem ……………….. 
 
Onset coincided with   
 
Menarche     Childbirth 
 
Oral Contraceptive    Sterilisation 
 
Other  (Describe …………………………………………………………..) 
 
None 
 
 
Family History of PMS/PMDD   Yes    No 
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Mother  Daughter  Sister   Twin    
 
Past medication 
1 = not effective 2 = mild 3 = moderate 4 = effective 5 = very effective 
 
Medication Effectiveness 
(1-5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Present medication 
0 = no treatment 1 = not effective 2 = mild 3 = moderate 4 = effective  
5 = very effective 
 
Medication Effectiveness 
(1-5) 
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Appendices 9: Control group – DRSP scores 
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1 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
2 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
6 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
9 7 11 57% 7 7 0% 7 9 29% 7 16 129% 7 11 57% 
12 9 12 33% 20 25 25% 12 18 50% 18 24 33% 19 18 -5.26% 
18 18 19 5% 21 27 33% 16 22 37% 24 30 25% 21 21 0% 
22 7 10 42% 7 7 0% 7 7 0% 7 10 42% 7 7 0% 
23 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
24 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
26 25 28 12% 26 33 26% 24 27 13% 20 25 25% 29 26 -10% 
27 20 25 25% 16 30 88% 17 30 76% 17 30 76% 14 27 93% 
30 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
32 7 9 29% 10 10 0% 9 8 -11% 10 12 20% 8 12 50% 
35 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
37 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
38 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
39 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
41 7 8 14% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
43 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
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Appendices 9: Control group – DRSP scores (continued) 
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46 7 8 14% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
49 7 7 0% 7 7 0% 7 7 0% 7 7  0% 7 7 0% 
50 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
51 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
54 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
55 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
56 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
57 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
58 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
59 7 11 57% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
61 9 7 -22% 9 7 -22% 9 7 -22% 9 9 0% 7 7 0% 
62 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
63 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 9 29% 
65 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
66 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
73 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
74 7 7 0% 7 12 71% 7 9 29% 10 11 10% 9 9 0% 
86 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
88 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
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Appendices 9: Control group – DRSP scores (continued) 
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89 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
90 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
94 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
95 7 9 29% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
96 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
97 7 7 0% 7 7 0% 7 10 42% 7 7 0% 7 7 0% 
98 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
99 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
100 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
102 7 7 0% 7 8 14% 7 7 0% 7 7 0% 7 7 0% 
103 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
104 7 7 0% 7 7 0% 7 7 0% 7 11 57% 7 7 0% 
105 7 7 0% 7 7 0% 7 7 0% 7 7 0% 7 7 0% 
106 7 7 0% 7 10 42% 7 7 0% 7 7 0% 7 7 0% 
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Appendix 10: PMDD group – DRSP scores 
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3 11 25 127% 14 28 100% 7 7 0% 11 25 127% 8 34 325% 
4 7 29 314% 7 41 485% 7 26 271% 8 40 400% 12 39 225% 
5 9 25 178% 9 31 244% 10 29 190% 10 31 210% 7 24 242% 
7 7 7 0% 7 42 500% 7 28 300% 7 27 285% 7 10 42% 
8  9 18  100% 7 14 100% 8 17 100% 7 15 100% 7 14  100% 
10 11 27 145% 15 15 0% 13 26 100% 16 12 -25% 12 28 133% 
11 9 21 133% 10 28 180% 7 20 185% 7 21 200% 9 27 200% 
13 9 19 111% 8 16 100% 7 14 100% 9 19 100% 9 20 100% 
14 15 19 27% 17 29 70% 13 31 138% 19 31 63% 10 25 150% 
15 9 11 22% 12 10 -17% 7 21 200% 12 18 50% 10 20 100% 
16 7 22 214% 8 23 187% 7 23 228% 8 27 237% 7 23 228% 
17 13 26 100% 19 34 78% 31 34 10% 14 34 142% 11 37 236% 
19 14 34 142% 12 33 175% 21 30 43% 16 19 19% 14 33 106% 
20 12 38 216% 13 41 215% 7 35 400% 12 36 200% 13 31 138% 
21 8 9 13% 8 8  0%  7 25 257% 7  7  0% 7  10  43%  
25 7 15  114% 8 18  125% 7 16 129% 9 21  133% 7  14  100% 
28 8 24 200% 8 21 163% 7 22 214% 8 22 175% 7 25 257% 
 
Appendices 10: PMDD group – DRSP scores (continued) 
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29 8 15 100% 8 21 162% 12 16 33% 13 26 100% 15 31 100% 
31 8 34 325% 9 40 344% 8 28 250% 11 40 263% 7 28 300% 
34 7 34 385% 9 32 255% 8 30 275% 8 35 337% 7 37 428% 
36 7 22 214% 7 27 285% 7 31 342% 7 25 257% 7 23 229% 
40 8 29 262% 7 35 400% 7 31 342% 7 34 385% 7 34 385% 
42 7 10 43% 7 21 200% 8 7 -14% 7 21 200% 9 21 133% 
44 9 31 244% 11 36 227% 14 31 121% 8 35 325% 8 34 325% 
45 7 28 300% 7 28 300% 7 28 300% 7 28 300% 7 28 300% 
47 9 36 300% 9 40 344% 9 39 333% 11 40 263% 10 39 290% 
48 7 34 385% 7 36 385% 7 29 314% 7 35 385% 7 32 320% 
52 7 31 342% 7 31 342% 7 35 400% 7 32 357% 7 24 242% 
53 8 16 100% 10 25 150% 7 16 129% 7 17 143% 8 16 100% 
60 7 21 200%  8 19 138% 7 16 129% 8 20 150% 9 19 111% 
64 8 12 50% 10 22 120% 8 18 125% 9 15 67% 7 14 100% 
67 7 31 342% 7 24 242% 7 29 314% 7 21 200% 7 19 171% 
68 7 22 214% 10 38 280% 7 35 400% 11 37 236% 8 35 337% 
69 7 19 171% 7 19 171% 7 7 0% 7 19 171% 7 16 129% 
70 7 17 143% 8 11 38% 7 12 71% 8 19 138% 10 18 80% 
71 7 23 229% 7 26 271% 7 27 289% 7 28 300% 7 24 242% 
72 7 25 257% 7 28 300% 7 28 300% 7 27 285% 7 42 500% 
 
 
Appendices 10: PMDD group – DRSP scores (continued) 
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75 7 32 357% 7 32 357% 7 32 357% 7 32 357% 7 32 357% 
76 13 26 100% 10 28 180% 10 28 180% 9 29 222% 7 31 342% 
77 20 37 85% 19 36 89% 17 35 105% 13 33 154% 16 34 113% 
78 9 21 133% 8 22 175% 9 16 77% 9 14 55% 8 17 113% 
79 7 18 157% 9 12 33% 7 18 157% 8 19 138% 7 22 214% 
80 7 29 314% 7 41 485% 7 26 271% 8 38 375% 13 39 200% 
81 15 21 40% 20 26 30% 15 22 47% 11 33 200% 7 22 214% 
82 9 19 111% 7 21 200% 7 22 214% 14 24 71% 8 24 200% 
83 10 20 100% 9 23 156% 8 17 113% 8 21 163% 9 20 122% 
84 7 11 57% 7 20 186% 7 7 0% 7 20 186% 7 21 200% 
85 12 26 117% 9 20 122% 7 19 171% 8 17 113% 7 14 100% 
87 7 14 100% 8 19 138% 12 29 142% 10 21 110% 9 18 100% 
91 9 12 33% 7 18 157% 8 26 225% 13 30 131% 7 20 186% 
93 12 28 133% 9 19 111% 8 22 175% 9 21 133% 10 22 120% 
101 11 21 90% 10 24 124% 8 24 200% 8 17 113% 9 22 144% 
107 7 16 129% 8 19 138% 8 26 225% 9 19 111% 19 22 120% 
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Appendices 11: Types Of Genetic Mutations 
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Appendices 12: Reagents for the extraction of DNA from Whole blood: 
 
 Reagent A 
10 ml of 1M Trizma-HCL [Sigma T-5941]  
109.5 g  of sucrose [Sigma S-7903] 
1.02 g of MgCl2.6H2O [Sigma M-2670] 
10 ml of Triton X-100 
 Approximately 800 ml deionised water 
Adjust the pH to 8.0 with 2 M NaOH, and make up to 1 litre with 
deionised water.  
 Autoclave before use.   
Store at room temperature. 
 Reagent B 
100 ml of 1M Trizma-HCL pH 8.0  
30 ml of 0.5 M EDTA pH 8.0 [Sigma EDS] 
15 ml of 2.5 M NaCl [Sigma S-3014]  
Make up to 237.5 ml with deionised water.   
Autoclave at this stage.   
Before use, add 12.5 ml of 20% w/v SDS.   
Store at room temperature. 
 5M Sodium perchlorate 
Dissolve 70.25 g of  NaHClO3 [Sigma S-1041] in 100 ml of deionised 
water (no autoclaving required).   
Store at room temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
 231 
 
Appendices 13: Reagents for PCR 
 
 Stock Primers 
Thaw at room temperature 
Vortex 
Dilute 1:20 stock primers: sterile water 
25µL (5µl) stock primer + 475µl (95µl) sterile water 
Spiral mix 
Keep on ice 
 
 dNTP's 
100 mM solutions of dATP, dCTP, dGTP and dTTP.   
Vortex 
10µL of each solution were pipetted into a single sterile 1.5mL 
Eppendorf tube 
160µL of sterile water added to give a working solution of 5 mM.   
Store @ -20°C Temperature 
 
 Taq DNA polymerase in storage buffer A(100 units) 
Storage buffer A consists of 50 mM Tris-HCL (pH 8.0 at 250C),  
100 mM NaCl,  
0.1 mM EDTA,  
1 mM DTT,  
50 % glycerol and 1% Triton X-100.  
Store at -20°C 
Thaw and vortex before use 
 
 Taq DNA Polymerase 10X Buffer containing 15 mM MgCl2  
50 KCl,  
10 mM Tris-HCL (pH 9.0 at 250C),  
1.5mM MgCl2 and 0.1 % Triton X-100 when diluted 1 in 10  
 Stored at -20°C 
Thaw and vortex before use 
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Appendices 14: Solutions for agarose gel 
 
 Tris-Borate-EDTA buffer [TBE 10X] 
107.8 g Tris base  
1.44 g ( 40ml of .5M EDTA solution Ph 8.0 
55.0 g boric acid 
Dissolve in 800 mL deionized water, then bring total volume to 1 L 
with deionized water 
Store in room temperature 
 
 Agarose 
100ml of 1X TBE 
1,2 or 3gms of Agarose to produce 1%,2% or 3% gel 
 
 Ethidium Bromide 
10mg/ml ethidium bromide.  
Prepare stock in deionized water (1g/100ml) 
Store at 4°C in dark  
 
 Gel loading buffer 
0.125gms of 0.25% bromophenol blue 
20gms of 40%sucrose in 50ml deionized water (heat) 
0.125gms of 0.25% xylene cyanol 
Store in room temperature 
 
* Ethidium bromide is a powerful mutagen/carcinogen and is moderately toxic. Gloves should 
always be worn when handling solutions and gels containing ethidium bromide. 
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Appendices 15: Solutions for polyacrylamide gel 
 Fixative 
5 mL acetic acid 
100 mL Methanol 
Dissolve in 1lt deionized water 
Store in room temperature 
 40% acrylamide:bis (29:1) 
290 g acrylamide 
10 g bisacrylamide 
dissolve in 250 mL deionized water, then bring total volume to 
500mL with deionized water 
store at 4°C 
 10X TBE buffer 
107.8 g Tris base 
1.45 g EDTA 
55.0 g boric acid 
Dissolve in 800 mL deionized water, then bring total volume to 1 L 
with deionized water 
Store in room temperature 
 10% Ammonium persulphate APS  
10dms APS 
100 mL deionized water 
Store in room temperature 
 staining solution 
1 g silver nitrate 
1000 mL deionized water 
Store in dark bottle and room temperature 
 developer solution 
15gms of sodium hydroxide 
1000 mL deionized water 
Store in room temperature 
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Appendices 16: 5-HT1A (-C1019G) Designing Primers 
www.ensembl.org : To obtain the nucleotide sequence 
 
CTAGCCACAAAGCTATGGGAAGTGGCAGTGTCACTGAAATTACAAGTGTAGTAGTGATGG 
AAAAGTGTGTGTGTGTTTAGAATATATATCACACTGAGTTTTGTTCTTCATTTCGAGATG 
CAGTTGTTTACCTCTCCTTGTCCTTTGACACGTCCTTTATAATTTCGTTCTCTCCCGGTT 
CCCCAACGTTAAAAAAAAAGTCACAGGCAATATTCTCCCTGAGGGAGTAAGGCTGGACTG 
TTAGATGATAACGGAGGTACCGTTTTGTTGTTGTTGTCGTCGTTGTTCGTTTGTTTTTGG 
AGACGGAGTCTCGCTCTGTCGCCCAGGCTGGAGTGCAATGGCGCGAGAACGGAGGTAGCT 
TTTTAAAAAGGAAGACACACTCGGTCTTCTTCCATCAATTAGCAATAATTGGGAGACTGA 
CCCAGGACTGTTCACCTTCCCATTCAGGCTCCCTATGCTTCCTTTTCTCATCTCCTATTG 
CCACTCTGGGATGCTGACACGATTTAAGAATTTGGCAGATAATATGAGGCAAGGAGTAGT 
TGGAATTCCCTCCCCCAAGTTTTTCCAACCCCAGTTTTGCTGGGTTGGAGGCGGAGTTTA 
TTTGTTACAACCTTGGTCTGACCGGCAGGGATCTGGTGTGTGTAAGTGAGTTCTGAGTCT 
CTGTTGACAAAAAGAGACTCGAATGCAAAGACGCTGAGCTAGAGGGAGAGGAGGGCGGGG 
ACCCAGAGGAAAGAGGCACTCCTCGGGGTTGGGGAAGTATTAGGAGGGGAGGGTTAGAGT 
GGGAGGGAAGGAGCCTGGCTTTCGAAGCGACTCACAGAGGGATAAATAAAGGGAAGTGAG 
GAGGAAGAGGGAGACTGAAAGGGAAGGCAGGTGGGGAGAAGGGGGACGAAAGAGGCAGAA 
GAGAGAGAAGAGAGGAGGAGAGAGGGGGAGAGAGGGAAGGAAGGAAATAGGGAGAGGAGG 
GTCACAGAGTGACCGTGGAGGATGGGGCTTCTCGGTTCTAGATATTTCTGGGATTGGAGA 
CTGTTTGCTAGTGGGGAGACTCCAGCTCCGGCAGCCAGTTCGGGAGCGGCAAAGTAAAAT 
GGACAGCGACAGACAGACGTTCCAGCCACCTCTCCGCCGCCGGGAGATCCTGGAGCTGCT 
TTCAGGCCAACTCCAGTTTCCCAGCTGGAGCTTCTGAACGCGCTGGACTGCGAGAGCCCA 
GGGAGCGCCTGAAAGCTGCTCCTCGGAGATACCCTTCGCCGAAGCAGTAAGAACTTCCTG 
CTTGGGTCTCTGCATTCCCTTCCTCCGAAACTTCCCAGGAGAAGGGCGGAAGACCCCAGG 
GGAAGGGGCGAGGCGAATCTTCGCGCTGCTTTTTCTTCCCTCCCCCTTCCCGCGCCGGGC 
GCGCAGGCATGGATGTGCTCAGCCCTGGTCAGGGCAACAACACCACATCACCACCGGCTC 
CCTTTGAGACCGGCGGCAACACTACTGGTATCTCCGACGTGACCGTCAGCTACCAAGTGA 
TCACCTCTCTGCTGCTGGGCACGCTCATCTTCTGCGCGGTGCTGGGCAATGCGTGCGTGG 
TGGCTGCCATCGCCTTGGAGCGCTCCCTGCAGAACGTGGCCAATTATCTTATTGGCTCTT 
TGGCGGTCACCGACCTCATGGTGTCGGTGTTGGTGCTGCCCATGGCCGCGCTGTATCAGG 
TGCTCAACAAGTGGACACTGGGCCAGGTAACCTGCGACCTGTTCATCGCCCTCGACGTGC 
TGTGCTGCACCTCATCCATCTTGCACCTGTGCGCCATCGCGCTGGACAGGTACTGGGCCA 
TCACGGACCCCATCGACTACGTGAACAAGAGGACGCCCCGGCGCGCCGCTGCGCTCATCT 
CGCTCACTTGGCTTATTGGCTTCCTCATCTCTATCCCGCCCATGCTGGGCTGGCGCACCC 
CGGAAGACCGCTCGGACCCCGACGCATGCACCATTAGCAAGGATCATGGCTACACTATCT 
ATTCCACCTTTGGAGCTTTCTACATCCCGCTGCTGCTCATGCTGGTTCTCTATGGGCGCA 
TATTCCGAGCTGCGCGCTTCCGCATCCGCAAGACGGTCAAAAAGGTGGAGAAGACCGGAG 
CGGACACCCGCCATGGAGCATCTCCCGCCCCGCAGCCCAAGAAGAGTGTGAATGGAGAGT 
CGGGGAGCAGGAACTGGAGGCTGGGCGTGGAGAGCAAGGCTGGGGGTGCTCTGTGCGCCA 
ATGGCGCGGTGAGGCAAGGTGACGATGGCGCCGCCCTGGAGGTGATCGAGGTGCACCGAG 
TGGGCAACTCCAAAGAGCACTTGCCTCTGCCCAGCGAGGCTGGTCCTACCCCTTGTGCCC 
CCGCCTCTTTCGAGAGGAAAAATGAGCGCAACGCCGAGGCGAAGCGCAAGATGGCCCTGG 
CCCGAGAGAGGAAGACAGTGAAGACGCTGGGCATCATCATGGGCACCTTCATCCTCTGCT 
GGCTGCCCTTCTTCATCGTGGCTCTTGTTCTGCCCTTCTGCGAGAGCAGCTGCCACATGC 
CCACCCTGTTGGGCGCCATAATCAATTGGCTGGGCTACTCCAACTCTCTGCTTAACCCCG 
TCATTTACGCATACTTCAACAAGGACTTTCAAAACGCGTTTAAGAAGATCATTAAGTGTA 
AGTTCTGCCGCCAGTGATGACGGAGGAGTAGCCGGCCAGTCGAGGCTACAGGATCCGTCC 
CATTCACTATGCTTCCCCCAACCCTAGGGAATCAACACTTAAGATAATTCGCCACTTCTC 
CTCTTTCTCTCTGCTCCGCTCACGGCTTGCAGACCTGGTCCCCTCCCCACTTCCTGCTCC 
ACGGCAGGGCCCTTTGTGCAAAGGAGACCCAGCGGAGGAGCGTTGAGAGCCCAGGAAATT 
CAGAGAGTTTGTGAGAAGCGACATTGGCTCAGACTTCGCCTGTATCATCAGTTTTGATCC 
CAGTAATTGCCTCTTCTCTCTTCTATCTCCTAAATCTTTGCGGTGGATGTTTAATGCTTA 
GTTCAAGGCAGAAAATCCAAAAAATAAATAAACTGTACACACAGCCGCCGCGCCCACTAA 
GGGGCTCCACCCCATCACCCAACTTCTAGAACTTGGACTTGAGGTTTGGGAATTTGCTCC 
ATCTCTCCCGCCCTGTGGCCCTTGAAATATTCACCTTTTTCTCCCCATTTTTATCTTTTC 
TTTTTTTCATTGCTTCCCTCTCTGCCCTCGCCCATCCTTATGCACGAATCTGCTGGTCCG 
GAGAGGCGGAAGAGGCTGCTTTTCCCCGTGCCAGCGGTGCCCCCGGGATTCCCCGTCTTC 
TCGCAGACTTGAGATTAACTCTCTCGTGCAGTGCACAACCCCTATTTCCTTT 
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Primer picked using http://frodo.wi.mit.edu and the general rules to design these primers 
applied: 
Primer3 Output 
 
PRIMER PICKING RESULTS FOR 5HT1A 
 
No mispriming library specified 
Using 1-based sequence positions 
WARNING: Right primer is unacceptable: High end self complementarity 
 
OLIGO            start  len      tm     gc%   any    3' seq  
LEFT PRIMER        225   23   57.22   47.83  3.00  0.00 GAGTAAGGCTGGACTGTTAGATG 
RIGHT PRIMER       393   22   59.78   50.00  7.00  7.00 GGAAGAAGACCGAGTGTGTCTT 
SEQUENCE SIZE: 420 
INCLUDED REGION SIZE: 420 
 
PRODUCT SIZE: 169, PAIR ANY COMPL: 3.00, PAIR 3' COMPL: 1.00 
 
    1 CTAGCCACAAAGCTATGGGAAGTGGCAGTGTCACTGAAATTACAAGTGTAGTAGTGATGG 
                                                                   
 
   61 AAAAGTGTGTGTGTGTTTAGAATATATATCACACTGAGTTTTGTTCTTCATTTCGAGATG 
                                                                   
 
  121 CAGTTGTTTACCTCTCCTTGTCCTTTGACACGTCCTTTATAATTTCGTTCTCTCCCGGTT 
                                                                   
 
  181 CCCCAACGTTAAAAAAAAAGTCACAGGCAATATTCTCCCTGAGGGAGTAAGGCTGGACTG 
                                                  >>>>>>>>>>>>>>>> 
 
  241 TTAGATGATAACGGAGGTACCGTTTTGTTGTTGTTGTCGTCGTTGTTCGTTTGTTTTTGG 
      >>>>>>>                                                      
 
  301 AGACGGAGTCTCGCTCTGTCGCCCAGGCTGGAGTGCAATGGCGCGAGAACGGAGGTAGCT 
                                                                   
 
  361 TTTTAAAAAGGAAGACACACTCGGTCTTCTTCCATCAATTAGCAATAATTGGGAGACTGA 
                 <<<<<<<<<<<<<<<<<<<<<<                    
 
KEYS (in order of precedence): 
>>>>>> left primer 
<<<<<< right primer 
 
Statistics 
Pair Stats: 
considered 1, ok 1 
primer3 release 1.1.4 
(primer3_results.cgi release 0.4.0) 
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Apendices 17: 5-HT1B (A-161T) Designing Primers 
www.ensembl.org : To obtain the nucleotide sequence 
 
GGCGTCCGCACCCGCCGCGCCGCACGAGTTGCACTGCTCTGGCGGACCGGACCTGGACTC 
TATATAAAGAGCCCATCTGCTCCGTAGCTCGCACGCTTCTCCCGGGCTGGTGCACGCCGC 
GTCCCTCCAGCTCCCCCAGACACCTGCCCCTTCCCAGTGTGCCGCGCCAGGTCCTCCAGA 
CCCGCGCACCCAGTGGCATGGCTCCGAGTGGCTCCCGTGGGACCAGGGTGGCGGTGGCGG 
CGGCGCGGCCCGAGCAGCCGCAACTCCAGCCCCCGTGTCCCCCCTTTTATGGCTCCGTCT 
CCGCGGGGCAGCTCGTCCGAGTGGCCAGAGAGTGAAAAGAGAGGGAGGGCAGAGCTCCGG 
CGCGAGGCGCGGCGCAGCGCTGCTCCTAGACTTCACCCCACCCAGCTCTGGCGGCCGCTG 
CAGCCCCCCAAAAGTGCCCCAGCTTGGGGCGAGGGGTGGGAATGCAAGATCTCGGGACCT 
CTCGCTGGCCTGCAAGCTTTGGTCTCTACACCTAGGAAACTCCTGTGGGCAAAGTCTGCA 
GATCCAAAAGCGTCCAGGTTAGGAGACGCTCAGCCTCAAGCAACTGGGGTAAGAGATCCC 
ATTTGGTCAAAGCCTTCTC CTCAAGCAGTACTTCACCCTCCTGCACTAGACGCCTCCAGG 
GAGCTGGAGCGGAGCAGGGCTCGGTGGGCCAGCTCTTAGCAACCCAGGTCTAAGACCCGG 
TGTGGAGAGGAACAACCACAGACGCGGCGGCTTAGCTAGGCGCTCTGGAAGTGCAGGGGA 
GGCGCCCGCCTGCCTTGGCTGCCGCACCCATGACCTCTAGTTTCAGCTGTGAACCTGGGC 
GGAGGAATAATTGAGGAACTCACGGAACTATCAACTGGGGACAAACCTGCGATCGCCACG 
GTCCTTCCGCCCTCTCCTTCGTCCGCTCCATGCCCAAGAGCTGCGCTCCGGAGCTGGGGC 
GAGGAGAGCCATGGAGGAAC CGGGTGCTCAGTGCGCTCCACCGCCGCCCGCGGGCTCCGA 
GACCTGGGTTCCTCAAGCCAACTTATCCTCTGCTCCCTCCCAAAACTGCAGCGCCAAGGA 
CTACATTTACCAGGACTCCATCTCCCTACCCTGGAAAGTACTGCTGGTTATGCTATTGGC 
GCTCATCACCTTGGCCACCACGCTCTCCAATGCCTTTGTGATTGCCACAGTGTACCGGAC 
CCGGAAACTGCACACCCCGGCTAACTACCTGATCGCCTCTCTGGCGGTCACCGACCTGCT 
TGTGTCCATCCTGGTGATGCCCATCAGCACCATGTACACTGTCACCGGCCGCTGGACACT 
GGGCCAGGTGGTCTGTGACTTCTGGCTGTCGTCGGACATCACTTGTTGCACTGCCTCCAT 
CCTGCACCTCTGTGTCATCGCCCTGGACCGCTACTGGGCCATCACGGACGCCGTGGAGTA 
CTCAGCTAAAAGGACTCCCAAGAGGGCGGCGGTCATGATCGCGCTGGTGTGGGTCTTCTC 
CATCTCTATCTCGCTGCCGCCCTTCTTCTGGCGTCAGGCTAAGGCCGAAGAGGAGGTGTC 
GGAATGCGTGGTGAACACCGACCACATCCTCTACACGGTCTACTCCACGGTGGGTGCTTT 
CTACTTCCCCACCCTGCTCCTCATCGCCCTCTATGGCCGCATCTACGTAGAAGCCCGCTC 
CCGGATTTTGAAACAGACGCCCAACAGGACCGGCAAGCGCTTGACCCGAGCCCAGCTGAT 
AACCGACTCCCCCGGGTCCACGTCCTCGGTCACCTCTATTAACTCGCGGGTTCCCGACGT 
GCCCAGCGAATCCGGATCTCCTGTGTATGTGAACCAAGTCAAAGTGCGAGTCTCCGACGC 
CCTGCTGGAAAAGAAGAAACTCATGGCCGCTAGGGAGCGCAAAGCCACCAAGACCCTAGG 
GATCATTTTGGGAGCCTTTATTGTGTGTTGGCTACCCTTCTTCATCATCTCCCTAGTGAT 
GCCTATCTGCAAAGATGCCTGCTGGTTCCACCTAGCCATCTTTGACTTCTTCACATGGCT 
GGGCTATCTCAACTCCCTCATCAACCCCATAATCTATACCATGTCCAATGAGGACTTTAA 
ACAAGCATTCCATAAACTGATACGTTTTAAGTGCACAAGTTGACTTGCCGTTTGCAGTGG 
GGTCGCCTAAGCGACCTTTGGGGACCAAGTTGTGTCTGGTTCCACAGGTAGGTCGAATCT 
TCTTTCGCGGTTTCTGGGTCCCAGCGAGGCTCTCTCTCCTGGGCAAGGGCAATGGATCCT 
GAGAAGCCAGAATAGTCCTGAGAGAGAGCTCTGAAAGGAGAAGTGTTGAAACTAAATGTA 
GAGCTTCCCTGCCCAGGAGGAGGCTCACTTCCTCCCCTCAAGCCCCGGGCTCAGCACTGA 
CCCTGCGGCAGCCAATCCCAAAGGGGGTTGCAACTTTTAAAAATTGATAATGGAAGGGAA 
TCCCTGCCCTGCTTTGGTATCGTGGATAATGCCCACTAGAAGCAGTGTACTTGTAATTGT 
TGTCTGAAGCCTGTCTGAGACAGATCTACATACAGCCTGGCAGTACTTGAACTAGACGCT 
TAATGCCCTGTGTTTTTGGGGGGAGAACTTTGTGTTACAGCTTAATTTAAGAACAGTTAC 
TTTGGCATCATTCAGTCTTCACTTTTTGTCTATTTAAACTTGGTTGGAGAAACTTGTGGA 
TTTGGTGCTTCAAACCCTATGTGTGGCTTGGATGGCGCAGAGA 
 
Primer picked using http://frodo.wi.mit.edu and the general rules to design these primers 
applied: 
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Primer3 Output 
 
 
No mispriming library specified 
Using 1-based sequence positions 
WARNING: Left primer is unacceptable: High 3' stability; Right primer is 
unacceptable: Tm too high/High 3' stability 
 
OLIGO            start  len      tm     gc%   any    3' seq  
LEFT PRIMER         20   22   60.30   54.55  6.00  0.00 CTCAAGCAGTACTTCACCCTCC 
RIGHT PRIMER       380   21   65.61   61.90  6.00  2.00 GTTCCTCCATGGCTCTCCTCG 
SEQUENCE SIZE: 540 
INCLUDED REGION SIZE: 540 
 
PRODUCT SIZE: 361, PAIR ANY COMPL: 3.00, PAIR 3' COMPL: 1.00 
 
    1 ATTTGGTCAAAGCCTTCTCCTCAAGCAGTACTTCACCCTCCTGCACTAGACGCCTCCAGG 
                         >>>>>>>>>>>>>>>>>>>>>>                    
 
   61 GAGCTGGAGCGGAGCAGGGCTCGGTGGGCCAGCTCTTAGCAACCCAGGTCTAAGACCCGG 
                                                                   
 
  121 TGTGGAGAGGAACAACCACAGACGCGGCGGCTTAGCTAGGCGCTCTGGAAGTGCAGGGGA 
                                                                   
 
  181 GGCGCCCGCCTGCCTTGGCTGCCGCACCCATGACCTCTAGTTTCAGCTGTGAACCTGGGC 
                                                                   
 
  241 GGAGGAATAATTGAGGAACTCACGGAACTATCAACTGGGGACAAACCTGCGATCGCCACG 
                                                                   
 
  301 GTCCTTCCGCCCTCTCCTTCGTCCGCTCCATGCCCAAGAGCTGCGCTCCGGAGCTGGGGC 
                                                                 < 
 
  361 GAGGAGAGCCATGGAGGAACCGGGTGCTCAGTGCGCTCCACCGCCGCCCGCGGGCTCCGA 
      <<<<<<<<<<<<<<<<<<<<                                         
 
  421 GACCTGGGTTCCTCAAGCCAACTTATCCTCTGCTCCCTCCCAAAACTGCAGCGCCAAGGA 
                                                                   
 
  481 CTACATTTACCAGGACTCCATCTCCCTACCCTGGAAAGTACTGCTGGTTATGCTATTGGC 
                                                                   
 
KEYS (in order of precedence): 
>>>>>> left primer 
<<<<<< right primer 
 
 
Statistics 
Pair Stats: 
considered 1, ok 1 
primer3 release 1.1.4 
 
 
(primer3_results.cgi release 0.4.0) 
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Appendices 18: 5-HT2A(102T/C) Designing Primers 
www.ensembl.org: To obtain the protein and nucleotide sequence 
5-HT2A Protein Sequence: 
MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGC 
LSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIAD 
MLLGFLVMPVSMLTILYGYRWPLPSKLCAVWIYLDVLFSTASIMHLCAISLDRYVAIQNP 
IHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLADDNFVLIGSF 
VSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSEKLFQRSIH 
REPGSYTGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFITNIMAVICKESCNEDVIGA 
LLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYK 
SSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV 
 
5-HT2A Nucleotide Sequence (Exon1): 
 
CCAGCCCCGGGAGAACAGCATGTACACCAGCCTCAGTGTTACAGAGTGTGGGTACATCAA   
GGTGAATGGTGAGCAGAAACTATAACCTGTTAGTCCTTCTACACCTCATCTGCTACAAGT        
TCTGGCTTAGACATGGATATTCTTTGTGAAGAAAATACTTCTTTGAGCTCAACTACGAAC        
TCCCTAATGCAATTAAATGATGACACCAGGCTCTACAGTAATGACTTTAACTCCGGAGAA        
GCTAACACTTCTGATGCATTTAACTGGACAGTCGACTCTGAAAATCGAACCAACCTTTCC        
TGTGAAGGGTGCCTCTCACCGTCGTGTCTCTCCTTACTTCATCTCCAGGAAAAAAACTGG        
TCTGCTTTACTGACAGCCGTAGTGATTATTCTAACTATTGCTGGAAACATACTCGTCATC        
ATGGCAGTGTCCCTAGAGAAAAAGCTGCAGAATGCCACCAACTATTTCCTGATGTCACTT        
GCCATAGCTGATATGCTGCTGGGTTTCCTTGTCATGCCCGTGTCCATGTTAACCATCCTG        
TATG  
 
Primer picked using http://frodo.wi.mit.edu and the general rules to design these primers 
applied: 
                                                               
 
Primer3 Output 
 
 
No mispriming library specified 
Using 1-based sequence positions 
WARNING: Left primer is unacceptable: Tm too low/High end self 
complementarity 
 
OLIGO            start  len      tm     gc%   any    3' seq  
LEFT PRIMER         71   21   54.61   38.10  4.00  4.00 GAGCAGAAACTATAACCTGTT 
RIGHT PRIMER       515   20   56.11   45.00  3.00  2.00 CAAGTGACATCAGGAAATAG 
SEQUENCE SIZE: 544 
INCLUDED REGION SIZE: 544 
 
PRODUCT SIZE: 410, PAIR ANY COMPL: 3.00, PAIR 3' COMPL: 3.00 
 
    1 CCAGCCCCGGGAGAACAGCATGTACACCAGCCTCAGTGTTACAGAGTGTGGGTACATCAA 
                                                                   
 
   61 GGTGAATGGTGAGCAGAAACTATAACCTGTTAGTCCTTCTACACCTCATCTGCTACAAGT 
                >>>>>>>>>>>>>>>>>>>>>                              
 
  121 TCTGGCTTAGACATGGATATTCTTTGTGAAGAAAATACTTCTTTGAGCTCAACTACGAAC 
 239 
 
                                                                   
 
  181 TCCCTAATGCAATTAAATGATGACACCAGGCTCTACAGTAATGACTTTAACTCCGGAGAA 
                                                                   
 
  241 GCTAACACTTCTGATGCATTTAACTGGACAGTCGACTCTGAAAATCGAACCAACCTTTCC 
                                                                   
 
  301 TGTGAAGGGTGCCTCTCACCGTCGTGTCTCTCCTTACTTCATCTCCAGGAAAAAAACTGG 
                                                                   
 
  361 TCTGCTTTACTGACAGCCGTAGTGATTATTCTAACTATTGCTGGAAACATACTCGTCATC 
                                                                   
 
  421 ATGGCAGTGTCCCTAGAGAAAAAGCTGCAGAATGCCACCAACTATTTCCTGATGTCACTT 
                                               <<<<<<<<<<<<<<<<<<<                    
 
  481 GCCATAGCTGATATGCTGCTGGGTTTCCTTGTCATGCCCGTGTCCATGTTAACCATCCTG 
      <                                        
 
  541 TATG 
           
 
KEYS (in order of precedence): 
>>>>>> left primer 
<<<<<< right primer 
 
ADDITIONAL OLIGOS 
                    start  len      tm     gc%   any    3' seq  
 
 1 LEFT PRIMER         71   21   50.61   38.10  4.00  4.00 GAGCAGAAACTATAACCTGTT 
   RIGHT PRIMER       484   20   60.24   45.00  4.00  0.00 TGGCAAGTGACATCAGGAAA 
   PRODUCT SIZE: 414, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 3.00 
 
 2 LEFT PRIMER         71   21   50.61   38.10  4.00  4.00 GAGCAGAAACTATAACCTGTT 
   RIGHT PRIMER       509   20   59.15   50.00  4.00  2.00 AGGAAACCCAGCAGCATATC 
   PRODUCT SIZE: 439, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 3.00 
 
 3 LEFT PRIMER         71   21   50.61   38.10  4.00  4.00 GAGCAGAAACTATAACCTGTT 
   RIGHT PRIMER       485   20   59.09   45.00  6.00  0.00 ATGGCAAGTGACATCAGGAA 
   PRODUCT SIZE: 415, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 2.00 
 
 4 LEFT PRIMER         71   21   50.61   38.10  4.00  4.00 GAGCAGAAACTATAACCTGTT 
   RIGHT PRIMER       508   20   61.00   50.00  4.00  1.00 GGAAACCCAGCAGCATATCA 
   PRODUCT SIZE: 438, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 3.00 
 
Statistics 
         con   too    in    in          no    tm    tm  high  high        high       
         sid  many   tar  excl   bad    GC   too   too   any    3'  poly   end       
        ered    Ns   get   reg   GC% clamp   low  high compl compl     X  stab    
ok 
Right   1267     0     0     0     0     0   403   486     0     2     0    27   
349 
Pair Stats: 
considered 14, unacceptable product size 9, ok 5 
primer3 release 1.1.4 
 
 
(primer3_results.cgi release 0.4.0) 
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Appendices 19: 5-HT2C (Cys23Ser) Designing Primers 
www.ensembl.org: To obtain the protein and nucleotide sequence 
5-HT2A Protein Sequence: 
MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSI 
VIIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVW 
PLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVWA 
ISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIYV 
LRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTM 
QAINNERKASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVC 
SGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTN 
EPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV 
 
5-HT2C Nucleotide Sequence (Exons): 
 
ACCCGCGCGAGGTAGGCGCTCTGGTGCTTGCGGAGGACGCTTCCTTCCTCAGATGCACCG        
ATCTTCCCGATACTGCCTTTGGAGCGGCTAGATTGCTAGCCTTGGCTGCTCCATTGGCCT        
GCCTTGCCCCTTACCTGCCGATTGCATATGAACTCTTCTTCTGTCTGTACATCGTTGTCG        
TCGGAGTCGTCGCGATCGTCGTGGCGCTCGTGTGATGGCCTTCGTCCGTTTAGAGTAGTG        
TAGTTAGTTAGGGGCCAACGAAGAAGAAAGAAGACGCGATTAGTGCAGAGATGCTGGAGG        
TGGTCAGTTACTAAGCTAGAGTAAGATAGCGGAGCGAAAAGAGCCAAACCTAGCCGGGGG        
GCGCACGGTCACCCAAAGGAGGTCGACTCGCCGGCGCTTCCTATCGCGCCGAGCTCCCTC        
CATTCCTCTCCCTCCGCCGAGGCGCGAGGTTGCGGCGCGCAGCGCAGCGCAGCTCAGCGC        
ACCGACTGCCGCGGGCTCCGCTGGGCGATTGCAGCCGAGTCCGTTTCTCGTCTAGCTGCC        
GCCGCGGCGACCGCTGCCTGGTCTTCCTCCCGGACGCTAGTG 
GGTTATCAGCTAACACCCGCGAGCATCTATAACATAGGCCAACTGACGCCATCCTTCAAA        
AACAACT  
GTCTGGGAAAAAAAGAATAAAAAGTAGTGTGAGAGCAGAAAACGTGATTGAAACACGACC        
AATCTTTCTTCAGTGCCAAAGGGTGGAAAAG                                     
AAAGGATGATATGATGAACCTAGCCTGTTAATTTCGTCTTCTCAATTTTAAACTTTGGTT        
GCTTAAGACTGAAGCAATCATGGTGAACCTGAGGAATGCGGTGCATTCATTCCT              
TGTGCACCTAATTGGCCTATTGGTTTGGCAATGTGATATTTCTGTGAGCCCAGTAGCAGC        
TATAGTAACTGACATTTTCAATACCTCCGATGGTGGACGCTTCAAATTCCCAGACGGGGT        
ACAAAACTGGCCAGCACTTTCAATCGTCATCATAATAATCATGACAATAGGTGGCAACAT        
CCTTGTGATCATGGCAGTAAGCATGGAAAAGAAACTGCACAATGCCACCAATTACTTCTT        
AATGTCCCTAGCCATTGCTGATATGCTAGTGGGACTACTTGTCATGCCCCTGTCTCTCCT        
GGCAATCCTTTATG         
 
 
 
Primer picked using http://frodo.wi.mit.edu and the general rules to design these primers 
applied: 
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Primer3 Output 
 
PRIMER PICKING RESULTS FOR HTR2C 
 
No mispriming library specified 
Using 1-based sequence positions 
WARNING: Right primer is unacceptable: Tm too low 
 
OLIGO            start  len      tm     gc%   any    3' seq  
LEFT PRIMER         14   19   59.78   47.37  5.00  3.00 
GGCCTATTGGTTTGGCAAT 
RIGHT PRIMER       195   18   55.58   50.00  6.00  0.00 
GCCATGATCACAAGGATG 
SEQUENCE SIZE: 314 
INCLUDED REGION SIZE: 314 
 
PRODUCT SIZE: 182, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 1.00 
 
    1 TGTGCACCTAATTGGCCTATTGGTTTGGCAATGTGATATTTCTGTGAGCCCAGTAGCAGC 
                   >>>>>>>>>>>>>>>>>>>                             
 
   61 TATAGTAACTGACATTTTCAATACCTCCGATGGTGGACGCTTCAAATTCCCAGACGGGGT 
                                                                   
 
  121 ACAAAACTGGCCAGCACTTTCAATCGTCATCATAATAATCATGACAATAGGTGGCAACAT 
                                                               <<< 
 
  181 CCTTGTGATCATGGCAGTAAGCATGGAAAAGAAACTGCACAATGCCACCAATTACTTCTT 
      <<<<<<<<<<<<<<<                                              
 
  241 AATGTCCCTAGCCATTGCTGATATGCTAGTGGGACTACTTGTCATGCCCCTGTCTCTCCT 
                                                                   
 
  301 GGCAATCCTTTATG 
                     
 
KEYS (in order of precedence): 
>>>>>> left primer 
<<<<<< right primer 
 
 
Statistics 
Pair Stats: 
considered 1, ok 1 
primer3 release 1.1.4 
 
 
(primer3_results.cgi release 0.4.0) 
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Appendices 20: 5-HT7 (Pro-279-Leu) Designing Primers 
www.ensembl.org: To obtain the protein and nucleotide sequence 
5-HT7 Protein Sequence: 
MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLSEVTASPAPTW 
DAPPDNASGCGEQINYGRVEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLI 
VSLALADLSVAVAVMPFVSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDR 
YLGITRPLTYPVRQNGKCMAKMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQDFGYT 
IYSTAVAFYIPMSVMLFMYYQIYKAARKSAAKHKFPGFPRVEPDSVIALNGIVKLQKEVE 
ECANLSRLLKHERKNISIFKREQKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCSC 
IPLWVERTFLWLGYANSLINPFIYAFFNRDLRTTYRSLLQCQYRNINRKLSAAGMHEALK 
LAERPERPEFVLRACTRRVLLRPEKRPPVSVWVLQSPDHHNWLADKMLTTVEKKVMIHD 
 
5-HT7 Nucleotide Sequence: 
5’ upstream sequence 
ATGATGGACGTTAACAGCAGCGGCCGCCCGGACCTCTACGGGCACCTCCGCTCTTTCCTTCTGCCAGAAGTGGGGCG
CGGGCTGCCCGACTTGAGCCCCGACGGTGGCGCCGACCCGGTCGCGGGCTCCTGGGCGCCGCACCTGCTGAGCGAGG
TGACAGCCAGCCCGGCGCCCACCTGGGACGCGCCCCCGGACAATGCCTCCGGCTGTGGGGAACAGATCAACTACGGC
AGAGTCGAGAAAGTTGTGATCGGCTCCATCCTGACGCTCATCACGCTGCTGACGATCGCGGGCAACTGCCTGGTGGT
GATCTCCGTGTGCTTCGTCAAGAAGCTCCGCCAGCCCTCCAACTACCTGATCGTGTCCCTGGCGCTGGCCGACCTCT
CGGTGGCTGTGGCGGTCATGCCCTTCGTCAGCGTCACCGACCTCATCGGGGGCAAGTGGATCTTTGGACACTTTTTC
TGTAATGTCTTCATCGCCATGGACGTCATGTGCTGCACGGCCTCGATCATGACCCTGTGCGTGATCAGCATTGA
CAGGTACCTTGGGATCACAAGGCCCCTCACATACCCTGTGAGGCAGAATGGGAAATGCATGGCGAAGATGATTCTC
TCCGTCTGGCTTCTCTCCGCCTCCATCACCTTACCTCCACTCTTTGGATGGGCTCAGAATGTAAATGATGATAAGGT
GTGCTTGATCAGCCAGGACTTTGGCTATACGATTTACTCTACCGCAGTGGCATTTTATATCCCCATGTCCGTCATGC
TTTTCATGTACTACCAGATTTACAAGGCTGCCAGGAAGAGTGCTGCCAAACACAAGTTTCCTGGCTTCCCTCGAGTG
GAGCCAGACAGCGTCATCGCCCTGAATGGCATAGTGAAGCTCCAGAAGGAGGTGGAAGAGTGTGCAAACCTTTCGAG
ACTCCTCAAGCATGAAAGGAAAAACATCTCCATCTTTAAGCGAGAACAGAAAGCAGCCACCACCCTGGGGATCATCG
TCGGGGCCTTTACCGTGTGCTGGCTGCCATTTTTCCTCCTCTCGACAGCCAGACCCTTCATCTGTGGCACTTCCTGC
AGCTGCATCCCACTGTGGGTGGAGAGGACATTTCTGTGGCTAGGCTATGCAAACTCTCTCATTAACCCTTTTATATA
TGCCTTCTTCAACCGGGACCTGAGGACCACCTATCGCAGCCTGCTCCAGTGCCAGTACCGGAATATCAACCGGAAGC
TCTCAGCTGCAGGCATGCATGAAGCCCTGAA        
GCTTGCTGAGAGGCCAGAGAGACCTGAGTTTGTGCT   
 
Primer picked using http://frodo.wi.mit.edu and the general rules to design these primers 
applied: 
 
 
 
 
Primer3 Output 
PRIMER PICKING RESULTS FOR 5HT7 
 
No mispriming library specified 
Using 1-based sequence positions 
OLIGO            start  len      tm     gc%   any    3'   seq  
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LEFT PRIMER         92   20   59.92   55.00  2.00  
0.00CCTCCATCACCTTACCTCCA 
RIGHT PRIMER       441   20   60.00   55.00  3.00  
0.00GGTGGCTGCTTTCTGTTCTC 
SEQUENCE SIZE: 755 
INCLUDED REGION SIZE: 755 
 
PRODUCT SIZE: 350, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 0.00 
    1 TACCTTGGGATCACAAGGCCCCTCACATACCCTGTGAGGCAGAATGGGAAATGCATGGCG 
                                                                   
   61 AAGATGATTCTCTCCGTCTGGCTTCTCTCCGCCTCCATCACCTTACCTCCACTCTTTGGA 
                                     >>>>>>>>>>>>>>>>>>>>          
 
  121 TGGGCTCAGAATGTAAATGATGATAAGGTGTGCTTGATCAGCCAGGACTTTGGCTATACG 
                                                                   
 
  181 ATTTACTCTACCGCAGTGGCATTTTATATCCCCATGTCCGTCATGCTTTTCATGTACTAC 
                                                                   
 
  241 CAGATTTACAAGGCTGCCAGGAAGAGTGCTGCCAAACACAAGTTTCCTGGCTTCCCTCGA 
                                                                
 
  301 GTGGAGCCAGACAGCGTCATCGCCCTGAATGGCATAGTGAAGCTCCAGAAGGAGGTGGAA 
                                                                   
 
  361 GAGTGTGCAAACCTTTCGAGACTCCTCAAGCATGAAAGGAAAAACATCTCCATCTTTAAG 
                                                                   
 
  421 CGAGAACAGAAAGCAGCCACCACCCTGGGGATCATCGTCGGGGCCTTTACCGTGTGCTGG 
       <<<<<<<<<<<<<<<<<<<<                                        
 
  481 CTGCCATTTTTCCTCCTCTCGACAGCCAGACCCTTCATCTGTGGCACTTCCTGCAGCTGC 
                                                                   
 
  541 ATCCCACTGTGGGTGGAGAGGACATTTCTGTGGCTAGGCTATGCAAACTCTCTCATTAAC 
                                                                   
 
  601 CCTTTTATATATGCCTTCTTCAACCGGGACCTGAGGACCACCTATCGCAGCCTGCTCCAG 
                                                                   
 
  661 TGCCAGTACCGGAATATCAACCGGAAGCTCTCAGCTGCAGGCATGCATGAAGCCCTGAAG 
                                                                   
 
  721 CTTGCTGAGAGGCCAGAGAGACCTGAGTTTGTGCT 
KEYS (in order of precedence): 
>>>>>> left primer 
<<<<<< right primer 
Statistics 
         con   too    in    in          no    tm    tm  high  high        high       
         sid  many   tar  excl   bad    GC   too   too   any    3'  poly   end       
        ered    Ns   get   reg   GC% clamp   low  high compl compl     X  stab    ok 
Left    1916     0     0     0     0     0   481   839     0     1     0    49   546 
Right   3525     0     0     0     1     0   657  2019     0     1     0    79   768 
Pair Stats: 
considered 756, unacceptable product size 741, high end compl 4, ok 11 
primer3 release 1.1.4 
(primer3_results.cgi release 0.4.0) 
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Appendices 21: Ethics Approval 
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